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Abstract:
Endogenous Mechanisms Regulating Myeloid Cell Mediated Inflammation During Acute Lung
Injuries
Nathaniel Karl Berg, B.S.E.
Advisory Professor: Holger Eltzschig, M.D, Ph.D.
Acute lung injuries (ALI) can result from both direct insults (e.g. pneumonia or inhalation injury),
or systemic conditions such as sepsis or trauma. Current treatment options for patients are
limited to supportive care and novel approaches are urgently needed. Appreciating the role of
excessive inflammation that underlies the pathophysiology of ALI, we sought to identify
endogenous mechanisms that dampen inflammation. Here we investigated two pathways that
worked to limit excessive pulmonary inflammation in myeloid cells using a mouse model of
sepsis-associated ALI. In the first approach we screened for microRNAs during the recovery
phase of ALI that could potentially regulate inflammation. We found that miR-147 is highly
expressed during the recovery phase of ALI and worked to dampen inflammation by targeting
the mitochondrial subunit, NDUFA4, which resulted in an accumulation of succinate in
macrophages. Succinate in turn inhibited the demethylation of Histone H3 to silence the
expression of inflammatory cytokines. In the second approach, we demonstrate that the
neuronal guidance protein, Netrin-1, is highly expressed in infiltrating alveolar macrophages
after the onset of ALI. Netrin-1 deletion in the myeloid compartment resulted in exacerbated ALI
and increased NK cell recruitment, which was dependent on the upregulation of the chemokine,
CCL2, in the alveolar space. Together, the studies described in this dissertation point to two
previously unappreciated mechanisms that serve to limit the pro-inflammatory processes of
macrophages and limit tissue damage during ALI. Future work focused on leveraging these
processes have great potential to guide the development of novel treatments for ALI.
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Chapter 1: An introduction to the acute respiratory distress syndrome (ARDS)

Some sections of this chapter were previously published in:
George W. Williams*, Nathaniel K. Berg*, Alexander Reskallah, Xiaoyi Yuan, Holger K.
Eltzschig; Acute Respiratory Distress Syndrome: Contemporary Management and Novel
Approaches during COVID-19. Anesthesiology 2021; 134:270–282
*Denotes co-first authorship
Re-use of these materials for this dissertation were allowed with permission from the publisher.

1.1 The historical context and definition of ARDS
In 1821 René Laennec, inventor of the stethoscope, described the gross edematous pathology
of lungs from patients with severe shortness of breath and cyanosis. 1 In his account, he noted
the pulmonary edema was not explained by heart failure and termed the finding as idiopathic
anascara of the lungs. At these times, the constellation of idiopathic anascara of the lungs,
shortness of breath and cyanosis was widely fatal. The descriptions from Laennec are perhaps
the earliest account of what we now recognize as the acute respiratory distress syndrome
(ARDS). In 1967, a seminal report by Ashbaugh et al. described cases of respiratory distress in
adults that closely resembled that seen in premature babies with infant respiratory distress
syndrome (IRDS), eventually referring to it as “adult” respiratory distress syndrome. 2 Then in
1994 the American-European Consensus Conference (AECC) agreed that the term “acute lung
injury” be used and that “acute respiratory distress syndrome” be saved for patients with a ratio
of arterial oxygen tension (PaO2) to inspired oxygen fraction (FiO2) of 200 or lower.3 The term
“adult” was replaced with “acute” because, unlike IRDS, ARDS does not respond to surfactant
1

replacement. In order to make the syndrome easier to describe more precisely and to aid the
classification of disease severity for clinical trial and research pursuits, the Berlin definition of
ARDS was published in 2012, which dropped the term “acute lung injury” for ARDS and
allowed for stratification of severity based on the degree of hypoxemia. 4 Nonetheless, the term
“acute lung injury” is still used to describe experimental studies of ARDS in animal models.
According the 2012 Berlin definition, ARDS is a clinical condition characterized by an
acute lung injury that leads to the onset of non-cardiogenic pulmonary edema and decreased
capacity for gas exchange that results in hypoxemia. 4-6 The diagnosis of ARDS is confirmed by
radiographic evidence of pulmonary edema and a blood gas analysis demonstrating hypoxemia
defined by a ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2:FiO2 ratio)
less than 300. ARDS is further stratified based on severity of hypoxemia, with PaO2:FiO2 ratios
of less than 300, 200, or 100 acting as cutoffs for mild, moderate or severe disease,
respectively.4 ARDS commonly afflicts critically ill and high-risk surgical patients and is
associated with a devastatingly large mortality rate (typically between 35% and 45%). 1, 7
1.2 Epidemiology of ARDS
Between April 1999 and July 2000, Rubenfeld and colleagues performed a prospective study in
Kings County, Washington aimed at measuring the incidence of ARDS in the United States by
identifying patients with bilateral opacities on chest radiography and a PaO 2/FiO2 < 300
mmHg.8 The investigators estimated that there were 190,000 annual cases in the US, with an
associated mortality rate of 38.5 %.8 A subsequent retrospective analysis of ARDS patients
identified in the National Inpatient Survey (NIS) between 2006 and 2014 suggested that the
incidence of ARDS is slightly increasing and mortality rates are declining. 9 However, the LUNGSAFE study, a 2014, 50 center, multinational prospective cohort, reported that ARDS has an
incidence of 10.4% across all ICU patients and 23.4% in all patients requiring mechanical
ventilation, indicating that ARDS is still a prevalent problem in the critically ill. 10 Multiplying the
2

LUNG-SAFE-reported incidence of 0.46 cases of ARDS per ICU bed per 4 weeks in North
America with 94,837 ICU beds in the United States (provided by American Hospital Association
2015 annual statistics) and adjusting for 52 weeks in one year, results in an updated estimate
of 567,000 ARDS cases per year in the United States.10, 11 Furthermore, the LUNG-SAFE study
demonstrated that ARDS mortality rates remain between 35% and 45%. 10 Using an estimate of
40% mortality, this would result in over 226,000 ARDS-associated deaths per year. Perhaps
the most worrisome trend is that reported mortality rates between 2000 and the 2014 LUNGSAFE study have largely remained unchanged, indicating and urgent need for the
advancement of recognition, prevention, and therapeutics for ARDS.
1.3 Etiologies and pathobiology of ARDS
Etiologic risk factors for ARDS encompass both direct- and indirect-lung injuries including, but
not limited to pneumonia, sepsis, non-cardiogenic shock, aspiration, trauma, contusion,
transfusion, inhalation injuries, gastroesophageal reflux, and ventilator induced lung injury.
Importantly, there are a number of clinical “mimics” of ARDS, such as interstitial lung disease
and vasculitis that can obfuscate proper diagnosis. 12 The activation of resident lung
macrophages through recognition of pathogen- and damage-associated molecular patterns
(PAMPS/DAMPS) plays a critical role in initiating and/or perpetuating ARDS by stimulating the
release of cytokines and recruitment of inflammatory monocytes and neutrophils. 13, 14 Immunecell effector molecules, such as cytokines and proteolytic enzymes, contribute to the activation
and loss of barrier function of endothelial cells. Additionally, alveolar epithelial cell inflammation
and death results from both direct (e.g. bacterial toxins, viruses, mechanical ventilation) or
indirect (i.e. collateral inflammation imparted by dysregulated immune cell activity) causes. 14
The loss of barrier function from epithelial and endothelial linings of the alveoli results in the
accumulation of protein-rich edema into the airspace.15 The ultimate physiological
consequence of alveolar fluid accumulation and alveolar inflammation is the impairment of
essential gas exchange leading to hypoxemia (Figure 1). 15
3

Figure 1: Pathophysiology of Acute Respiratory Distress Syndrome (ARDS) in
Coronaviruas Disease 2019 (COVID-19).
The activation of resident lung macrophages through recognition of pathogen- and damageassociated molecular patterns (PAMPS/DAMPS) plays a critical role in initiating and/or
4

Figure 1 (Continued):
perpetuating ARDS by stimulating the release of cytokines and recruitment of inflammatory
monocytes and neutrophils.13, 14 Additionally, injury to epithelial and endothelial cells can also
initiate and enhance inflammation. Cellular injury or infectious pathogens can result in the
release of of inflammatory Damage and Pathogen Associated Molecular Patterns
(DAMPs/PAMPs). Recognition of PAMPs/DAMPs and cytokines activates alveolar
macrophages and chemokines act to recruit inflammatory immune cells to the lung. Excessive
immune cell release of antimicrobial effectors, such as metallomatrix proteases (MMPs),
elastases, and reactive oxygen species (ROS), induce collateral tissue injury that results in loss
of epithelial and endothelial barrier integrity and infiltration of proteinaceous fluid into the
alveolar airspace.40 Furthermore, ARDS can involve development of extensive pulmonary
intravascular coagulopathy.41-43

5

Histologically, ARDS is characterized by diffuse alveolar damage (DAD) that is hallmarked by
hyaline membranes.16 The presence of DAD – as assessed by autopsy or open lung biopsy –
is associated with ARDS mortality, which would make it a useful prognostic, but clinical
parameters have not been identified that might predict DAD in ARDS patients. 17, 18 Several comorbidities and behavioral or environmental factors have also been correlated with increased
risk for ARDS such as alcohol abuse19, cigarette smoking20, 21, air pollution22, 23, and low total
serum protein.24 Interestingly, obesity appears to be a risk factor for ARDS development but is
protective against the mortality of ARDS, the so-called “obesity paradox”.25, 26 Some proposed
explanations for this “obesity paradox” include altered inflammatory responses consisting of
decreased levels of pro-inflammatory cytokines (Il-6 and IL-8) in obese ARDS patients, 27 a
confounding role for optimized or aggressive medical management given the increased risk for
co-morbidities in obese patients such as diabetes and heart disease, 28, and the potential role
that obese patients may have increased energy stores to counteract the catabolic stress of
critical illness. Although several reports suggest a role for diabetes in ARDS risk, data from
large, prospective observations offered no association between ARDS development and
outcomes in patients with diabetes.10
1.4 ARDS in Coronavirus disease 2019 (COVID-19)
Coronavirus disease-2019 (COVID-19) is caused by infection of the lower airway by Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). SARS-CoV-2 emerged in
December 2019 in Wuhan, Hubei province, central China where it is believed to have
transmitted to humans at a seafood market.29, 30 Since then, it has spread globally and has
resulted in the current COVID-19 pandemic. At the time of this writing (April 20, 2019), there
are over 142 million confirmed cases globally and over 3 million deaths. 31 The cases reported
in the United States account for roughly 31 million positive cases and over 568,000 deaths. 31

6

SARS-CoV-2 is a strain of coronavirus of zoonotic origins. 29 The virus infects the lower
lung primarily through binding of Spike protein found on the surface of the virus to its receptor,
angiotensin converting enzyme 2 (ACE2), found on the surface of alveolar epithelial cells
(Figure 1).29, 32 After the entrance into cells via endocytosis, the virus releases its positivestranded RNA genome, which relies on host translational machinery to produce viral proteins.
One such protein is an RNA-depended RNA polymerase (the drug target of Remdesivir) that
replicates the viral genome, which becomes assembled within newly synthesized viral particles
that are then released from the cell through exocytosis, completing the SARS-CoV-2 life
cycle.33 Virus infection by SARS-CoV-2 results in injury and destruction of cells as a result of its
cytopathic life cycle. Cell death can occur through pyroptosis, which is a highly inflammatory
mechanism of programmed cell death that results in the release of cytokines and Pathogen and
Damage Associated Molecular patterns (PAMPs and DAMPs), such as RNA, DNA, and ATP.
Recognition of PAMPs and DAMPs results in the recruitment and activation of immune cells,
primarily monocytes, and lymphocytes in COVID-19. 34 In most cases, immune cell recruitment
and inflammatory responses are sufficient to clear the invading virus, but then subsequently
resolve to allow for a return to normal tissue homeostasis. However, in a subset of patients
inflammation can become dysregulated leading to excess release of cytokines and recruitment
of immune cells, resulting in widespread collateral lung injury34. Dysregulated inflammation in
COVID-19 patients is evident as increased levels of inflammatory cytokines were found in the
serum of patients that required intensive care and patients that had relatively increased levels
of serum IL-6, a potent inflammatory cytokine, were statistically more likely to not survive. 35, 36
Furthermore, cell and animal models of SARS-CoV-2 infection, as well as serum samples from
COVID-19 patients, demonstrate a diminished innate anti-viral response coupled with
inappropriate cytokine expression.37 Clinically, dysregulated and persistent lung inflammation in
COVID-19 disease results in the development of ARDS with associated characteristic
pathological features of diffuse alveolar damage and pulmonary edema. 38, 39
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ARDS is highly prevalent in COVID-19 hospitalized patients, with reports indicating an
incidence of 30-40%, and is associated with 70% of fatal cases. 36, 45 ARDS in COVID-19
patients present with several unique characteristics that are not regularly described in nonCOVID-19 associated ARDS. Among these characteristics is the significant development of
microvascular thrombosis within the lung vasculature that contributes to the shunting of blood
and right ventricular stress.36, 46, 47 In severe cases, patients develop disseminated intravascular
coagulation (DIC). Tang et al. reported that DIC was present in 71.4% of fatal COVID-19
cases.48 Though the cause for widespread activation of the coagulation cascade is not yet fully
understood, dysregulated inflammation and direct injury to endothelial cells by SARS-CoV-2
contribute to the development of microthrombotic immunopathology.46, 47, 49 Additionally,
endothelial cell damage in COVID-19 infection impairs pulmonary vasoconstriction that
normally occurs in response to hypoxia to restrict blood flow to poorly ventilated areas of the
lung. Disruption in this physiologic adaptation in COVID-19 patients results in a ventilationperfusion mismatch. To this end, Gattioni et al. have described severely hypoxemic patients
with well-preserved lung compliance in non-ARDS COVID-19 pnemonia. 50-52 There are also
reports of non-ventilated SARS-CoV-2 patients who appear comfortable at oxygen saturation
levels between 50 and 70%, a phenomenon of COVID-19 often referred to as ‘happy
hypoxia’.53, 54 Patients presenting in this early stage of the disease can benefit from limited
PEEP (8–10 cmH2O) and prone positioning due to improved distribution of pulmonary
perfusion. Furthermore, early mechanical ventilation with sedation may prevent exacerbation of
lung inflammation caused by potentially injurious transpulmonary pressure swings produced by
strong respiratory drives.55 However, in patients that present with or progress to ARDS (severe
hypoxemia with low pulmonary compliance), a conventional lung-protective strategy utilizing
low tidal volumes, prone positioning, and PEEP up to 14–15 cmH2O is recommended.56 On the
other hand, an effort to prevent early mechanical ventilation through increased use of noninvasive ventilation (NIV) methods and proning have been suggested in order to minimize
unnecessary invasive intubation and to preserve resources for patients who present with more
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critical respiratory failure.57 Indeed, a small trial reported by Sartini et al. demonstrated that NIV
combined with proning in COVID-19 patients was feasible and resulted in improvements in
respiratory rate and oxygenation.58 However, it still remains to be determined whether NIV and
proning can prevent or delay mechanical ventilation in randomized controlled study.
1.5 Current treatment and management approaches for ARDS
Nationally Organized Research Consortia to Study ARDS
In order to improve outcomes and develop treatment protocols for ARDS, the National Heart,
Lung, and Blood Institute (NHLBI) of the NIH funded a series of multi-center clinical trials,
which formed a research collaboration called the ARDS Network (http//:ardsnet.org). 59
Beginning in 1994, the network studies enrolled over 5,500 patients, included 10 clinical trials
and 1 observational study, led to the development of new clinical parameters such as ventilator
free days (VFD)60 and resulted in seminal advances that have helped to shape current ARDS
management. NHLBI-funded clinical trials continue presently under the Prevention and Early
Treatment of Acute Lung Injury (PETAL) Network (http://petalnet.org). In this section, we will
discuss many of the ARDS management guidelines that were elucidated by these trial
networks as well as ideas that are emerging from other rigorously-conducted clinical research
(Figure 2).
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Figure 2: A summary of 25 years of Acute Respiratory Distress Snydrome (ARDS)
intervention trials.
Interventions are chronologically displayed with corresponding clinical trials italicized
underneath and color-coded to denote clinical efficacy. Interventions that have clear clinical
efficacy, in blue boxes, include the use of small tidal volumes,61 prone positioning,62 and
restrictive fluid administration,63 which have demonstrated clear mortality or ventilator-free days
benefits. Interventions in grey boxes include those that have mixed results from different trials,
as is the case for conservative oxygen treatment64-66 and early neuromuscular blockade.67, 68
This category (grey boxes) also includes interventions with indeterminate results, such as the
case for Positive End Expiratory Pressure (PEEP)69 – itself is a component of lung-protective
ventilation, but the appropriate amount to use is still contended – or those that have value in
ARDS patients aside from improving ARDS outcomes, such as early trophic enteral nutrition to
prevent gastric intolerance70 and Extracorporeal Membrane Oxygenation (ECMO) as a rescue
therapy.71, 72 In orange boxes are interventions that failed to demonstrate improvements in
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Figure 2 (continued):
ARDS outcomes, such as antifungals, lisofylline, albuterol, simvastatin, vitamin C and vitamin
D.73-79 Dexamethasone is also listed in this category given that the DEXA-ALI trial was
conducted in an unblinded fashion80 and prior randomized trials showed no clinical efficacy for
steroid administration in ARDS. Methylprednisolone, 81 rosuvastatin80 and ω-3 Fatty Acids,82
listed in red boxes, have shown to cause potential harm in randomized controlled trials.
Currently, ongoing or planned trials and emerging therapeutic targets are displayed in green.
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Small tidal volumes
Amongst the best-established guidelines in managing ARDS patients is the use of small tidal
volumes during mechanical ventilation (Figure 2). In 2000, Investigators from the ARDSNet
Lower Tidal Volume Trial (ARMA) trial reported significantly decreased rates of mortality
(31.0% vs. 39.8 %) in ARDS patients ventilated with 6ml/kg of predicted body weight (kg PBW)
tidal volumes versus those with 12 ml/kgPBW.61 While small tidal volume ventilation remains a
tenant of lung-protective ventilation during ARDS, recent efforts have sought to determine
whether small tidal volumes play a lung-protective role more broadly in all critically-ill ventilated
patients. Though results of a meta-analysis suggested decreased development of lung injury
and mortality through the use of small tidal volumes in non-ARDS patients 83, in 2018 the
Protective Ventilation in Patients Without ARDS (PReVENT) trial demonstrated that ventilation
with low tidal volumes may not be more effective than intermediate volumes in non-ARDS ICU
patients.84 The trial randomized 961 non-ARDS patients expected to receive more than 24
hours of mechanical ventilation to either receive low (≤ 6 ml/kgPBW) or intermediate tidal
volumes (≥ 10 ml/kgPBW). The investigators reported no statistically significant changes in
ventilator-free days or mortality between the two groups, however, by one day after
randomization, 59% of patients allocated to the low tidal volume group received ventilation with
pressure support ventilation resulting in tidal volumes in excess of 6 ml/kgPBW. Because the
trial’s ventilation targets were clearly not met, whether low tidal volumes improves outcomes in
non ARDS critically ill patients remains to be evaluated in a randomized control trial.

Small tidal volumes in the operating room
Of particular interest to the practicing anesthesiologist is a growing body of evidence that
suggests the application of lower tidal volumes plays a protective role in reducing the rate of
postoperative pulmonary complications. 85 In a small (n=58) randomized clinical trial of open
abdominal surgery patients who were randomized to a protective ventilation strategy (tidal
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volumes of 7 ml/kgPBW, 10 cm H2O PEEP, and recruitment maneuvers) had improved
respiratory function and decreased pulmonary infectious complications than those allocated to
received mechanical ventilation with a standard strategy (tidal volume of 9 ml/kg PBW and no
PEEP).86 Furthermore, a retrospective observational study of 4,694 cardiac surgery patients
found that intraoperative lung protective ventilation (tidal volumes < 8 ml/kg PBW, modified driving
pressure [peak inspiratory pressure - PEEP] < 16 cm H2O, and PEEP ≥ 5 cm H2O) was
associated with reduced pulmonary complications. 87 However, future large-scale prospective
interventional studies will be required to establish whether such ventilation strategies should
become part of guidelines and if they are indicated for all or just a subset of patients
undergoing surgery.

Positive End Expiratory Pressure (PEEP) and Lung Recruitment Maneuvers (LRMs)
In their seminal 1967 report of ARDS cases, Ashbaugh et al reported that improvement of
hypoxemia and atelectasis was achieved by the implementation of PEEP.2 Since then, PEEP
continues to be employed in ARDS management and remains the focus of many clinical
research efforts. Conceptually, PEEP is administered in order to reduce atelectrauma
(repetitive opening and closing of alveoli) by recruiting collapsed alveoli. 88 Much attention has
been directed at the levels at which PEEP is applied, with clinical evidence yielding mixed
results (Figure 2). Several trials that report protective benefits from higher versus lower targets
of PEEP employed higher tidal volumes in their control (lower PEEP) groups, which perhaps
introduced bias in their conclusions.89, 90 Trials that have controlled for low tidal volumes (6
ml/kg), including the 2004 ARDS Network ALVEOLI trial, have failed to demonstrate a survival
benefit for higher PEEP, though there was some efficacy towards secondary endpoints such as
hypoxemia and use of rescue therapies.69,91 A more recent systematic review of the clinical
evidence supports the overall conclusion that higher versus lower levels of PEEP is not
associated with improved hospital survival.92 Subgroup analysis does, however, suggest that
higher PEEP is associated with improved survival among the subgroup of patients with ARDS
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who objectively respond to increased PEEP (patients who show improved oxygenation in
response to increased PEEP).93 Still, it has yet to be demonstrated whether survival in selected
patients improves with increased PEEP in large randomized trials. Furthermore, determination
of an optimal PEEP level for an individual ARDS patient remains an important challenge.
Currently, several methods, such as compliance-, FiO 2-, and electrical impedance tomographyguided PEEP titration, are being investigated, but ARDS mortality outcome data from large
randomized trials implementing these personalized techniques are still not available. 94, 95
Lung recruitment maneuvers (LRMs) are a set of techniques aimed at recruiting
collapsed alveoli in order to increase the lung volume receptive to tidal ventilation. LRMs
include methods that employ sustained increases in airway pressure to open collapsed alveoli
(e.g. prolonged high continuous positive airway pressure (30–40 cm H2O for 30-40 seconds),
which are followed with sufficient PEEP that maintain the recruited lung volume. 96 Though
some studies implementing lung recruitment maneuvers have shown promising results in
managing ARDS, the confidence regarding these effects were confounded by the use of higher
PEEP ventilation in LRM groups.97 In 2017, the Writing Group for the Alveolar Recruitment for
Acute Respiratory Distress Syndrome Trial (ART) Investigators reported the results of a trial in
which 1010 ARDS patients were randomized to receive recruitment maneuvers with PEEP as
high as 45 cm H2O and peak airway pressures as high as 60 cm H2O, followed by decremental
PEEP to identify optimal lung compliance.98 Patients receiving the lung recruitment protocol
had significantly increased 28-day and 6-month mortality, providing strong evidence against the
use of recruitment maneuvers in ARDS patients.

Prone positioning
Beneficial effects of prone positioning during mechanical ventilation of ARDS patients are
considered in order to establish a more even distribution of gravitational force in pleural
pressure allowing for improved ventilation of the dorsal lung space 99 and to limit over-distention
of alveoli.100 In 2013, Guérin and colleagues reported the results of the Proning Severe ARDS
14

Patients (PROSEVA) trial in which severe ARDS patients (PaO 2/FiO2 less than 150 on FiO2 of
at least 0.6) were randomized to prone positioning for a minimum of 16 hours a day. Patients
randomized to prone positioning had a 50% reduction in mortality (16% versus 32.8%) at 28
days (Figure 2).62 A recent meta-analysis corroborates these results and supports the survival
benefits of prolonged prone positioning (greater than 12 hours) in patients with severe
ARDS.101 Despite these encouraging results in reducing mortality with the use of prone
positioning, data from a large, multinational prospective observational study indicate that the
maneuver was employed in only 16.3% of severe ARDS patients. 10 Possible reasons for this
low implementation could be attributed to the relative complexity and logistic considerations of
prone positioning (e.g. multiple persons required for the maneuver, increased workloads,
management of secretions, and nutrition) or due to the inherent risks of the procedure such as
endotracheal tube and vascular line displacement. Nonetheless, the use of prone positioning
for more than 12 hours per day remains a strong recommendation for patients with severe
ARDS.102
Although the efficacy of prone positioning is almost exclusively suggested in patients
with PaO2/FiO2 ratios of 150 or less, trials that failed to show efficacy in mild and moderate
ARDS are largely underpowered and failed to administer prone positioning for recommended
lengths of time.103 As such, randomized trials implementing early prone positioning in mild to
moderate cases of ARDS are necessary in order to determine any survival benefits and to
make recommendations for clinical implementation.

Neuromuscular Blockade
Neuromuscular blockade is administered in order to reduce patient-ventilator dyssynchrony and
the work of breathing in patients.104 Investigators from the 2010 ARDS et Curarisation
Systematique (ACURASYS) study sought whether two days of neuromuscular blockade early
in the course of severe ARDS would improve outcomes (Figure 2).67 Patients in the treatment
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arm (bolus and infusion of cisatracurium for 48 hours) demonstrated improved 90-day survival
and increase in ventilator-free days. Despite these positive results, early neuromuscular
blockade was not widely adopted given concerns of long-term effects of paralysis, including
ICU-acquired weakness. A 2019 follow-up study from the PETAL Network re-visited the
findings with the Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) trial (Figure
2).68 The trial was stopped early for futility as there was no difference in 90 day mortality
between patients randomized to receive early deep sedation and those randomized to the
lighter sedation targets. Additionally, the results of the ROSE trial indicated that early
neuromuscular blockade was associated with an increase in serious adverse cardiovascular
events, which may be attributed to the deeper sedation targets in the intervention group.
Nonetheless, the outcomes of the ROSE trial do not provide evidence for the systematic early
administration of neuromuscular blockade. However, these results do not preclude the notion
that early neuromuscular blockade might provide efficacy in patients with severe refractory
hypoxemia or ventilator dyssynchrony.105
Steroids
In the report of ARDS patients by Ashbaugh et al. in 1967, it was suggested that corticosteroids
appeared to have clinical value in cases associated with fat emboli and viral pneumonia. 2
Randomized control trials conducted in the 1980s have since demonstrated that early
administration of methylprednisolone did not result in improved ARDS survival.106, 107 However,
in 1998 a prospective trial by Meduri and colleagues showed an improved outcome in ARDS
patients treated with prolonged methylprednisolone.108 The results of the study were subject to
scrutiny due to the small sample size (n=8) of the control group, significant cross-over into the
methylprednisolone group (all of which died) and a relatively large mortality rate of 60%.
Subsequently, in 2006 the ARDS Network addressed the role of corticosteroid administration
late in ARDS with the Late Steroid Rescue Study (LaSRS) in which 180 patients were
randomized to methylprednisolone administration 7 to 28 days after diagnosis of ARDS.
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Administration of methylprednisolone was associated with no significant reduction in mortality
(Figure 2).81 Furthermore, patients who started steroid treatment after 14 days of diagnosis
experienced increased mortality.
Based on the postulate that, compared to other corticosteroids, dexamethasone has an
improved potency, lengthened duration of action, and weak mineralocorticoid effect, Villar and
colleagues performed a prospective trial randomizing ARDS patients to receive either
dexamethasone or placebo.80 Compared to Patients in the control group, dexamethasone
treatment group showed a reduced time on mechanical ventilation and 60-day mortality,
however, drug allocation and data analysis were performed in an unblinded fashion, potentially
leading to bias. Furthermore, 250 patients were excluded for already receiving steroids prior to
randomization, indicating that participating physicians already favored the use of corticosteroids
which might have influenced clinical decisions to modify mechanical ventilation duration. In
summary, guidelines supporting routine glucocorticoid administration in ARDS based on
rigorously performed RCTs are currently not supporting their use.

Steroids in COVID-19 ARDS
Recent data from the UK RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial
investigating the use of dexamethasone in hospitalized COVID-19 patients have demonstrated
that dexamethasone is the first drug to improve mortality.109 Mechanically ventilated patients
that were randomized to receive 6 mg once per day for 10 days were found to have a reduction
of mortality by one third when compared to patients who underwent usual care. Interestingly,
this mortality benefit was not observed in patients who did not require respiratory support. In
response to these findings, current COVID-19 treatment guidelines from the National Institutes
of Health recommend its use in patients that are mechanically ventilated or require oxygen
supplementation.110 Moreover, similar to ARDS and PETAL Network studies, the RECOVERY
trial provides an example for the power of organized multicenter investigations for new
treatment approaches in critically-ill patients, especially those with ARDS. Moving forward, data
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from the dexamethasone arm are likely to reinvigorate studies for its use in non-COVID-19
ARDS patients that may support the open-label dexamethasone studies previously
mentioned.80

Fluid Management
Fluid management in ARDS patients requires physicians to carefully consider both the alveolar
and intravascular compartments. A decreased barrier function in the lungs calls for limitation of
fluid administration and promotion of renal excretion in order to mitigate pulmonary edema.
Conversely, an excessive decrease in intravascular volume can have negative effects on
under-perfused non-pulmonary organs (for example rates of acute kidney injury).111 The 2006
ARDS Network Fluids and Catheters Treatment Trial (FACTT) sought to identify an optimal
fluid strategy by randomizing patients to liberal (central venous pressure [CVP] of 10-14) or
conservative (CVP <4) fluid management strategies (Figure 2).63 The investigators reported no
survival benefit in either strategy, though the conservative group was associated with increased
ventilator-free days and a reduction in ICU length of stay. Interestingly, post hoc analysis of the
FACCT trial found that non-Hispanic black patients had a mortality benefit when treated with
conservative versus liberal fluid therapy indicating that race may play an important role in
determining the efficacy of conservative fluid management.112 Nonetheless, conservative fluid
management in ARDS patients is preferred given its reported improvement in ventilator free
days and ICU lengths of stay. Additionally, a 2018 retrospective study analyzing day 3 fluid
balance in critically ill patients found that a negative fluid balance was associated with
decreased mortality, further supporting the use of conservative fluid protocols in ARDS
patients.113 The use of restrictive fluid administration for the resuscitation of sepsis patients who
are at high risk for ARDS development is currently under investigation in the PETAL Network
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) trial
(NCT03434028). Outcome measures for the trial include whether a restrictive fluid strategy will
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reduce overall 90 day mortality or the incidence of ARDS (primary and secondary outcomes,
respectively).

Nutritional pharmacology and management
Several vitamins and nutritional supplements have experimentally been shown to have antiinflammatory and injury-reducing properties, but attempts to determine if these effects translate
into disease-modifying clinical benefits have largely been unsuccessful (Figure 2). Large
randomized controlled trials investigating the use of Vitamins C and D both failed to
demonstrate therapeutic benefits in ARDS patients. 114, 115 Similarly, ω-3 fatty acids, γ-linolenic
acid, and antioxidants were associated with decreased ventilator-free days, decreased ICU free
days, and non-statistically significant (p=0.054) increase in 60-day mortality. 82 Collectively,
these results provide strong evidence that the use of vitamin or fatty acid supplements is not
supported as interventions to improve mortality or morbidity in ARDS patients.
ARDS patients have high energetic demands and require nutritional support in order to
offset catabolic losses. When possible, a strategy using enteral feeding is preferred over
parenteral nutrition as it is associated with decreased infectious morbidity. 116 Additionally,
attention has been placed on the amount of nutrition ARDS patients receive. In a 2012 ARDS
Network clinical trial, a strategy using initial trophic enteral feeding (10-20 kcal/h) versus full
enteral feeding (25 to 30 kcal/kg per day of non-protein calories and 1.2 to 1.6 g/kg per day of
protein) for up to 6 days did not improve clinical endpoints but was associated with improved
gastrointestinal tolerance (Figure 2).70 Currently, recommendations support the use of initial
trophic feeding of the first week of mechanical ventilation in ARDS before switching to full
nutritional targets116.

Conservative Oxygenation
Among the most common therapies implemented in critically ill patients and nearly all ARDS
patients is the supplemental provision of oxygen. Oxygen is frequently delivered generously in
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order to increase PaO2 and oftentimes patients become hyperoxic while attempting to reverse
tissue hypoxia. However, evidence indicates that liberal oxygen use is associated with
vasoconstriction, decreased cardiac output, absorption atelectasis, increased pro-inflammatory
responses, and increased mortality.117, 118 As such, establishing a protocol of oxygen treatment
that balances essential delivery to organs while preventing excessive harmful effects of
hyperoxia has been an important subject of recent investigations (Figure 2). In a single-center
randomized trial published in 2016, critically ill ICU patients with a length of stay of 3 days or
longer who were assigned to receive conservative oxygen therapy (PaO 2 between 70 and 100
mm Hg) had lower mortality than those who received more conventional care (PaO 2 up to 150
mm Hg).64 Two recently published multicenter trials aimed to further investigate the effects of
conservative oxygen delivery in mechanically ventilated patients. In the first study, the 2019
Intensive Care Unit Randomized Trial Comparing Two Approaches to Oxygen Therapy (ICUROX), Mackle and colleagues randomized intensive care unit patients to usual (no upper limit
on SpO2 targets) or conservative oxygen (target SpO2 between 90 and 97%). Patients
assigned to conservative oxygen treatment spent a significantly higher time on atmospheric
oxygen concentration (FiO2 = 0.21) than the usual care arm, however, there were no reported
differences in ventilator free days or survival.65 The failure to detect changes in clinical
outcomes in the two treatment groups may have resulted from the small differences between
the targeted SpO2 intervals compared with previous studies that used more distanced
intervals.64
In the second recently published study, the 2020 Liberal Oxygenation versus
Conservative Oxygenation in Acute Respiratory Distress Syndrome (LOCO 2) trial, Barrot et al.
recruited ARDS patients to conservative (SpO 2 between 88 and 92%) or liberal (SpO2 greater
than 96%) oxygen treatment arms. The trial was terminated early due to an associated
increase in mortality at 28 days and five episodes of mesenteric ischemia in the conservative
oxygen treatment group.66 Worse outcomes in the LOCO2 may be attributed to the deteriorated
gas exchange in ARDS patients, making them more prone to hypoxemia in the conservative
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oxygen treatment arm. Furthermore, the target oxygen levels in the LOCO2 conservative group
were significantly lower than in the ICU-ROX trial, thereby increasing the risk for detrimental
hypoxemia. Going forward, trials will need to carefully assess how to determine target
oxygenation levels (e.g. SpO2 and PaO2 targets, measurements from mixed venous blood,
different targets for different organ injuries) to better answer how oxygen concentrations are
selected. In the meantime, clinical guidelines recommending avoidance of excessive oxygen,
such as restraining the use of supplemental oxygen when SpO 2 is greater than 96% (or even
greater than 92-93% is some guidelines), are practical for current ARDS management 119, 120.

ECMO and inhaled nitric oxide rescue therapies
Extracorporeal membrane oxygenation (ECMO) is a rescue therapy that has been employed in
ARDS patients that fail to improve on mechanical ventilation management and as a means to
avoid potential injurious aspects of ventilator associated lung injury (Figure 3).
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Figure 3: Venovenous (V-V) Extracorporeal Membrane Oxygenation (ECMO).
V-V ECMO is primarily employed to oxygenate blood and to remove carbon dioxide in the
setting of compromised pulmonary gas exchange, as is the case in severe ARDS. Portrayed is
a single cannula, double-lumen ECMO access whereby blood can be removed and returned to
a large vein, typically the vena cava. Blood is pumped from the body through a membrane
oxygenator that allows for gas exchange before being returned to the right atrium where it
mixes with deoxygenated venous blood (depicted in purple). In V-V ECMO, blood is pumped by
the heart into the systemic arterial vasculature.
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Advances in ECMO delivery have been associated with an increase in the number of centers
and cases using it, particularly since the 2009 H1N1 influenza pandemic. 121 Investigators from
the 2009 Conventional Ventilatory Support versus Extracorporeal Membrane Oxygenation for
Severe Adult Respiratory Failure (CESAR) trial group sought to answer whether the use of
ECMO during severe ARDS would provide a survival benefit when compared to conventional
support by mechanical ventilation (Figure 2).71 The results of the trial indicated that there was a
survival benefit in favor of patients being randomized to ECMO treatment, but this difference
was not statistically significant. Furthermore, the study was impaired by the use of
heterogeneous mechanical ventilation strategies in the control group (including the use of large
tidal volumes). Additionally, a large percentage of patients in the ECMO group who were
transferred to ECMO-capable hospitals never received ECMO, allowing for the potential
confounding effects attributed to the fact that ECMO-capable hospitals may attain enhanced
ARDS survival regardless of whether patients actually received ECMO.
A subsequent international multi-center study was conducted to specifically address
weaknesses of previous trials implementing ECMO in early severe ARDS, the 2018 ECMO to
Rescue Lung Injury in Severe ARDS (EOLIA) trial.72 Despite achieving a high quality of control
for ventilation strategies in both groups and nearly universal implementation of ECMO in
patients randomized to receive it, the results demonstrated that there was no significant
difference in mortality between the ECMO group and the control group. Given the lack of strong
evidence supporting the use of ECMO as a routine early treatment for ARDS, it is
recommended that ECMO is reserved as rescue therapy in patients that remain hypoxemic
despite conventional evidence-based approaches.
As a rescue therapy, inhaled nitric oxide (iNO) is used to target pulmonary vasodilation
and improved oxygenation by reducing ventilation-perfusion mismatch. 122 Although iNO
improves short term oxygenation, randomized control trials were unsuccessful in demonstrating
clinical benefits such as an increase in ventilator-free days or survival with iNO use in ARDS
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patients.123 Furthermore, in a 2016 systematic review, the use of iNO in ARDS was associated
with a statistically increased risk of renal failure. 124

Other treatment concepts
A large number of pharmacologic approaches have been tested in large, randomized controlled
trials in order to improve clinical outcomes in patients with ARDS. These trials have included
approaches such as the use of β2-adrenergics, interferon β-1a, inhaled anticoagulants,
selenium, ketoconazole, lisofylline, and statins (Figure 2).73-79, 125 However, clinical benefit for
these interventions was not demonstrated in any of the trials.

1.5.1 Harnessing heterogeneity in ARDS to personalize therapy
Recent advancements in our understanding of ARDS pathophysiology demonstrate that there
are likely important subtypes (or subendotypes) of ARDS that might be capable of better
indicating prognosis, predicting response to particular interventions, and directing personalized
therapies.126 Subendotypes of ARDS can be partitioned using clinical data such as disease
severity (i.e. degree of hypoxia),4 precipitating factors,127 sepsis vs. non-sepsis causes of
ARDS (the latter associated with better outcomes in mortality and ventilator free days), 128, 129
and the presence of trauma-associated ARDS.130 Genetic risk factors have also been
discovered and partly explain underlying heterogeneity of ARDS, with over 30 identified genes
shown to influence ARDS influence susceptibility.131, 132 Additionally, measured soluble
biomarkers have been used to define subendotypes of ARDS that effectively predict severity
and outcomes in patients.133-139 Though these clinical, genetic and soluble factors are capable
of classifying ARDS patients’ risk for outcome and severity of disease, an ideal utilization for
subendotyping ARDS cases would be to direct treatment decisions. Indeed, such work has
been performed by numerous investigators, mostly in a retrospective manner.
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One method of subendotyping is by categorizing ARDS as being associated with direct
lung injuries (e.g. pneumonia and caustic aspiration), versus indirect lung injuries (e.g. sepsis
and non-pulmonary trauma). In particular, studies measuring systemic markers of injury have
found that direct lung causes are associated with elevations in epithelial markers, such as
surfactant proteins and soluble receptor for advanced glycation end products (sRAGE), while
systemic injuries are associated with endothelial markers such as angiopoietin-2 and von
Willebrand Factor.140-146 This distinction might suggest that the etiologic site of lung injury could
influence targeted therapy towards epithelial and endothelial directed treatments.
Another method of anatomical subendotyping of ARDS injury is through radiographic
approaches. In these classifications, ARDS was categorized as focal – defined as loss of
airspace a particular region of the lung (e.g. a segment or lobe of lung) – and non-focal –
defined as airspace attenuation evenly distributed amongst the entire lung fields. 147-151 In
regards to treatment effects, it was found that lung recruitment maneuvers such as PEEP were
more effective in non-focal ARDS and that such maneuvers resulted in significantly higher
over-distention in the focal ARDS groups. Furthermore, systemic markers of sRAGE were
elevated in patients with focal ARDS.150 These findings are important in two regards: 1) the
determination of focal versus non-focal ARDS is relatively easy and rapid as it can be achieved
through computed tomography (CT) imaging and 2) the radiographic distinction could predict
whether lung recruitment using PEEP is harmful or beneficial. Indeed, further prospective,
large-cohort, randomized trials will be critical in demonstrating clinical efficacy in patient-centric
outcomes such as mortality and ventilator free-days.
Among the most recent approaches to define subendotypes is by classifying ARDS
cases as hyper- and hypo-inflammatory using specific inflammatory biomarkers. 152 Using a
statistical method called latent class analysis, which uses multivariate data to identify groups,
investigators have been able to retrospectively detect hypo- and hyper-inflammatory
subendotypes of ARDS.153-155 Inflammatory subendotypes have been classified with as few as
three soluble markers (e.g. interleukin-8, bicarbonate, and tumor necrosis factor receptor-1)
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and also by peripheral leukocyte transcriptional profiles. 156, 157 Furthermore, when these
subtypes were applied post-hoc to large scale clinical trials, it was found that there was a
mortality benefit for simvastatin and a liberal-fluid strategy in hyper-inflammatory ARDS
subendotypes.156, 158 The results of these analyses provide convincing inferences that there
exist ARDS subtypes that are important for deciding personalized treatment approaches. As
such, future clinical trials will likely need to implement subendotyping at the time of
randomization to rigorously demonstrate efficacy of categorizing patients to choose the optimal
treatment approaches. The undertaking of subendotyping ARDS patients will likely be met with
many challenges: the acuity and haste of care needed in critical care patients might prevent the
results of necessary studies prior to randomization and access to laboratories and technologies
might not yet be universal for specific inflammatory biomarker measurements. Nonetheless,
categorizing ARDS patients into groups that better allows for identification of disease severity,
prognostication, and allocation to particular treatment regimens is an exciting and growing
approach to ARDS research that will ideally lead to improved clinical outcomes.

1.6 Conclusion: The urgent need for novel ARDS treatment
The past 25 years of large, randomized clinical trial efforts have contributed a tremendous
amount of insight that has advanced the clinical practice of lung-protective mechanical
ventilation. Indeed, implementation of clinically proven management interventions, such as the
use of low tidal volumes and prone positioning, have dramatically improved the outcomes for
ARDS. However, mortality remains high and there is a lack of targeted treatment options.
Nonetheless, emerging basic science research has resulted in novel therapeutic targets, such
as hypoxia, adenosine, and microRNA signaling, that might pave the way for new
pharmacologic ARDS treatments. Advancements in our appreciation for pathological and
clinical subtypes of ARDS will likely also play a critical role in designing clinical trials to identify
efficacy for treatments in specific cohorts of ARDS patients.126 Furthermore, the recent COVID26

19 pandemic has stimulated the rapid initiation of clinical trials aimed at targeting ARDS. At the
time of this writing, there are over 100 registered controlled trials for COVID-19 ARDS listed on
ClinicalTrials.gov. Potential interventions that demonstrate clinical efficacy in COVID-19 ARDS
could also provide usefulness in treating ARDS patients independent of SARS-CoV-2 infection.
It is important to note, however, that insights gained from proven therapies for COVID-19
ARDS could translate to non-COVID-19 ARDS subtypes that share pathophysiological
components with COVID-19 cases. For example, the efficacy reported with dexamethasone
could indicate specific use for patients with viral-associated ARDS that are characterized by
immune profiles similar to what is seen in COVID-19 and not for patients with other etiologic
types of ARDS. Additional clinical studies will be required to carefully address such
hypotheses. Lastly, to establish efficacy for novel ARDS interventions, collaborative efforts,
such as the multicenter trials ongoing in the PETAL Network, will continue to be vital for the
successful improvement of ARDS outcomes. In addition to these large scale studies, a network
of smaller clinical trials investigating the efficacy of novel treatment concepts 159, 160 may be
required to identify new approaches for ARDS therapy. Channeling enthusiasm for new trials
targeting COVID-19 ARDS may provide a catalyst and framework for these important
collaborations going forward.
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Chapter 2: Pre-clinical insights into ARDS

2.1 Modeling ARDS in the laboratory: acute lung injury
Key to understanding and developing targeted therapies for ARDS, as with any other organ
injury, is the ability to model disease pathophysiology in a way that allows investigators to gain
insight into disease progression, resolution and treatment responses. Lung biopsies from
humans have been essential to the advancement of ARDS insights such as demonstrating the
presence of inflammatory infiltration and diffuse alveolar damage, but these methods are both
highly invasive or only account for patients that have died from their disease. 16 Furthermore,
human-derived tissue samples are typically limited to one or two time points of disease: after
ARDS onset or post-mortem. Modeling ARDS in the laboratory setting allows for researchers to
study disease pathophysiology serially among all time points. Additionally, a critical factor for
ARDS research is the dissection of cellular and molecular contributions to pathophysiology,
both of which are possible using modeling techniques. These techniques include cell culture,
animal models, and protocols that utilize primary tissue isolated from both animal and human
sources.
The following is a discussion of laboratory based techniques for modeling ARDS and
previous work that has contributed the accumulated understanding of ARDS pathophysiology
onset, progression, resolution, and potential novel treatment approaches. Lastly, an important
distinction for the next discussion is that, in the pre-clinical research setting, ARDS research is
referred to as acute lung injury (ALI). The reason for this is that ‘ARDS’ is typically reserved for
the clinical definition for which it describes (i.e. it is dependent on a clinical set of criteria that
are not relevant or readily measured in the pre-clinical setting). 4 For this reason, ALI will be
used henceforth to describe pre-clinical work in ARDS research, including the work presented
in chapters 3 and 4.
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2.1.1 Cell culture systems for studying ALI
Since the advent of obtaining single cell suspensions from tissues in early 20 th century and the
first established cell lines 1950s and 1960s, cell culture has been a vital tool for investigating
biology and human diseases.161, 162 From understanding the mechanisms that drive cancerous
transformation, to diagnosis of viral infection, to the generation of monoclonal antibodies, cell
culture has been a critical player in the advancement of nearly all biomedical fields. 163-166
Furthermore, comparative genetics have allowed for cells derived from distant species to reveal
functional genes that are important for human physiology and disease, such as the discovery of
toll-like receptors (TLRs) in drosophila that are found on mammalian cells which are
responsible for recognizing foreign pathogens and initiating the innate immune response. 167, 168
In the context of ALI, cell culture can be used to investigate individual components of
the microscopic lung environment (e.g. epithelial, endothelial, immune cells) or mediators of
inflammation (e.g. cytokines, chemokines, and toxins). Alveolar epithelial cell (AECs) primary
cells derived from mammals and immortalized cell lines (e.g. A549) have been used in cellmonolayer cultures to examine the role of lipopolysaccharide (LPS)-induced expression
intercellular adhesion molecule-1 (ICAM-1), which promotes immune cell adherence to
epithelial cells during lung inflammation. 169 Alveolar type II cells (ATII) isolated from human
lungs have also been treated with LPS in vitro which demonstrated that alveolar epithelial cells
also contribute to the expression of inflammatory cytokines.170 Endothelial cell culture models
have been used to demonstrate that endothelial cell apoptosis is a likely contributor to the
onset of pulmonary microvascular leak during ALI during systemic inflammatory conditions
such as sepsis.171-173 Furthermore, cell culture systems that co-culture two or more cell types
have been employed to study how cell-to-cell signaling plays a role in ALI. For example, coculture of activated neutrophils and AECs was used to demonstrate that micro-particles
containing miR-223 were transferred from neutrophils to AECs during ventilator induced lung
injury, which played a protective role by dampening lung inflammation. 174
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On the basis that inflammation plays a particularly important role in the pathogenesis of
ALI, in vitro studies using immune cells are frequently performed to study their functions in
orchestrating lung inflammation. Cells can be isolated from primary sources, usually from
human peripheral blood, mouse blood, or mouse bone marrow. Using standardized
centrifugation techniques, neutrophils, monocytes and T cells can be readily isolated from
freshly isolated blood and then activated or differentiated into terminal cell types such as
macrophages and subsets of T cells.175-180 Additionally, bone marrow can be isolated from mice
and treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage
colony-stimulating factor (M-CSF) to promote the differentiation of stem cells into dendritic and
macrophage cells, respectively.181, 182 Isolation of immune cells from genetic knockout or
transgenic mice also provides an advantage of genetic manipulation without the need for
transfection or transduction methods that can potentially lead to unwanted activation or
stimulation of cells.183, 184 Furthermore, immune cells can be isolated from the alveolar airspace
using a bronchoalveolar lavage of either ARDS patients or healthy volunteers. 185-187 In this way,
the inflammatory signatures and functions of immune cells can be directly interrogated from the
alveolar space during injury. A study by Morrell et al. demonstrated an important distinction
between paired peripheral monocytes and alveolar macrophages transcriptional activation
wherein they reported that enrichment in immune-inflammatory genes in alveolar macrophages
or peripheral monocytes was associated with improved or worsened outcome, respectively. 188
Several more advanced in vitro systems also exist that closely model physiologic
conditions of the lung. One such technique is the culturing of AECs on flexible membranes that
can then be subjected to vacuum-mediated deformation to induce noxious strain in the cells. 189,
190

Using a flexible membrane system to induce stretch-mediated injury in Calu-3 cells, Eckle et

al. demonstrated that stretched cells become injured and upregulate inflammatory genes. 187 An
even more complex in vitro system is the ‘lung-on-a-chip’ method.191, 192 The technology is a
microphysiologic system allows for epithelial and endothelial cells to be plated on a flexible
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membrane that also incorporates air and fluid flow approximated with the opposed cell layers.
In this way organ-level pathophysiology can be modeled in vitro. For example, when human
alveolar epithelial cells from asthma and chronic obstructive pulmonary disease patients were
used in a lung-on-a-chip system, Benam et al. were able to closely model hyper-inflammatory
responses that are dependent on the presence of endothelial cells as well as neutrophils. 193
Indeed, several components of ALI have been studied on microphysiologic systems that are
able to demonstrate impaired gas exchange, edema, transmigration of neutrophils and fibrin
deposition, exhibiting the utility of this in vitro system to model organ-level physiological
processes.191, 192, 194
2.1.2 Animal models of ALI
Though in vitro models have played, and continue to play, critical roles in the advancement of
molecular and biochemical insights of ALI, they are limited by being pathophysiologically
oversimplified. ALI is a complex syndrome that has multiple stages of disease that are defined
by the participation of different cellular and molecular effectors.14 Furthermore, research
focused on in vitro readouts such as inflammation and cell trafficking fall short in demonstrating
meaningful organ- and organism-centered outcomes, including measures of respiration and
mortality. As such, animal models of ALI are essential tools for realizing the implications for in
vitro findings. Animal models can also serve as initial studies to begin understanding the
mechanisms for lung injuries induced by a large number of etiologies and are used as
platforms to test therapies for ALI.195 Another useful characteristic of animal research is that
human studies are rather slow and tissue is not typically readily available, both of which are not
barriers in animal studies.
Among the most utilized animal models for studying ALI is rodents, particularly mice.
There are numerous advantages to using mice to model ALI: they breed rapidly, have similar
pulmonary anatomy to that of humans, and can develop a wide array of ALI types. 196 A unique
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advantage to using mice to model ALI is the ability to readily develop genetically modified mice,
which has become increasingly affordable and timely using modern technology based on
clustered regularly interspaced short palindromic repeats (CRISPR). 197-200 Through deletion or
insertion of genes of interest, genetically modified mice subjected to models of ALI can be
utilized to precisely study the functions of proteins and non-coding RNAs. 160, 190 Furthermore,
genetic modifications in mice can be targeted to specific tissue compartments using Cre-Lox
recombination whereby the deletion or alteration of a gene-of-interest is flanked by palindromic
DNA sequences, called Loxp sites. DNA flanked by loxp sites is excised by the Crerecombinase enzyme, which can be expressed in mice by introducing a second transgene that
codes for Cre. If the transgene is placed under the upstream control of a promoter for a tissue
specific gene (e.g. the albumin promoter is only active in hepatocytes), Cre is expressed in a
targeted tissue compartment and subsequently deletes the loxp-flanked DNA sequence. 200, 201
In this manner, not only can gene products be investigated genetically in mouse models of ALI,
but they can also be interrogated specifically in tissues where they function. This consideration
is of utmost importance when whole-body deletion of a targeted gene is embryonically lethal.
Mouse models of ALI can be performed using agents that typically correspond to ARDS
risk factors in patients, such as sepsis, trauma, aspiration and ventilation induced lung injury
(VILI).14, 127 Agents to induce lung injury can be injected systemically in the blood stream or
intraperitoneal cavity, or directly into the alveolar airspace of mice through endotracheal
catheterization.202 Commonly administered agents used to induce acute lung injury in mice
include, bacteria, viruses, lipopolysaccharide (LPS), hydrochloric acid (HCl), and high pressure
ventilation.195 The intratracheal injection of viruses or bacteria into mice causes pneumonia that
can lead to acute lung injury and pathology in mice that is commonly seen in humans. 203 For
example, Pseudomonas aeruginosa instillation into the lungs of mice leads to acute pneumonia
that is dependent on bacterial burden, with higher burdens resulting in worsened inflammation,
respiratory failure, and increased mortality.204 Viruses are also commonly instilled into the lungs
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of mice, though an important consideration is to establish the adaptability of viral strains that
typically cause disease in humans to mice. A recent example of this is the inability for severe
acute respiratory syndrome coronavirus coronavirus-2 (SARS-CoV-2) to infect mouse alveolar
epithelial cells because the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2),
does not efficiently bind to the virus.205 To circumvent this limitation, mice have to be genetically
derived to express human-version of ACE2 or mouse-adapted strains for SARS-CoV-2 need to
be generated, both of which have been utilized.206-208 Mouse adaptation of human viruses has
been performed in several other viruses, including influenza. 209, 210
In addition to mice, many other animals are used to study ALI. Other species used to
study ALI include hamsters, rats, rabbits, sheep, pigs, and non-human primates. 211-215 Using
different species for ALI research requires several special considerations. Firstly, different
animals developed evolutionary variations in their Toll-like receptor structures that recognize
different structures on identical pathogen associated molecular patterns that result in different
sensitivities and activities of receptors.216, 217 Secondly, species have differences in their
mononuclear phagocyte systems. For example, species such as sheep, cattle, pigs, cats and
goats have pulmonary intravascular macrophages (PIMs) that adhere to endothelial cells in
lungs, while rats, mice, monkeys, and humans do not contain PIMs, which effects the
development of ALI in experimental models.218-220 Thirdly, animal size plays a large role in a
number of ways: larger animals have easier vascular access allowing for monitoring of
physiological parameters, but larger animals are also considerably more expensive. 221, 222
Lastly, ALI studies can be limited in particular species due to a lack in species specific
reagents, such as antibodies for Western blots and enzyme-linked immunosorbent assays
(ELISA).223, 224
As sepsis is among the leading causes of clinical ARDS, sepsis-related models of ALI
are heavily utilized in animal models.6, 14, 45 Lipopolysaccharide (LPS) is commonly used to
induce a form of ALI that models the systemic inflammation typically associated with bacterial
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sepsis. LPS is an endotoxin present on the outer-membrane of gram-negative bacteria, which,
when present in the blood stream, is recognized by Toll-like receptor-4 (TLR4) on the
membrane of many cell types including macrophages, endothelial and epithelial cells, leading
to the activation of inflammatory functions.225-228 When injected intravenously, the vascular
endothelium is the first site of injury, resulting in decreased arterial tone and drop in blood
pressure.217 In the lungs, LPS-induced activation of capillary endothelial cells results in
apoptosis, which precedes neutrophil entrapment. 229-232 Additionally, LPS stimulates resident
alveolar macrophages in the lung to produce inflammatory mediators such as interleukin-1,
tumor necrosis factor-alpha, and prostaglandin E2 that all act to promote local inflammation
leading to enhanced recruitment of neutrophils.233, 234 Excessive accumulation and activation of
neutrophils in the lung is a key step to the onset of epithelial barrier damage resulting to
pulmonary edema and hypoxemia associated with ALI.235-238 When LPS is administered intratracheally, as opposed to intravenously, recruitment of neutrophils is up to 10-fold higher. 239
Indeed, LPS-induced ALI in mice is advantageous for its simplicity, its ability to model the
pathophysiology resulting from bystander lung injury from the host’s own inflammatory
response (i.e. the scenario of ARDS in the setting of sepsis), and its reproducibility, however, it
is limited for several reasons. Firstly, species’ responses to LPS vary significantly. For
example, mice require much higher doses of LPS to initiate pulmonary inflammation when
compared with humans.240 Secondly, purified LPS does not cause severe epithelial and
endothelial damage that is consistent with human ARDS, which is likely due to the fact that
addition bacterial exotoxins and secreted proteins also contribute to the diffuse alveolar
damage.239, 241, 242
In order to more closely model microbial sepsis-induced ALI, animal models of
peritonitis are used. The most common peritonitis model is the cecal ligation and puncture
(CLP) model, which consists of ligating the cecum subsequently puncturing it three to five times
to permit leakage of the colonic contents into the peritoneum.243 CLP results in sepsis, with
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features of leukopenia, pulmonary hypertension, and lung injury within 18-72 hours 244 CLPassociated ALI presents with features including hypoxemia, neutrophilic alveolitis, and
edema245-247 Major limitations to the CLP model are that it requires a surgical procedure and
has a mortality rate of 70-90% 30 hours after the procedure, which makes it difficult model to
study recovery and treatment responses for ALI.244, 245
Several models have also been utilized to directly injure the alveolar epithelium, which
occurs in clinical scenarios of ARDS such as gastric contents aspiration and VILI. 248, 249 As a
method to mimic gastric content aspiration, hydrochloric acid (HCl) is instilled into the lungs of
animals to reduce the alveolar pH to about 1.5. Instillation of HCl is followed by injury to the
alveolar epithelium with loss of epithelial fluid transport function, which then undergoes a repair
process including the renewal of epithelium by alveolar type II cells.250-253 The capillary
endothelium is also injured during acid aspiration in a neutrophil-dependent manner. 250, 251
Several considerations that limit the HCl aspiration model are that it requires pH levels that are
much lower than typical human gastric contents to achieve alveolar injury (i.e. it requires a pH
of about 1.5, whereas gastric contents are usually between pH 3.0 - 4.0) and that it does not
account for the additional gastric contents aside from the acidity (e.g. food particles, bacterial
products, and cytokines).254-256
Modeling ALI by primarily targeting the alveolar epithelium is also achieved by injurious
mechanical ventilation.257-259 VILI studies in animals were the premise for the landmark ARDS
Network trial that established lower tidal volumes were effective at reducing mortality in
mechanically ventilated ARDS patients.61 Ventilation of animals with pressures resulting in
injurious strain (i.e. over-distension) results in endothelial and epithelial disruptions and
pulmonary edema.260 The presence of hyaline membrane formation and increased permeability
of the alveolar blood-air barrier is dependent on the presence of neutrophils, indicating that
inflammatory-mediated damage is required in addition to the injurious strain of mechanical
ventilation.261 One important consideration for the VILI model is that it involves the ventilation of
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healthy lungs, as opposed to lungs that are already injured or at high risk for injury, such as in
patients with pneumonia or sepsis.262, 263 Additionally, the VILI model is complex, requires
practiced technical skills for accurate reproducibility, and varies significantly based on the
ventilation modes used (e.g. pressure vs. volume modes, tidal volume and pressure levels, and
whether the use of PEEP is incorporated).258, 259, 263

2.2 The underlying role of dysregulated inflammation in ALI
Given that the large majority of risk factors for the development of ALI are conditions that cause
systemic inflammation, such as sepsis and trauma, it is natural to consider that maladaptive
inflammation is a likely culprit for the lung pathology of ALI. 6, 14, 264 Indeed clinical and basic
research have provided a breadth of insight demonstrating that triggering of the inflammatory
response is critical to ALI pathogenesis.264 The initial event leading to the onset of ALI is the
activation of the innate immune system. The resident cells in the lung that sense invasion of
microbes or respond to systemic inflammatory signals are the alveolar macrophages. 265 These
cells work to sense pathogen associated molecular patterns (PAMPs) and damage associated
molecular patterns (DAMPs) that may be present in the lung or in the blood from distant sites of
infection or injury, leading to the secretion of cytokines and chemokines that recruit
inflammatory monocytes and neutrophils to the lung. Together, these recruited inflammatory
cells secrete proteases, reactive oxygen species (ROS), eicosanoids, phospholipids, and
cytokines that further amplify inflammation and also have direct, tissue-damaging effects. 265 In
particular, injury to alveolar type II epithelial (ATII) cells leads to loss of surfactant production,
alveolar cell thickening and leakage of protein rich fluid into the airspace (hyaline membranes),
resulting in the pathological hallmark of ARDS, diffuse alveolar damage (DAD). 266, 267
Furthermore, dysregulated inflammation in ALI is exemplified through clinical studies
demonstrating that a prolonged inflammatory phenotype of invading monocytes, when
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compared with resolution-type phenotypes, is associated with protracted cases of ARDS. 268
Additional evidence for the critical role of inflammation in ALI pathogenesis is demonstrated by
elevated levels of inflammatory cytokines interleukin-1-beta (IL1β), tumor necrosis factor-alpha
(TNFα), interleukin-6 (IL6), and interleukin-8 (IL-8) measured in the BAL and plasma of ARDS
patients.269 Interestingly, there have also been measured humoral responses in ARDS patients:
it was found that 57% of ARDS patients have at least one significantly elevated autoantibody
either during or after the development of lung injury, though the implications of these findings
are not yet understood.270
Among the several recruited cell types found in the lungs of ARDS patients, neutrophils
are perhaps the most notorious cell for their role as effectors of inflammation and for causing
destructive tissue injury in a large number of organ pathologies. 271-273 Indeed, neutrophilic
inflammation is hallmark characteristic of DAD in ALI.274 Histologically, neutrophils accumulate
early in the pulmonary microvasculature during ARDS. 275 Furthermore, BAL samples also
support the high concentration of neutrophils in the alveolar airspace. 236 In addition to the
presence of neutrophils in the BAL of ARDS patients, it was found that the BAL also has a
profound chemoattractant activity to recruit neutrophils ex vivo, and that the extent of
neutrophils in BAL is correlative with worse clinical outcomes, supporting the idea that
neutrophil recruitment is a key event in disease pathophysiology.187, 276 Neutrophils collected
from ARDS patients are also phenotypically more inflammatory when compared to healthy
control patients. ARDS-associated neutrophils have increased expression of the inflammatory
marker CD11b, increased oxidative burst capacity, and delayed constitutive apoptosis (i.e. they
remain alive and performing tissue destructive activities for longer periods of time). 277, 278
Indeed, targeted approaches aimed at inducing selective apoptosis of neutrophils using
exogenous administration of interleukin-4 (IL4) have been demonstrated to be protective in a
pre-clinical model of ALI.237, 279 Altogether, excessive neutrophil effector functions are strongly
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associated with ALI severity and outcomes and their role in disease pathology builds upon the
picture that dysregulated inflammation is the key process leading to ALI.
In addition to neutrophils, monocytes and macrophages have also been found to be key
cell types that contribute to the inflammatory immunopathology of ALI. Peripheral monocytes
develop in the bone marrow, where they are released into the circulating blood and recruited to
sites of infection or tissue injury in response to cytokine and chemokine gradients. 280 Once
recruited into tissues, monocytes can differentiate into macrophages, amplify the immune
response by secreting inflammatory cytokines and chemokines, partake in phagocytosis of
pathogens and damaged tissues, and also play a role in tissue repair. 280 Experimental models
of ALI have revealed the importance of monocytes and macrophages for the initiation and
maintenance of inflammatory responses and that their activities, when excessive, contribute to
the lung pathology of ALI.281 Though macrophages and monocytes are critical for controlling
and neutralizing infections pathogens that invade the lung and alveolar airspace, infectious
models of viral- and fungal-related ALI have demonstrated that inflammatory monocytes and
macrophages were also responsible for detrimental bystander injury to the lung. 282-284 Similarly,
in non-infectious (sterile) models of ALI, including allergic rhinitis, asthma, mechanical
ventilation, intra-tracheal LPS, and intra-tracheal bleomycin models, recruited monocytes were
found to promote to injurious inflammation of the lung.285-288 The role of inflammatory
monocytes in the initiation and progression of ALI is further demonstrated by evidence
signifying that recruited monocyte apoptosis is a necessary step for the termination and
inflammation and for the recovery of ALI.289, 290 Janssen et al. showed that in mice with
monocytes that did not contain the cell death receptor, Fas, there was delayed resolution of ALI
in both viral pneumonia models and intra-tracheal LPS-induced ALI. 290 Furthermore, when
Dhaliwal et al. performed monocyte depletion using clodronate nanoparticles, genetic inducible
deletion, or antibody-mediated clearance in the intra-tracheal LPS-induced ALI mouse model,
they reported significant decreases in emigration of neutrophils and measures of ALI. 288 Taken
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together, pre-clinical evidence strongly support the notion that both neutrophils and monocytes
play an essential role in triggering immunopathology of the lungs that results in ALI.
Further convincing evidence for inflammation’s role in the pathogenesis of ALI is the
dependence on classical inflammatory cell-signaling pathways that are required for the
development of ALI in systemic inflammatory models. Several pre-clinical investigations have
revealed that Toll-like receptors (TLRs) are critical in the development of ALI. TLRs are an
evolutionary conserved part of the innate immune system that act as receptors to recognize
PAMPs (e.g. LPS, flagellin, and intracellular RNA/DNA) and DAMPs (e.g. hyaluronan,
mitochondrial DNA, and histones) to initiate intracellular inflammatory signaling events such as
the activation of mitogen-activated protein kinase pathways and activation of transcription
factors, namely interferon regulatory factors (IRFs) and nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB).291, 292 In a preclinical mouse-model of VILI, increased
levels of degraded hyaluronan, an extracellular matrix glycosaminoglycan, were found in the
lungs and plasma of mice and were responsible for the initiation of ALI through the recognition
by TLR2 and TLR4.293 Furthermore, elevated levels of hyaluronan degradation products were
also found in the plasma of ARDS patients.293 Similarly, mice with genetic deletion of TLR4
were protected from sepsis-induced models of ALI, which was demonstrated by reduced
pulmonary microvascular leakage, neutrophil recruitment, and cytokine and chemokine
production.294
Another critical mediator of inflammatory signaling in ALI is inflammasome signaling,
especially the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome. 295
The NLRP3 inflammasome is an intracellular sensor of both endogenous danger signals and
pathogen associated molecules that when assembled, leads to the activation of caspase-1.
Caspase-1 activity is necessary for the proteolytic cleavage and release of pro-IL-1β and proIL-18, which are both pro-inflammatory cytokines that contribute to inflammatory pathologies,
including ALI.296 In studies of models combining LPS- and mechanical ventilation- induced ALI,
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it was shown that the NLRP3 inflammasome was required for the development of acute lung
injury and hypoxemia.297 Lastly, in ARDS patients, NLRP3-regulated cytokines IL-1β and IL-18
where found to be associated with severity of ARDS.298
2.2.1 Endogenous mechanisms for the regulation of inflammation and their potential as
treatments for ALI
Given than inflammation is a critical driver for the pathogenesis of ARDS and ALI, there has
been an enthusiastic effort to investigate the mechanisms that are involved. Many molecular
pathways are currently under investigation that have the potential to modulate or limit the
inflammatory processes in pulmonary inflammation, and several have shown the potential to be
translated into clinical trials. In the next sections, some of these areas of active research are
highlighted with a few examples for potential treatments that target excessive lung
inflammation, which are unique in that current ARDS approaches are focused on ideal clinical
management and the prevention of iatrogenic injury, such as with protective ventilation. The
highlighted mechanisms include: hypoxia signaling, adenosine signaling, and the role of
microRNAs with examples of recent discoveries that contribute to the current wealth of
evidence for their protective effects. Studies have demonstrated that these mechanisms play
several important functions in controlling of alveolar inflammation through a number of
mechanisms such as the repression of pro-inflammatory pathways, the promotion of ALI
resolution, and the optimization of carbohydrate metabolism.
2.2.1.1 The role of Hypoxia Inducible Factors
“The power to destroy a thing is the absolute control over it.”
― Frank Herbert, Dune
Hypoxia (defined as oxygen tensions below the necessary level to sustain cellular functions in
organs or tissues) and inflammation are intimitely linked conditions that are frequently
encountered simultaneously in ARDS.299 Tissue hypoxia can occur during inflammation due to
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increased consumption of oxygen by activated immune cells and invading pathogens, while
hypoxia itself can induce inflammation, such as in hypoxic adipose tissue and in tumors. 299
Cells are able to sense and respond to hypoxia through the activation of Hypoxia-inducible
factors (HIFs), which are transcription factors that are stabilized and activated under hypoxic
conditoins (Figure 4). HIFs were first identified in 1991 as important transcription factors
leading to the production of hypoxia-induced erythropoietin. 300 Structurally, HIF works as a
heterodimer with two distinct subunits (HIF-α and HIF-β), which dimerize during conditions
such as hypoxia and inflammation.301, 302 HIF is regulated at the protein level, meaning that the
α subunit of HIF is constitutively transcribed and translated into protein, but is constantly
subjected to proteasome-dependent degradation under normoxic conditions. Oxygen sensing
is not directly performed by HIFs themselves, instead enzymes called prolyl hydroxylase
domain proteins (PHDs) act as oxygen sensors due to their requirement for molecular oxygen
needed to hydroxylate HIF-α subunits. Hydroxylated HIF-α subunits are recognized by VonHippel Lindau (VHL) protein tumor suppressors, which then conjugate ubiquitin proteins to HIFα, labeling it for targeted proteasomal degradation. 303, 304 When cells become hypoxic, the lack
of molecular oxygen renders PHDs inactive, preventing the hydroxylation and ultimate
degradation of HIF-α (stabilization of HIF-α). Before translocating to the nucleus and initiating
gene transcription, stabilized HIF-α dimerizes with a HIF-β subunit (Figure 4). 305 HIF-α/β
complexes activate hundreds of genes in the nucleus by recognition of the hypoxia response
element (5’-RTGCG-3’) in gene promoters.306, 307 Target genes of HIF are those that promote
adaptations to the hypoxic environment, such as anaerobic ATP production, increased
vasculogenesis, red blood cell production.302, 308, 309
Although the lung is a highly oxygenated organ, it has been shown that HIFs are
stabilized during ALI.190 Stabilization of HIFs during ALI is likely due to several mechanisms,
including local hypoxia resulting from pulmonary edema, the infiltration of immune cells with
high levels of oxygen consumption, and through the accumulation of intermediate molecules
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that act to inhibit PHDs, such as increased levels succinate. 190, 299, 310 Additionally, HIF can be
stabilized under normoxic conditions during acute lung injury. 311 For example, mechanical
stretch of alveolar epithelial cells results in the inhibition of succinate dehydrogenase (SDH)
activity, leading to the accumulation of intracellular succinate. Accumulated succinate acts to
directly inhibit PHD activity, leading to the stabilization of HIFs, even in the presence of
molecular oxygen.311, 312
Previous studies have shown that HIF is capable of regulating endogenous antiinflammation pathways in multiple inflammatory organ injuries, including ARDS. 311, 313, 314 For
example, HIF-1α stabilization in alveolar epithelial cells during models of VILI in vitro and in
vivo, has been shown to be protective for cellular and organism survival. 190, 315-318 These
findings were confirmed when HIF-1α deletion in alveolar-epithelial cells lead to increased
mortality in murine models of VILI.190 Mechanistically, HIF-1α-mediated lung protection in VILI
models was shown to be dependent on optimizing the glycolytic capacity and the reduction of
oxygen consumption in alveolar epithelial cells, mediated through the induction of HIF target
genes such as pyruvate dehydrogenase kinase 1 (PDK1) and glucose transporters GLUT1. 308,
319-321

As a result of the large amount of pre-clinical evidence demonstrating the protective role
of HIFs in acute organ injuries, therapeutic targeting of HIFs has gathered much attention.
Pharmacologic modulation of HIFs is achievable through both physiological and
pharmacological interventions. Physiological interventions include permissive hypoxia,
conservative oxygen administration for ventilated patients, and through the use of remote limb
ischemia to precondition surgical patients.65, 66, 120, 322-324 Pharmacological approaches to
stabilizing HIFs has been achieved with novel inhibitors of PHDs that enhance HIF signaling
without modulation of oxygen therapy.325, 326 In mice, pharmacologic stabilization of HIF by PHD
inhibition was found to be protective by reducing mortality and decreasing inflammation. 190
Several oral, small molecule PHD inhibitors have been developed: Roxadustat (FG-4592) by
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FibroGen, Astellas, & AstraZeneca, Vadadustat (AKB-6548) by Akebia, and Daprodustat (GSK1278863) by GlaxoSmithKline). Roxadustat has demonstrated significant efficacy in clinical
trials for anemia associated with chronic kidney disease. Oral administration was shown to be
safe and successfully enhanced HIF signaling, which was indicated by increased hemoglobin
levels.327, 328 Furthermore, the oral HIF activator, Vadadustat, is currently under investigation as
a therapy for the prevention and treatment of ARDS in hospitalized patients with COVID-19
(NCT04478071).
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Figure 4: Hypoxia Inducible Factor (HIF)-α stabilization in the Acute Respiratory Distress
Syndrome (ARDS) lung.
HIFα is a transcription factor that has two major isoforms (HIF1α and HIF2α) and that is
constitutively transcribed and translated.300 Under normoxic conditions, proline hydroxylases
(PHDs) use oxygen as a substrate to hydroxylate HIFα subunits, which targets them for
ubiquitination by Von Hippel Lindau (VHL) for downstream proteolysis. 303, 304 In conditions of
cellular hypoxia, such as in the inflamed ARDS lung,190, 299 PHDs are inactive due to lack of
oxygen substrate. HIFα isoforms dimerize with HIF1β (a constitutively expressed binding
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Figure 4 (Continued):
partner), which stabilizes them for translocation into the nucleus to induce gene transcription.
Target genes of HIF include those that provide adaptation to hypoxic conditions, such as
increasing glycolytic capacity and angiogenesis, and genes that contribute to the antiinflammatory and tissue-protective functions. 311, 313, 314 Indeed, pharmacologic HIF stabilization
is targeted by an emerging class of PHD inhibiting drugs that provide exciting potential for the
treatment of tissue inflammation during ARDS.325, 326
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2.2.1.2 The role of adenosine signaling
Adenosine is a purine nucleoside that is perhaps best known for its role as a building block for
DNA nuecleotides and as an energy carrier in the form of adenosine tri- and d-phosphate (ATP
and ADP). In addition to these well-known roles, adenosine also acts as a signaling molecule in
a wide array of biological processes.329, 330 Adenosine generation is first initiated by the
ezymatic conversion of ATP and ADP to adenosine monophosphate (AMP) via the extracellular
mebrane bound protein, CD39, and then further processed into adenosine by another
membrane bound enzyme, CD73 (Figure 5).331 Adenosine initiates lung-protective signaling by
interacting with one of its receptors that have been identified in multiple cell types such as
immune cells, endothelial cells and alveolar epithelial cells. 331-339 For example, deletion of the
A2B adenosine receptor (A2BAR) in alveolar epithelial cells results in worsened lung
inflammation and pulmonary edema in a mouse model of ALI that combines intratracheal
instillation of LPS and injurious mechanical ventilation. 316 A2BAR has also shown a protective
role in models of hemorrhagic shock-induced lung injury.340 Exogenous administration of
adenosine and a non-selective agonist of adenosine receptors, 5′-(N-Ethylcarboxamido)
adenosine have been shown to promote endothelial barrier function in vitro, while
pharmacologic antagonism or genetic deletion of A2AAR/A2BAR diminished this effect. 341 In
contrast to the largely benficial roles of adenosine during acute injury states, chronic and
sustained elevation of adenosine can lead to tissue injury, fibrosis, and chronic pain via
mechanisms that include IL-6 and soluble IL-6 receptors.342-344
Adenosine can be targeted therapeutically via multiple strategies. Several preclinical
studies have indicated that direct administration of adenosine attenuates lung injury. 345, 346
Furthermore, adenosine administration has been safely demonstrated in previous clinical
studies.347, 348 For instance, a phase 3 trial published by Garcia-Dorado et al. recruited patients
to investigate the impact of intracoronary adenosine treatment immediately before re46

vascularization and within six hours of ST-elevation myocardial infarction (STEMI). 347 Although
the study did not show a clinical benefit for adenosine treatment in terms of reducing infarct
sizes, patients receiving adenosine showed a modest improvement in myocardial salvage and
left ventricular failure evolution. A challenge to utilizing adenosine is that it has a relatively short
half-life in vivo. Alternative methods to targeting adenosine is through the use of adenosine
analogs or inhibitors of adenine deaminase, which are responsible for the metabolism of
adenosine. Furthermore, using selective adenosine receptor agonists could also serve as
feasible approach to harnessing adenosine signaling as a therapy. Previous studies in animal
models demonstrated the protective role of BAY 60-6583, an A2BAR agonist, in ALI models. 340,
349

Unfortunately, the efficacy and safety of these types of agonists have not yet been recorded

in clinical studies. Finally, a third modality to target adenosine signaling is to use HIF activators,
which are discussed in the previous section. As a direct transcriptional target of HIF-1α, A2BAR
levels can be enhanced through the stabilization and activation of HIF-1α. 315 Additionally,
extended use of therapeutic adenosine could potentially increase the risk for development of
chronic lung disease such as fibrosis, given the face that sustained adenosine has been shown
to lead to have detrimental effects.342-344
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Figure 5: Adenosine signaling during inflammation.
The precursor to adenosine, Adenosine tri- and di-phosphate (ATP/ADP), is released into the
extracellular space by activated or dying cells.331 ATP is then converted to adenosine
monophosphate (AMP) by membrane-bound ecto-nucleoside, CD39, and then subsequently
into adenosine by the membrane-bound nucleotidase, CD73. 331 Once formed, extracellular
adenosine plays several anti-inflammatory roles on numerous tissue compartments by
interacting with surface A2A and A2B adenosine receptors (A2AAR/A2BAR). 331-339
Adenosine acts on epithelial and endothelial cells to promote barrier integrity and decrease
inflammation.341 Adenosine also acts on immune cells to dampen inflammatory activity.
Negative regulation of adenosine signaling occurs through re-uptake by equilibrative
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Figure 5 (Continued):
nucleoside transporters 1 and 2 (ENT1/2), which results in the intracellular metabolism of
adenosine by adenosine kinase or deaminase.341 During hypoxic conditions, HIF-stabilization
further promotes adenosine signaling by inducing expression of CD73 and repressing the
expression of ENT1/2.317, 318
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2.2.1.3 The role of microRNAs

MicroRNAs (miRNAs) are members of the non-coding RNA family (i.e. they are nuclear coded
genes whose transcripts aren’t translated into proteins). miRNAs are initially transcribed as
primary transcripts that can be several kilobases long (sometimes they are located inside of
gene introns or exons) and are then enzymatically cleaved in a two-step process into
approximately 22-25 nucleotides in length.350 miRNAs were initially discovered in the worm,
Caenorhabditis elegans, but have since been found in the genomes of essentially all animal
species, inculding mammals.351-353 In the most recent miRBase database (an online library of
known miRNAs, http://www.mirbase.org/), there were more than 2,500 miRNAs recorded in
humans. miRNAs work to regulate gene expression by inhibiting the translation of mRNA
targets via binding to specific sites in the 3’-untranslated region (UTR).350 Furthermore, miRNAs
are capable of targeting multiple mRNAs at once and mRNAs can contain multiple sites in their
3’UTRs allowing them to be targeted by multiple miRNAs. In this way, individual miRNAs can
regulate several biological pathways at multiple levels. It is hypothesized that more than half of
the human genome is regulated by miRNAs.354 Indeed, leveraging miRNAs as a therapeutic
approach for a number of diseases is under intense investigation. 355 miRNAs have also been
described to have important roles in regulating inflammation during ALI. 356 One such miRNA is
miR-155. Upon pulmonary infection or intratracheal instillation of LPS in mice, miR-155 is
highly upregulated in the lungs.357-359. Mechanistically, miR-155 plays an important role in
promoting inflammation by targeting suppressor of cytokine signaling-1 (SOCS-1), an important
negative regulator in inflammatory signaling. Genetic deletion of miR-155 in mice results in
attenuated lung inflammation and injury during Staphylococcal enterotoxin B-induced and LPSinduced ALI models, suggesting that blocking miR-155 could be a potential therapeutic for
ALI.358, 359 Another well-studied miRNA in the context of inflammation is miR-223. 360 In a study
by Neudecker et al. it was demonstrated that miR-223 is shuttled in microparticules that
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originate from neutrophils into alveolar epithelial cells that served to attenuate lung
inflammation in mouse models of VILI.174 When miR-223 was deleted in mice, they experienced
increased lung inflammation and edema when compared to wildtype mice after exposure to
VILI. In addition to being more succeptible to VILI, miR-223 knock-out mice also showed
increased inflammation and mortality during Staphylococcus aureus pneumonia models.174
Taken together, these studies are examples for how miRNAs can potentially be therapeutic
targets for ALI.
Logistically, pharmacologic modulation of miRNA activity can be achieved through
several strategies. These methods include administering synthetically created miRNA mimics
to enhance function, anti-sense miRNA inhibitors to block miRNAs and small molecule drugs to
up- or down-regulate specific miRNA expression. For example, in murine models of ALI,
nanoparticle-packaged miR-223 mimics were effective at attenuating lung inflammation and
injury when injected intravenously during murine VILI vili.174 Furthermore, clinical trials have
demonstrated that miRNA mimics can be safely and effectively utilized in human disease. The
intradermal injection of Remlarsen (MRG-201), a miR-29 mimic, is being evaluated by two
clinical trials in patients with keloid lesions (NCT02603224 and NCT03601052). Cobomarsen
(MRG-106), a miR-155 inhibitor, is being evaluated by phase 2 clinical trials for patients with
cutaneous T-cell lymphoma (NCT03713320 and NCT03837457). Small molecule drugs are
another promising therapeutic strategy to modify miRNA functions in patients. ABX464, from
Abivax S.A., works by promoting the splicing of non-coding RNAs to promote the expression of
miR-124, which is an anti-inflammatory miRNA and is being investigated as a treatment for
inflammatory conditions such as inflammatory bowel diseases and rheumatoid arthritis
(NCT02735863, NCT03760003, and NCT03813199).361 In an exciting next step, ABX464 is
now being investigated as a therapeutic for COVID-19 in hopes of dampening lung
inflammation and preventing the development of acute respiratory distress syndrome in
hospitalized patients (NCT04393038).
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2.3 Conclusion: The therapeutic potential for regulating inflammation of ARDS
Inflammation in the lung triggered by local (i.e. bacteria, aspirated contents, etc.) or systemic
(i.e. sepsis, trauma, multiple transfusion, etc.) cues is well accepted as the key driver for both
the initiation and progression of ALI. The immune-inflammatory pathology of ALI is multifaceted
and involves many immune-cell types, a myriad of cytokines and chemokines, effector
enzymes and molecules that directly induce tissue injury, and a complex web of cellular
signaling pathways. As such, there is a great deal of knowledge still to be attained in
understanding how exactly all these mediators function and contribute to lung pathology.
Advancing our comprehension for the mechanisms that govern the pathophysiology of ALI is a
critical step in identifying novel treatment approaches and for the improvement of
prognostication and personalization of management approaches for ARDS patients.
Though there are many molecular and cellular components involved in ALI
pathogenesis, the complex nature of the disease also implies that there is potentially a large
number of novel treatment approaches to be discovered. As stated in the previous sections,
there is already an expanding breadth of insights into how different cell types and molecular
pathways contribute to ALI with several demonstrations of how they might be harnessed to
promote the resolution of ALI. In this dissertation, I present work that resulted from our efforts
to identify novel endogenous mechanisms that lead to the regulation of inflammation or the
promotion of resolution during experimental models of ALI. While detailing new pathways that
regulate inflammatory functions during ALI, I also present work that suggests these findings are
targetable as treatment approaches and may lay the foundation for future translational research
in clinical ARDS.
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General methods and materials
The purpose of this section is to list the methods and materials that are common to both
Chapter 3 and Chapter 4, in an effort to minimize the length of the dissertation and the need to
duplicate the content in both chapters.
Isolation of human monocyte-derived macrophages (hMDMs). A protocol for the collection
of blood from healthy donors was approved by the UTHealth Institutional Review Board and
participants provided consent prior to collection. A 60 mL was pre-loaded with 10mL of citratedextrose buffer (Sigma-Aldrich), and then used to obtain 50 mL of blood by venipuncture. Next,
the blood was centrifuged for 10 minutes at 400g. Centrifuge steps were all performed at 4 ℃.
The plasma supernatant was separated into two clean tubes and then centrifuged for 10
minutes at 400g. The cell pellets were then added back into previously centrifuged blood along
with 20 ml of 3% dextran in normal saline and then allowed to incubate at room temperature for
40 minutes to promote sedimentation. After sedimentation, the upper layer was then moved
into new conical tubes and filled to the top with HBSS (ThermoFisher, Waltham, MA) and
subsequently centrifuged at for 10 minutes at 400g. Red-blood cell lysis was then performed
using a Lysis Solution (Miltenyi Biotec, US) and then centrifuged at for 10 minutes at 400g. The
cell pellet was then re-suspended in 2.5 mL of HBSS(-) +25mM HEPES + 1mM EDTA and
delicately added on top of 10 mL of Ficoll-Paque PLUS (GE Healthcare, Sweden) and then
centrifuged for 30 minutes at 700g with no brake. The interphase peripheral blood mononuclear
cells (PBMCs) were pipetted into two tubes and washed twice with cold HBSS(-)+25mM
HEPES+10% FCS. To differentiate PBMCs into hMDMs, we cultured PBMCs for 7 days in
macrophage differentiation media (RPMI 1640 supplemented with 10% heat inactivated fetal
bovine serum and 10 ng/mL recombinant human M-CSF (R&D, Minneapolis, MN)).
Lipopolysaccharide (LPS, Sigma-Aldrich) stimulation was done using a concentration of 1
μg/mL in macrophage differentiation media.
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RNA isolation, reverse transcription, and quantitative PCR. Isolation of RNA was achieved
using a Trizol Reagent extraction method according to the protocol provided by the
manufacturer (QIAzol Lysis Reagent, Qiagen). RNA concentrations were assessed with a
BioTek Cytation 5 Take3 plate (Winooski, VT, USA). Reverse transcription was done using the
Thermo Fisher Applied Biosystems High Capacity Reverse Transcription Kit on a Bio-Rad T100
thermal cycler (Hercules, CA, USA). Quantitative PCR was performed using TaqMan probes
with the TaqMan Universal PCR Master Mix (ThermoFisher) on a Bio-Rad real-time PCR
system
LPS-induced acute lung injury in mice. Acute lung injury (ALI) was modeled in mice aged 810 weeks old. Mice were anesthetized using an intraperitoneal injection of 70 mg/kg of
pentobarbital. Intra-tracheal access was acquired utilizing the BioLite Intubation System
(Braintree Scientific, Inc., Braintree, MA). Lipopolysaccharide (LPS, Sigma Aldrich, Escherichia
coli O111:B4, Cat# L4391) was injected into lungs at a dose of 3.75ug/g. PBS was used for
vehicle controls. Daily recording of mouse weights was performed. Humane euthanasia was
performed when mice had two consecutive days of 25% or more weight loss, were unable to
consume food or water, or had gross moribund appearance. Euthanasia was performed using
pentobarbital overdose (250 mg/kg) (Socumb, animal NDC Code: 11695-4836-5, Henry Schein
Animal Health, Melville, NY) and subsequent exsanguination. Bronchoalveolar lavage (BAL)
was obtained with three 500 uL washes using ice-cold PBS. BAL cell densities were counted
on a hemocytometer. 50 uL of BAL cells were spun onto glass slides with a Rotofix 32A
centrifuge (Hettich, Tuttlingen, Germany). Slides were then stained using the Hema3 Stat Pack
(Fisher Scientific, Waltham MA) and relative amounts of neutrophils were manually counted
using light microscopy. The remaining BAL cells were centrifuged for 5 minutes at 300g. The
resulting supernatant fluid (BAL Fluid) and cell pellets were separated into different tubes and
flash frozen. 10 mL of pre-chilled PBS was injected into the right ventricle to perfuse the mouse
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lungs and then the right lobes were excised and snap-frozen and the left upper lobe was
inflated using 20 cmH2O hydrostatic pressure of 10% formalin, then placed into 10% formalin.
Western blot. Specific information for the antibodies used in this work is listed in table 2.
Protein extraction was performed using RIPA Buffer (ThermoFisher, cat.# 89900) with freshly
added phosphatase and protease inhibitors (New England Biolabs). For Hif-1α and Hif-2α
Western blots, the NE-PER Nuclear and Cytoplasmic Extraction kit (ThermoScientific, Cat#
78835) was used with 60 mg of lung tissue to extract nuclear protein. Protein quantification was
performed using a BCA method. Gel electrophoresis was followed by blocking of membranes
for 1 hour at room temperature with 5% skim milk in PBS containing 0.1% tween. Primary
antibodies were incubated with membranes overnight at 4°C. After subsequent incubation with
HRP-conjugated secondary antibodies, chemiluminescence was captured on a Bio-Rad
ChemiDoc Touch Imaging System. ImageJ software (National Institutes of Health) was used for
protein quantification.
Hematoxylin and eosin staining of lung tissue and ALI scoring. Lungs were fixed in 10%
formalin for 24-48 hours and then processed with a Leica TP1020 Semi-enclosed Benchtop
Tissue Processor (Leica Camera, Wetzlar, Germany). Five-micrometer thick lung sections were
stained with hematoxylin & eosin and then analyzed in a blinded fashion by a pathologist to
asses for acute lung injury magnitude using a scoring system. Acute lung injury scoring was
based on a previously described protocol with minor modification (0 = no injury; 1 = injury to
25% =; 2= injury to 50%; 3 = injury to 75%; and 4 = diffuse injury).362 Four categories of injury
were assessed for separately on each lung section: (1) atelectasis; (2) cellularity; (3) alveolar
wall thickening; (4) and alveolar over-distention. The total score was calculated as the sum of
all the individual injury categories.
Measurements of BAL fluid cytokines, chemokines, and albumin. BAL fluid levels of Il-1β
(R&D Systems, Cat# DY401), Tnf-α (R&D Systems, Cat# DY410), Il-6 (BD Biosciences, Cat#
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550950), and albumin (Bethyl Laboratories, Cat# E99-134) were measured using enzymelinked immunosorbent assays (ELISA) according the manufacture’s protocols.
days after the onset of LPS-induced ALI using 5 ug doses.
Transcriptomic profiling of BAL cells. BAL cells were collected from mice three days after
the onset of ALI. After red blood cell lysis, neutrophil deletion was performed using a magnetic
antibody-mediated positive selection method utilizingng the MojoSort Mouse Ly-6g Selection
Kit (BioLegend) and subsequent RNA was isolated (RNeasy Mini Kit, Qiagen, Cat#: 74104).
RNA-sequencing was done at the UTHealth CPRIT Cancer Genomics Core. Libraries were
generated with the KAPA mRNA Hyper Prep Kit (KK8581, Roche Holding AG, Switzerland).
Pooled libraries underwent 75-cycle paired-end sequencing on the Illumina NextSeq 550
System (Illumina, Inc., USA) using the High Output Kit v2.5 (#20024907, Illumina, Inc., USA).
Bases with quality scores less than 20 and adapter sequences were removed from raw data
using Cutadapt (v1.15),363 followed by alignment to GRCm38 with STAR (v2.5.3a)364. Transcript
abundance was quantified with HTseq-count uniquely-mapped reads number using default
settings on GencodeM15. Transcripts with more than 5 reads in at least one sample were
included in subsequent differential expression analysis using DESeq2. 365 The P-values were
adjusted using Benjamini and Hochberg’s methods366 to account for false discovery rates
(FDR). Transcripts with fold change > 2 and FDR < 0.05 were considered differentially
expressed genes.
Chromatin immunoprecipitation-quantitative PCR. Human monocytye-derived
macrophages (hMDMs) were treated with LPS for eight hours prior to cross-linking with a 1%
methanol-free formaldehyde solution (ThermoFisher Scientific) for 8 minutes at room
temperature. The formaldehyde was quenched with 140 mM glycine. Nuclei isolation was
performed using lysis buffer I (50 mM HEPES-KOH pH 7.5, 10% glycerol, 1 mM EDTA, 140
mM NaCl, 0.5% NP-40, 1 mM PMSF, 0.25% Triton X-100, 1 μg/ml leupeptin, and 1X PIC) for
10 minutes with rotation at 4˚C. Washing of nuclei was performed with lysis buffer II (10 mM
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Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1 mM PMSF, and 1X PIC for 10
minutes with rotation at 4˚C. Shearing of nuclei was performed in lysis buffer III (10mM Tris-HCl
pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.5% sarkosyl, 1 mM PMSF, and 1X PIC)
using 30 second cycles for eight minutes on a S220 focused-ultrasonicator (Covaris, Woburn,
MA). Next, protein A/G UltraLink Resin (ThermoScientific) was to pre-clear samples at 4˚C with
rotation for one hour. 10% of the lysate was set aside to be used as the input sample, while
primary antibodies, isotype control IgG (Cat#: ab171870, Abcam) and HIF-1α (clone: D2U3T,
Cell Signaling Technology), were added to separate 45% aliquots of the remaining lysate and
allowed to incubate overnight with rotation at 4˚C. The next day, antibody containing lysates
were mixed with A/G UltraLink resin and then allowed to incubate while rotating at 4˚C for 4
hours. The bead-conjugated antibody mixes were washed twice with high salt buffer (20 mM
Tris-HCl pH7.5, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 1 mM PMSF, and 1X PIC), then
twice with a LiCl buffer (20 mM Tris-HCl pH 7.5, 250 mM LiCl, 2 mM EDTA, 0.5% NP-40, 1 mM
PMSF, and 1X PIC), and then lastly washed once more with TE buffer (10 mM Tris-HCl pH7.5,
1 mM EDTA, and 1X PIC). Conjugates were then re-suspended in 100 ul of elution buffer (10
mM Tris-HCl pH 7.5, 5 mM EDTA, and 0.5% sodium dodecyl sulfate), and incubated for 15
hours at 65˚C in order to reverse cross-link transcription factors from DNA. The transcription
factor-enriched chromatin and 10% input samples were purified using the Qiagen PCR
purification kit (Qiagen). The enrichment of ChIP was measured using qPCR. Primers flanking
the promoter regions were designed (primers described in chapters 3 and 4). SYBR green
supermix (Qiagen) was used to perform ChIP-qPCR. The following PCR cycling conditions
were used: 1) 95°C for 15 minutes, 2) 35 cycles of 94°C for 15 seconds, 3) 60°C for 30
seconds, 4) and then 72°C for 30 seconds. Fold-enrichment was determined by calculating the
ratio of HIF-1α-enriched signals compared to input and then normalize them to isotype control
IgG-enriched signals.
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Statistical analysis. Data was analyzed using GraphPad Prism (version 7, San Diego, CA).
Data are presented as mean and standard deviation (SD). We tested the normality of data
using Shapiro-Wilk tests. F tests and Brown-Forsythe tests were used to assess for equal
variances. We used unpaired t tests to compare means when the equal-variance assumption
held and the data were found to be normal. Welch’s t tests were used in normal data when
variances were found to be significantly different. Mann-Whitney tests were used to compare
medians when the data from two groups contained significantly different dispersions and
locations. One-way ANOVA tests were performed for K-sample settings and the two-way
ANOVA tests were used for experimental data containing two factors. P values were corrected
by using the Dunnett method when comparisons were to a control group, the Bonferroni
method in all other data sets, and the false discovery rate (FDR) method for genomic screens.
For survival curve data, the Kaplan-Meier method was utilized to determine survival
probabilities and a log-rank test was performed to assess survival outcomes. We considered Pvalues less than 0.05 to be statistically significant.
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Chapter 3: The role of miR-147 in the regulation of inflammation during ALI
3.1 Introduction
Acute lung injuries (ALI), including the acute respiratory distress syndrome (ARDS), are
devastating conditions defined by the rapid onset of pulmonary edema and hypoxemia and are
a leading cause of death in critically-ill patients.3-6 Etiologies for ALI include pneumonia, sepsis
and trauma, which are related in that they trigger potent systemic inflammatory responses. 12
Indeed, ALI is initiated by the activation of resident macrophages in the lung that amplify
pulmonary inflammation via the recruitment of peripheral immune cells, such as proinflammatory neutrophils and monocytes.13, 14 In an appropriate response to infection or tissue
injury, pulmonary inflammation achieves a necessary intensity and duration so that an infection
is cleared or an injury is resolved, without causing harm to the lung parenchyma itself.
However, during ALI, inflammation becomes dysregulated and results in injury to the alveoli,
leading to a breakdown in the alveolar-capillary barrier with subsequent accumulation of
pulmonary edema and hypoxemia.14 Targeting inflammation during ALI is a critical area for
ongoing research for novel treatment approaches.
MicroRNAs (miRNAs) are a class of non-coding RNAs that are ~22 nucleotides in
length and function as negative regulators of gene expression by blocking the translation of
mRNA transcripts into protein.350-353 A growing body of evidence suggests that miRNAs partake
in critical roles in controlling inflammatory processes in a large number of different organ
injuries, including ALI.356 For instance, in a murine model of ventilation induced lung injury,
miR-223 is transferred from infiltrating neutrophils into alveolar epithelial cells where it
dampens inflammation by repressing poly(adenosine diphosphate-ribose) polymerase–1
(PARP-1).174 Furthermore, miR-223 could be exogenously over-expressed in mice in order to
therapeutically dampen pulmonary inflammation. However, most studies have focused on
miRNAs during the onset of ALI, which does not address the challenge that ALI and ARDS are
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not recognized until after a lung injury is established.367-374 To better our efforts in identifying
novel miRNA-based treatment approaches that reverse inflammation and resolve lung function
after ALI has already occurred, it is important to study the role of miRNAs during the period of
time when lung injury is fully established.
In this work, we screened for miRNAs that were expressed after the onset of ALI in
order to interrogate their ability their abilities to reverse lung injury. Our studies identified that
miR-147 is significantly expressed in recruited pulmonary macrophages during the recoveryphase of ALI. Furthermore, we demonstrate that miR-147 functioned by modulating the
accumulation of succinate within cells that, in turn, down-regulated inflammation by promoting
the epigenetic silencing of pro-inflammatory genes.
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3.2 Materials and Methods
Mouse Strains. Wild type (C57BL/6J), Hif1αloxp/loxp,375 Hif2αloxp/loxp,376 FVB.129S6Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J (ODD-Luc),377 and LysM Cre378 mice were purchased from
Jackson Laboratory. miR147-/- and miR147loxp/loxp mice were generated as previously
described.379 Mice were kept in a pathogen-free breeding facility at the Center for Laboratory
Animal Medicine and Care at the University of Texas Health Science Center at Houston
(UTHealth). Approved was granted by the UTHealth Institutional Animal Care and Use
Committee for all mouse protocols utilized in this work. To account for sex as a biological
variable, we performed experiments with equal numbers of male and female, age and weightmatched mice throughout all groups.
Generation of miR147loxp/loxp LysM Cre, Hif1αloxp/loxp LysM Cre, Hif2αloxp/loxp LysM Cre, and
B6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J (B6.ODD-Luc) mice. Myeloid-cell specific genetic
knockout mice were generated by crossing LysM Cre mice with miR147loxp/lox, Hif1αloxp/loxp and
Hif2αloxp/loxp mice. Efficiency of knockout in miR147loxp/loxp LysM Cre mice was measured by
performing RT-qPCR miR-147 transcript expression in bronchoalveolar lavage (BAL) cells of
intra-tracheal LPS-treated mice. Hif1αloxp/loxp LysM Cre and Hif2αloxp/loxp LysM Cre mice have
been previously genotyped and characterized.380, 381 B6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J
(B6.ODD-Luc) mice were generated by crossing FVB.129S6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J
(ODD-Luc) with C57BL/6 mice for at least six generations.
Cells. All cells were kept at 37 ℃ and 5 % CO2 in humidified incubators. Bone marrow-derived
macrophages (BMDMs) from mice were harvested according to previously described
protocols.382 In short, bone marrow cells were incubated in RPMI containing 10 % heat
inactivated fetal calf serum (FCS) and 1% antibiotic/antimycotic mix with 10 ng/mL of M-CSF
(R&D Systems, cat# 416-ML) for 6 days, with fresh media added on day 3. HEK-293 cells were
purchased from ATCC (CRL-1573) and cultured in DMEM containing 10 % heat inactivated
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fetal calf serum (FCS) and 1% antibiotic/antimycotic mix. HEK-293 cells were sub-cultured 1:6
when they reached 90 % confluency.
CRISPR-mediated deletion of NDUFA4 in THP-1 cells, as well as control THP-1 cells
generated with non-gene-targeting guide RNA, was performed by Synthego (Redwood, CA).
CRISPR editing efficiency was determined by the Inference of CRISPR Edits (ICE) tool, which
demonstrated 95 % CRISPR editing efficiency.383 Knockout efficiency was verified with
Western blot analysis for NDUFA4 expression. THP-1 cells were cultured in RPMI containing
10 % heat inactivated fetal calf serum (FCS) and 1% antibiotic/antimycotic mix. To differentiate
THP-1 cells into macrophage-like cells, cells were incubated in media contiaing phorbol 12myristate 13-acetate (PMA) at a concentration of 100 nM for 24 hours. The next day, the media
was replaced and cells were incubated for another 24 hours. Experiments were carried out the
next day (48 total hours after starting differentiation).
Quantitative PCR. Specific probe information is listed in table 1.
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Table 1: PCR probes used for Chapter 3.
Target Gene
Vendor / Source
hsa-miR-16 (TaqMan Probe)
ThermoFisher
hsa-miR-147b (TaqMan Probe)
ThermoFisher
hsa-miR-155 (TaqMan Probe)
ThermoFisher
hsa-miR-195 (TaqMan Probe)
ThermoFisher
hsa-miR-27b (TaqMan Probe)
ThermoFisher
hsa-miR-223* (TaqMan Probe)
ThermoFisher
AA467197 (Mouse Nmes1) (Taqman Probe) ThermoFisher
pre-miR-147 (Mouse) (Taqman Probe)
ThermoFisher
IL6 (Human)
ThermoFisher
Il6 (Mouse)
ThermoFisher
TNFA (Human)
ThermoFisher
Tnfa (Mouse)
ThermoFisher
IL1B (Human)
ThermoFisher
Il1b (Mouse)
ThermoFisher

Catalog Number
4427975-000391
4427975-002262
4427975-002623
4427975-000494
4427975-000409
4427975-002098
4351372-Mm01268692_m1
4427012-Mm03308429_pri
4331182-Hs00174131_m1
4331182-Mm00446190_m1
4331182-Hs00174128_m1
4331182-Mm00443258_m1
4331182-Hs01555410_m1
4331182-Mm00434228_m1
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MicroRNA microarray. Screening for up-regulated was performed using RNA isolated from
mouse lungs three days after the onset of ALI. To analyze all current mature miRNA
sequences provided in miRBase Release 20, we used the Affymetrix GeneChip miRNA 4.0.
Data analysis was carried out using Transcriptome analysis Console (TAC) Software (Applied
Biosystems). MicroRNAs with differential expression associated with an false discovery rate of
less than 0.05 were considered to be significant.
In vivo locked nucleic acid miRNA antagomir (LNA) treatments. LNAs targeting miR-147
and scrambled controls were purchased from Qiagen using the miRCURY LNA miRNA
Inhibitor platform. Stock solutions of LNAs were re-suspended at a concentration of 50 mg/mL
in sterile normal saline. One day prior to intra-tracheal LPS instillation, mice were given a 50 ul
of LNA solutions intra-tracheally. On the day of delivering intra-tracheal LPS, LNAs were added
the LPS solutions at a concentration of 50 mg/mL. For each day after intra-tracheal LPS
instillation, mice were given a 50 uL intraperitoneal injection of stock LNA solutions.
Western blot. Specific information for the antibodies used in this work is listed in table 2.

64

Table 2: Antibodies used in Chapter 3.
Target antigen / Protein
Vendor / Source Catalog Number Working Concentration
Anti-mouse CD16/CD32
BioLegend
101301
Flow Cytometry 1:100
Anti-mouse AF488-B220
BioLegend
103228
Flow Cytometry 1:100
Anti-mouse FITC-CD3
BioLegend
100203
Flow Cytometry 1:100
Anti-mouse APC/Cyanine7-Ly6G
BioLegend
127623
Flow Cytometry 1:100
Anti-mouse PB-CD11b
BioLegend
101223
Flow Cytometry 1:100
Anti-mouse PE-CD11c
BioLegend
117307
Flow Cytometry 1:100
HIF-1α (D2U3T)
Cell Signaling
14179
Western Blot 1:1000
HIF-2α Polyclonal
Novus Biologicals
NB100-122
Western Blot 1:1000
TATA-binding protein (TBP)(D5G7Y)
Cell Signaling
12578
Western Blot 1:2000
NDUFA4 polyclonal
Invitrogen
PA5-50068
Western Blot 1:1000
β-Actin (C4)
Santa Cruz
sc-47778
Western Blot 1:2000
Phospho-NF-κB p65 (Ser536) (93H1)
Cell Signaling
3033
Western Blot 1:1000
NF-κB p65 (D14E12)
Cell Signaling
8242
Western Blot 1:1000
IκBα (L35A5)
Cell Signaling
4814
Western Blot 1:1000
Phospho-IκBα (Ser32) (14D4)
Cell Signaling
2859
Western Blot 1:1000
IRF-3 (D83B9)
Cell Signaling
4302
Western Blot 1:1000
Phospho-IRF-3 (Ser396) (4D4G)
Cell Signaling
4947
Western Blot 1:1000
Tri-Methyl-Histone H3 (Lys4) (C42D8)
Cell Signaling
9751
Western Blot 1:1000
Tri-Methyl-Histone H3 (Lys9) (D4W1U)
Cell Signaling
13969
Western Blot 1:1000
Tri-Methyl-Histone H3 (Lys27) (C36B11) Cell Signaling
9733
Western Blot 1:1000
Histone H3 (D1H2)
Cell Signaling
4499
Western Blot 1:1000
Anti-rabbit IgG, HRP-linked
Cell Signaling
7074
Western Blot 1:2000
Anti-mouse IgG, HRP-linked
Cell Signaling
7076
Western Blot 1:2000
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Lung imaging for luciferase bioluminescence. B6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J (B6.ODDLuc) mice were instilled with intra-tracheal LPS. On days 1, 3, 5, and 7 after the onset of ALI,
B6.ODD-Luc mice were anesthetized with isoflurane (Henry Schein) and then administered 25
mg/kg D-luciferin diluted in sterile normal saline (Sigma, cat# L9504). Five minutes later, mice
were euthanized with pentobarbital overdoes, lungs were excised and then imaged with an
IVIS Lumina III Series (PerkinElmer). PBS treated mice were collected in parallel each day in
order to have equal exposure-time controls. Fold change in luciferase activity was normalized
to PBS control signals.
Lung digestion and CD45 enrichment. Three days after the onset of LPS-induced ALI, mice
were euthanized and excised lungs were cut into small (0.2 to 0.4 cm) pieces and allowed to
incubate with 2 mL of pre-warmed Dispase (Stemcell Technologies, cat# 07923) at 37 ℃ for
one hour. Next lungs were ground through a 40 uM cell strainer into a 50 mL conical tube. Cells
were then centrifuged at 300g for 5 minutes and treated with red blood cell lysis buffer (Miltenyi
Biotec, US). After red blood cell lysis, CD45+ cell enrichment was performed using MojoSort
magnetic beads (BioLegend, Cat# 480027). RNA was isolated from both CD45+ and CD45fractions for downstream qPCR.
Fluorescence activated cell sorting (FACS). BAL from three mice was pooled into a single
sample. After collection red blood cell lysis was performed using Lysis Buffer (Miltenyi Biotec,
US) and cells were pelleted and then re-suspended in FACS buffer (PBS + 1 % heat
inactivated FCS). Blocking with anti-mouse CD16/32 Antibody (Clone 93, BioLegend, San
Diego) was performed on ice for 10 minutes. Next, incubation with fluorophore conjugated
antibodies (BioLegend) targeting B220-AF488 (Cat# 103228), CD3-FITC (Cat# 100203), Ly6GAPC/Cyanine7 (Cat# 127623), CD11b-Pacific Blue (Cat# 101223), and CD11c-PE (Cat#
117307) was carried out on ice for 30 minutes. After two washes with FACS buffer, cells were
sorted using a BD FACS Aria II (BD BioSciences) directly into tubes containing Trizol LS
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Reagent (ThermoFisher, Cat# 10296028). RNA isolation from sorted cells was performed using
the RNeasy Mini Kit (Qiagen, Cat#: 74104).
In vivo microRNA mimic treatments. miR-147 or scrambled mimic miRNAs (miRIDIAN
microRNA mimics, Horizon Discovery Biosciences, Cambridge, UK) were incorporated into dioleoyl-phosphatidylcholine (DOPC) liposomes according to a previously described method. 384,
385

DOPC and miRNA were combined in tertiary butanol in excess at a ratio of 1:10 (w/w)

miRNA:DOPC. Then, Tween 20 was added at a ratio of 19:1 miRNA/DOPC mixture : Tween
20. After vortexing, the mixture was frozen in acetone chilled with dry ice and then lyophilized.
Prior to intravenous injections, lyophilized preparations were hydrated in sterile normal saline at
a concentration of 100 ug/mL. Intravenous injections of miRNA were performed two and four
Clodronate-mediated depletion of peripheral monocytes. Clodronate liposomes (5 mg/mL)
and PBS control liposomes were purchased from Liposoma BV (Amsterdam, The Netherlands).
24 hours prior and 24 hours after intra-tracheal instillation of LPS, mice were given a 100 uL
intravenous injection of clodronate or PBS liposomes.
Antibody-mediated depletion of PMNs. For PMN depletion, mice were treated with
intraperitoneal injections of 1 mg anti-mouse Ly6G (clone 1A8, cat# BE0075-1) or IgG control
(clone 2A3, Cat# BE0089) one day before and one day after intra-tracheal LPS instillation. Both
antibodies were purchased from BioXCell (Lebanon, NH).
Chromatin immunoprecipitation-quantitative PCR. Primers flanking the promoter region of
the NMES1 gene were used for qPCR (Forward: ACAGAGGGGTGCAGACAGAA, Reverse:
ACTCAGAGAGGCTCTGGTCA).
3’ UTR luciferase reporter assays. miTarget™ 3′ UTR miRNA Target Clones were purchased
from GeneCopoeia (Rockville, MD). Two plasmid clones were generated: one containing the
human NDUFA4 3’ UTR inserted downstream of a secreted Gaussia luciferase (GeneCopoeia,
product# HmiT102777) and another clone with the miR-147 binding-site in the NDUFA4 3’ UTR
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mutated from 5’-CCGCACA-3’ to 5’-CCTACAA-3’. To account for transfection efficiency, both
plasmids also encode for secreted alkaline phosphatase (SEAP) under the transcriptional
control of the constitutively active CMV promoter. HEK-293 cells were transfected with 5 ug of
reporter plasmids using Lipofectamine 2000 (ThermoFisher, cat# 11668019). The next day, the
media was replaced and then subsequent transfection with 25 pmol of either miR-147 or
scrambled mimic miRNAs (miRIDIAN microRNA mimics, Horizon Discovery Biosciences,
Cambridge, UK) was performed using Lipofectamine RNAiMAX (ThermoFisher, Cat#
13778075). 48 hours after transfecting the miRNA mimics, 100 uL of media was removed from
wells and luciferase and SEAP activity was assessed using the Secrete-Pair Dual
Luminescence Assay Kit (GeneCopoeia, Cat# LF033) on a Cytation 5 Cell Imaging Multi-Mode
Reader (BioTek, Winooski, VT). Luciferase activity was normalized by the SEAP activity for
each individual sample.
Metabolic flux bioanalysis. To measure extracellular oxygen consumption rates (OCRs),
100,000 THP-1 cells were differentiated onto Seahorse XFp cell culture plates and analyzed on
a Seahorse XFp Analyzer (Agilent, Santa Clara, CA). For mitochondrial function testing, we
utilized the Seahorse XF Cell Mito Stress Test Kit according the manufacture protocol (Agilent,
Cat# 103015-100) with the following concentration of reagents: 1 uM oligomycin, 1.5 uM
Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and then 1 uM of rotenone
and actinomycin A.
To measure redox capacity across individual mitochondrial electron transport chain
(ETC) complexes, cells were permeabilized with Seahorse XF Plasma Permeabilizer (Agilent,
Cat# 102504-100) at 1 nM in Mitochondrial Assay Buffer (220 mM mannitol, 70 mM sucrose,
10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1mM EGTA, 4mM adenosine diphosphate, and
0.2% w/v bovine serum albumin; all reagents acquired from Sigma). Next OCR was measured
while cells were sequentially treated with 10 mM pyruvate and 1mM malonate (to provide
electrons that enter the ETC at complex I), 2 uM rotenone, 10 mM succinate (to provide
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electrons that enter the ETC at succinate dehydrogenase (SDH, complex II)), 2 mM
actinomycin A, and then 10 mM ascorbate with 100 uM tetramethyl-p-phenylene diamine (to
provide electrons that enter the ETC at complex IV).386 All reagents were purchased from
Sigma.
After Seahorse assays were complete, cells were stained with 2 mM Hoechst 33342
Solution (ThermoFisher, Cat# 62249) and then counted on a BioTex Lionheart LX (BioTek.
Winooski, VT). Cell counts were then used to normalize OCR data.
Analysis of Polar metabolites by LC/IC-HRMS
To determine the incorporation of glucose and glutamine carbon the intracellular tricarboxylic
acid (TCA) cycle, extracts were prepared and analyzed by high-resolution mass spectrometry
(HRMS). Approximately 80% confluent cells were seeded in 60 mm dishes. Cells were washed
with glutamine or glucose-free medium before incubated in fresh medium containing 11.1mM
13

C2-Glucose or 2mM 13C5-Glutamine 6 hours. Cells were quickly washed with ice-cold

deionized water to remove extra medium components. Metabolites were extracted using cold
80/20 (v/v) methanol/water with 0.1% ammonium hydroxide. Samples were centrifuged at
17,000 g for 5 minutes at 4 degree, and supernatants were transferred to clean tubes, followed
by evaporation to dryness under nitrogen. Samples were reconstituted in deionized water, then
5 μL was injected into a Thermo Scientific Dionex ICS-5000+ capillary ion chromatography (IC)
system containing a Thermo IonPac AS11 250×2 mm 4 μm column for TCA cycle metabolites
analysis. IC flow rate was 360uL/minute (at 30ºC) and the gradient conditions are as follows:
started with an initial 1mM KOH, increased to 35 mM at 25 minutes, then to 99 mM at 39
minutes, held 99 mM for 10 minutes. The total run time is 50 min. To assist the desolvation for
better sensitivity, methanol was delivered by an external pump and combined with the eluent
via a low dead volume mixing tee. Data were acquired using a Thermo Orbitrap Fusion Tribrid
Mass Spectrometer under ESI negative mode.
For amino acid analysis, samples were diluted in 90/10 acetonitrile/water containing 1%
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formic acid, then 15 μL was injected into a Thermo Vanquish liquid chromatography (LC)
system containing an Imtakt Intrada Amino Acid 2.1 x 150 mm column with 3 µm particle size.
Mobile phase A (MPA) was acetonitrile containing 0.1% formic acid. Mobile phase B (MPB)
was 50 mM ammonium formate. The flow rate was 300 µL/min (at 35°C), and the gradient
conditions were: initial 15% MPB, increased to 30% MPB at 20 min, then increased to 95%
MPB at 30 min, held at 95% MPB for 10 min, returned to initial conditions and equilibrated for
10 min. The total run time was 50 min. Data were acquired using a Thermo Orbitrap Fusion
Tribrid mass spectrometer under ESI positive ionization mode at a resolution of 240,000. Then
the raw files were imported to Thermo Trace Finder software for final analysis. The fractional
abundance of each isotopologue is calculated by the peak area of the corresponding isotoplogy
normalized by the sum of all isotopoloy areas.387 The relative abundance of each metabolite
was normalized by total peak intensity.
Octyl-α-ketoglutarate and GSK126 cell culture treatments. Octyl-α-ketoglutarate was
purchased from Sigma (Cat# SML2205), diluted in DMSO, and used in vitro at a concentration
of 1.5 mM for 24 hours before cell collection or LPS stimulation. GSK126 was purchased from
Cayman Chemical (Cat# 15415), diluted in DMSO, and used in vitro at a concentration of 2 uM
for 24 hours before cell collection or LPS stimulation.
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3.3 Results
MicroRNA-147 is highly upregulated in lungs after the onset of ALI
We hypothesized that miRNAs could play an important role in the regulation of inflammation
after the onset of ALI and promote recovery of injury. To this end, we utilized a survivable,
sterile model of ALI using intra-tracheal LPS instillation that recapitulates many features of
sepsis associated ALI such as the rapid onset of pulmonary leukocyte infiltration, disruption of
the endothelial-epithelial barrier, and increased expression of inflammatory cytokines. 388 In our
hands, the weight-dosed intra-tracheal LPS model (2 mg/kg) resulted in a reproducible lung
injury that peaks in severity around day three and resolves at around seven days, as
demonstrated by measuring animal weight loss (Figure 6A). Because mice were at their peak
phenotype around 3-days post LPS instillation, we considered this a critical time point when
mice transitioned to recovery. We isolated RNA from the lungs of mice three days after the
onset of ALI and submitted them for a miRNA microarray (Figure 6B). Compared to PBStreated control mice, lungs from ALI mice were found to have significant differential expression
of a large number for miRNAs (Figure 6C). After narrowing our list of differentially expressed
miRNAs to those that are conserved within the human transcriptome, there was at least a
twofold upregulation or downregulation in in 12 and 5 miRNAs, respectively (Figure 6D). We
next sought to investigate how the top upregulated miRNAs were expressed over the entire
course of the ALI model. To do this, we measured the top six upregulated miRNAs in lung
tissue over up to seven days after the onset of ALI using qPCR (Figure 6E). By performing an
area-under-the-curve calculation for these six miRNAs, we found that miR-147 was the highest
expressed miRNA over the course of ALI (Figure 6F). Interestingly, miR-147 expression was
not substantially elevated until three days after the onset of ALI and peaked at 5 days post LPS
instillation, indicating that it might potentially play a role during the timeframe in which mice
recover from ALI (Figure 6E).
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miR-147 is encoded in the genome within the 3’ untranslated region (3’ UTR) of the
gene, normal mucosa of esophagus specific 1 (Nmes1).389, 390 Nmes1 transcripts serve as the
primary form for miR-147, which is processed into mature miR-147 via a pre-miR-147
intermediate. In order to determine if the increased pulmonary miR-147 expression during ALI
was due to a transcriptional upregulation (as opposed to a purely stoichiometric upregulation
contributed by infiltrating cells), we measured the expression of the Nmes1 and pre-miR-147 in
the lungs of ALI mice. We found that both Nmes1 and pre-miR-147 transcripts were
upregulated over the course of ALI, with a peak in expression three-days after the onset, which
precedes the peak in miR-147 on day 5 (Figure 6G and H). In summary, we report that miR147 is amongst the highest expressed miRNAs in lungs of mice during the course of ALI and
that it’s increased expression is transcriptionally regulated.
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Figure 6: MicroRNA-147 is highly upregulated in lungs after the onset of ALI.
A) Calculated fractional weight loss curves for intra-tracheal LPS and PBS (controls) treated
mice demonstrating peak weight loss at 3 days post ALI onset with subsequent recovery.
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Figure 6 (Continued):
B) Experimental schematic illustrating that RNA was isolated from ALI and control mice 3 days
after the onset of ALI and submitted for microRNA microarray anaylsis.
C) Volcano plot for up- and down-regulated miRNAs in the lungs of mice 3 days after the onset
of ALI (n=4 mice in both groups, the designated threshold for significant changes was an
FDR <0.05, miRNAs with fold change greater than 2 or less than 0.5 are portrayed as red
or blue, respectively).
D) Heat map listing the significantly differentially expressed miRNAs from the miRNA
microarray results that are conserved with the human genome.
E) Quantitative PCR measurements from mouse lung tissue for the top-six induced miRNAs
identified from the miRNA microarray analysis (n>4 mice per group).
F) Calculated area under the curve (AOC) for each of the top-six induced miRNAs over the
entire seven days of the ALI model.
G) Quantitative PCR results for Nmes1 expression in the lungs of mice during ALI at the
indicated time points. (n=4 per group, one-way ANOVA with Dunnett’s correction for
multiple comparisons).
H) Quantitative PCR results for pre-miR-147 expression in the lungs of mice during ALI at the
indicated time points. (n=4 per group, one-way ANOVA with Dunnett’s correction for
multiple comparisons).
All data are represented as mean ± SD; * P-value <0.05.
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Pharmacologic inhibition or genetic deletion of miR-147 exacerbates ALI
Next, we sought to determine if miR-147 is functionally important during the course of ALI. We
first took a pharmacologic approach to inhibit miR-147 using locked nucleic acid (LNA)
antisense oligonucleotides targeting the mature form of miR-147. LNAs are RNA derivatives
that have chemically stabilized backbones that have previously been used in vivo systemically
to effectively inhibit both mRNAs and miRNAs.391-393 We treated mice with LNAs antisense to
miR-147 directly into the lungs via intra-tracheal injections the day prior to and the day of LPS
instillation. On the days after the onset of ALI, we gave mice daily LNA boosters via
intraperitoneal injections (Figure 7A). This treatment regimen was effective at reducing the
pulmonary expression of miR-147 as measured by qPCR (Figure 7B). Mice treated with miR147-targerting LNAs had a significant increase in ALI mortality when compared with mice
treated with scrambled control LNAs (Figure 7C). Furthermore, we found that mice treated with
miR-147-targeting LNAs had increased residual pulmonary edema seven days after the onset,
as measured by bronchoalveolar lavage fluid (BALF) albumin levels (Figure 7D).
As a next step, we utilized mice that have a genetic deletion for miR-147 (miR147-/-). As
previously described,379 miR147-/- mice were generating by crossbreeding mice containing loxP
sequences flanking the miR-147 loci (miR147loxp/loxp mice) with mice encoding ubiquitously
expressed Cre recombinase under the transcriptional regulation by the cytomegalovirus (CMV)
promoter. We confirmed that there was efficient deletion of miR-147 by qPCR using RNA
isolated from the lungs of miR147-/- mice (Figure 7E). When given LPS-induced ALI, miR147-/mice experienced significantly increased mortality and a delayed recovery in their weight loss
when compared with wild type (C57BL/6) mice (Figure 7F and G). Blinded histopathological
analysis of hematoxylin and eosin stained lungs revealed that miR147-/- mice had increased
evidence for ALI (Figure 7H and I). Furthermore, miR147-/- mice also developed worsened
pulmonary edema as indicated by increased BALF albumin levels three and five days after the
onset of ALI (Figure 7J). Lastly, miR147-/- mice had increased neutrophilic inflammation during
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ALI, indicated by increased levels of neutrophils counted in the BAL (Figure 7K). Altogether,
these data support the notion that miR-147 plays a protective role in dampening inflammation
and reducing tissue dysfunction during ALI.
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Figure 7: Pharmacologic inhibition or genetic deletion of miR-147 exacerbates ALI
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Figure 8 (Continued):
A) Experimental scheme for locked nucleic acid (LNA) antisense inhibition of miR-147 in vivo.
Mice were injected with LNAs intra-tracheally (i.t.) 1 day prior to and on the day of i.t. LPS
instillation. After the onset of ALI, mice were treated with intra-peritoneal (i.p.) doses daily.
B) Quantitative PCR demonstrating reduced expression of miR-147 in lungs of mice treated
with anti-miR-147 LNAs (147) compared with mice treated with scrambled control LNAs
(SCR) (n=4 mice in the SCR group, n=5 mice in the 147 group, unpaired t-test).
C) ALI-associated mortality in mice treated with either anti-miR-147 LNAs or scrambled
controls (n=24 mice in each group, Kaplan-Meier curves, log-rank test).
D) Pulmonary edema was determined by albumin concentration (ug/mL) in bronchoalveolar
lavage fluid (BALF) using enzyme-linked immunosorbent assays (ELISA) in mice treated
with anti-miR-147 and scrambled LNAs (n=10 mice in each group, Mann-Whitney test).
E) Quantitative PCR for miR-147 expression in the lungs of wild type (WT) and miR147-/- mice
(n=17 mice in each group, Mann-Whitney test).
F) ALI-associated mortality in WT and miR147-/- mice (n=19 mice in the WT group, n=18 mice
in the miR147-/- group, Kaplan-Meier curves, log-rank test).
G) ALI-associated fractional weight loss in WT and miR147-/- mice (n=4-8 mice per group,
Bonferroni-adjusted Welch’s or unpaired t-tests).
H and I) Representative hematoxylin and eosin stained sections and blinded ALI scoring of
lungs collected from WT and miR147-/- mice (40X magnification, n=5-11 mice per group,
Bonferroni-adjusted unpaired t-tests).
J) Pulmonary edema was determined by albumin concentration (ug/mL) in BALF using ELISA
in WT and miR147-/- mice (n=4-9 mice in each group, Bonferroni-adjusted unpaired t-tests).
K) Quantification of neutrophils in the BAL of WT and miR147-/- mice during ALI (n=4-9 mice in
each group, Bonferroni-adjusted unpaired t-tests).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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Liposomal miR-147-mimic treatment promotes resolution of ALI
Given that whole-body deletion of miR-147 resulted in increased tissue dysfunction and
inflammation during ALI, we next investigated whether miR-147 over-expression could act in an
opposite manner by reducing LPS-induced ALI. To do this, we delivered miR-147-mimic
oligonucleotides that were packaged in liposomal 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine
(DOPC) intravenously two and four days after intra-tracheal LPS instillation (Figure 8A). DOPC
liposomes have been shown to effectively deliver antisense oligonucleotides in vivo while also
having minimal toxic properties.394-396 We confirmed that intravenous administration of
liposomal miR-147 resulted in a significant over-expression of miR-147 in the lungs of mice
using qPCR (Figure 8B). When treating mice with LPS-induced ALI, we observed a rebound in
recovery of weight loss associated with ALI (Figure 8C). Histopathological analysis of
hematoxylin and eosin stained lungs demonstrated decreased scores of ALI (Figure 8D and E).
Lastly residual pulmonary edema at seven days after the onset of ALI was significantly
reduced, as measured by BAL albumin levels (Figure 8D). Altogether, these findings
demonstrate that miR-147 over-expression reduced ALI severity and promoted recovery in
mice, which is in align with our previous results indicating miR-147 deficiency was associated
with worsened ALI.
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Figure 8: Liposomal miR-147-mimic treatment promotes resolution of ALI
A) Experimental scheme for liposomal miR-147 treatments. Mice were given intravenous (i.v.)
injections of liposomal miR-147 mimics or scrambled controls 2 and 4 days after the onset
of ALI.
B) Quantitative PCR measurements for miR-147 expression in lungs from mice treated with
exogenous liposomal miR-147 (147) or scrambled controls (SCR) (n=4 mice in the SCR
group, n=5 in the 147 group, Mann-Whitney test).
C) ALI-associated fractional weight loss in mice treated with liposomal miR-147 mimics or
scrambled controls (n=6-8 mice per group, unpaired t-tests).
D and E) Representative hematoxylin and eosin stained sections and ALI scoring of lungs
collected from mice treated with liposomal miR-147 mimics or scrambled controls (40X
magnification, n=6-7 mice per group, unpaired t-test).
F) Pulmonary edema was determined by albumin concentration (ug/mL) in BALF using ELISA
(n=6-7 mice per group, unpaired t-test).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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Myeloid-specific deletion of miR-147 phenocopies whole-body deletion
To begin investigating the function for how miR-147 confers tissue protection during ALI, we
first sought to identify in which cell(s) it is expressed. Given that ALI associated with intratracheal LPS instillation is characterized by the activation of resident alveolar macrophages
followed by a substantial infiltration of inflammatory immune cells 239 – both of which are cell
types that highly express TLR4, the receptor for LPS – we first explored whether miR-147
expression was attributed to inflammatory immune cells. To do this, we digested lungs from
mice three days after the onset of ALI into single cell suspensions and then used magneticallyconjugated antibodies to enrich for CD45 expressing cells, which is present on the surface of
all hematopoetic lineage cells including, monocytes and macrophages. 397, 398 There was a
significantly increased expression of miR-147 in the CD45+ cells compared with CD45- in
digested lungs three days after the onset of ALI (Figure 9A). To further interrogate which of the
CD45+ cells may be primarily expressing miR-147 during ALI, we used fluorescence activated
cell sorting (FACS) of cells isolated from BAL of mice three days after the onset of ALI using a
previously described strategy to gate for polymorphonuclear cells (PMNs, CD3 - B220- Ly6G+),
resident alveolar macrophages (CD3- B220- Ly6G- CD11blow CD11chigh), and peripherally
recruited macrophages (CD3- B220- Ly6G- CD11bhigh CD11clow).290, 399 After sorting for cells,
qPCR-based measurements for miR-147 demonstrated that recruited macrophages contained
significantly higher expression when compared with PMNs and alveolar macrophages (Figure
9B). Furthermore, by depleting circulating monocytes using liposomal clodronate, there was a
decrease in the relative amount of miR-147 expression in the BAL cells three days after the
onset of ALI (Figure 9C). Conversely, treating mice with intravenous PMN-depleting antibodies
resulted in an increase in the relative expression of miR-147 in BAL cells isolated three days
after intra-tracheal LPS instillation (Figure 9D). Altogether, these studies demonstrate that
during ALI, miR-147 is highly expressed in recruitment macrophages.
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To specifically address the function of miR-147 in the inflammatory immune
compartment during ALI, we generated mice with myeloid-targeted deletion of miR-147 by
crossbreeding miR147loxp/loxp mice with mice encoding Cre recombinase under the
transcriptional control by the lysozyme promoter (LysM Cre).378 We confirmed the knockout
efficiency in BAL cells using qPCR which showed deletion for miR-147 expression (Figure 9E).
When compared with LysM Cre control mice, miR147loxp/loxp LysM Cre mice had a significantly
increased mortality and delay in recovered weight loss associated with ALI (Figure 9F and G).
Histopathologic analysis of hematoxylin and eosin stained lungs revealed significantly
increased acute lung injury scores in miR147loxp/loxp LysM Cre mice (Figure 9H and I).
Furthermore, miR147loxp/loxp LysM Cre mice also had significantly higher levels of pulmonary
edema neutrophilic infiltration as measured by BALF albumin and BAL neutrophil counts,
respectively (Figure 9J and K). In summary, these findings established that inflammatory
immune cells, especially recruited macrophages, contributed to the expression of miR-147
during ALI and that specific deletion of miR-147 in the myeloid cell compartment was sufficient
to phenocopy the exacerbated ALI we observed in the whole body deletion mouse.
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Figure 9: Myeloid-specific deletion of miR-147 phenocopies whole-body deletion
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Figure 9 (Continued):
A) Quantitative PCR measurements for miR-147 expression in CD45+ and CD45- cells after
whole lung digestion of mouse lungs collected three days after the onset of ALI (n=4-6 mice
in each group, Bonferroni-adjusted unpaired t-tests).
B) Bronchoalveolar lavage (BAL) cells were collected three days after the onset of ALI and
then separated into polymorphonuclear nueutrophils (PMN), alveolar macrophages
(AlvMΦ), and recruited macrophages (RecMΦ) populations using fluorescence assisted cell
sorting (FACS). Quantitative PCR was used to determine the expression of miR-147 in
each cell type (n=4 mice per group, Tukey-adjusted one-way ANOVA).
C) BAL cells were collected three days after the onset of ALI from mice that were treated with
either liposomal clodronate (to deplete peripheral monocytes) or liposomal PBS control
(Ctrl). Quantitative PCR was used to determine the expression of miR-147 (n=5 mice per
group, unpaired t-test).
D) BAL cells were collected three days after the onset of ALI from mice that were treated with
either PMN neutralizing (to deplete PMNs) or IgG control antibodies. Quantitative PCR was
used to determine the expression of miR-147 (n=4-6 mice per group, Mann-Whitney test).
E) BAL cells were collected from miR147loxp/loxp LysM Cre and LysM Cre control mice.
Quantitative PCR was used to determine the expression of miR-147 in order to confirm
knockout efficiency (n=9 mice per group).
F) ALI-associated survival in miR147loxp/loxp LysM Cre and LysM Cre control mice. (n=10 mice
per group, Kaplan-Meier curves, log-rank test).
G) ALI-associated fractional weight loss in miR147loxp/loxp LysM Cre and LysM Cre control mice.
(n=7-10 mice per group, Bonferroni-adjusted Welch’s or unpaired t-tests).
H and I) Representative hematoxylin and eosin stained sections and ALI scoring of lungs
collected from miR147loxp/loxp LysM Cre and LysM Cre mice (40X magnification, n=4-8 mice
per group, unpaired t-test).
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Figure 9 (Continued):
J) Pulmonary edema was determined by albumin concentration (ug/mL) in BALF using ELISA
in miR147loxp/loxp LysM Cre and LysM Cre mice (n=5-8 mice in each group, Bonferroniadjusted unpaired t-tests).
K) Quantification of neutrophils in the BAL of miR147loxp/loxp LysM Cre and LysM Cre mice
(n=4-8 mice in each group, Bonferroni-adjusted unpaired t-tests).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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miR147loxp/loxp LysM Cre mice have higher levels of inflammation during ALI
We next sought to determine whether exacerbated ALI in miR147loxp/loxp LysM Cre mice was
associated with increased levels of inflammatory cytokine expression. We measured mRNA
levels of the inflammatory genes Il1b, Tnfa, and Il6 in the BAL cells of mice with LPS-induced
ALI and found that miR147loxp/loxp LysM Cre mice had significantly increased levels of
inflammatory transcripts when compared with LysM Cre controls (Figure 10A, B, and C). These
findings were also consistent with the protein levels of inflammatory cytokines measured in the
BALF isolated from miR147loxp/loxp LysM Cre mice (Figure 10D, E and F). These findings, in
combination with the presence of increased infiltration of PMNs (Figure 9K), indicate that
increased levels of inflammation are responsible for exacerbated ALI in miR147loxp/loxp LysM Cre
mice and that miR-147 is a critical regulator of inflammation.
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Figure 10: miR147loxp/loxp LysM Cre mice have higher levels of inflammation during ALI
A,B and C) Il-1b, Tnf-α, and Il-6 protein concentration were measured using enzyme-linked
immunosorbent assays in bronchoalveolar lavage fluid (BALF) collected from miR147loxp/loxp
LysM Cre and LysM Cre mice with ALI at the indicated time points (n=4-8 mice per group,
Bonferroni-adjusted unpaired t-tests).
D, E and F) Il1b, Tnfa and Il6 transcript levels were quantified using PCR in BAL cells collected
from miR147loxp/loxp LysM Cre and LysM Cre mice with ALI at the indicated time points (n=511 mice per group, Bonferroni-adjusted unpaired t-tests).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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miR-147 is induced during ALI in a Hif1α-dependent manner
We next investigated how miR-147 expression is regulated. First, we confirmed that miR-147
was transcriptionally up-regulated in LPS treated macrophage cells in vitro using mouse bone
marrow-derived macrophages (BMDMs) and human peripheral monocyte-derived
macrophages (hMDMs). Both cell lines showed upregulated expression of miR-147 in response
to LPS stimulation (Figure 11A and B). By analyzing the promoter region of the NMES1 gene
(which codes for the primary transcript that contains miR-147), we identified several regulatory
elements that are associated with inflammatory signaling, including NF-κB binding motifs and
hypoxia response elements (HREs) (Figure 11C). Inflammation and hypoxia commonly co-exist
during organ injuries, including in the lung, where hypoxia inducible factors (HIFs) and NF-κB
partake in complex bi-directional crosstalk.299, 400-404 We therefore hypothesized that HIFs could
function as transcriptional regulators for miR-147 during LPS stimulation of macrophages. First,
we isolated BMDMs from mice lacking functional genes for either the Hif1α or Hif2α isoforms in
the myeloid compartment by isolating bone marrow from Hif1aloxp/loxp LysM Cre or Hif2aloxp/loxp
LysM Cre mice, respectively. After treating the BMDMs with LPS for 24 hours, we measured a
significant decrease in miR-147 expression by about 50 % specifically in the Hif1α-deficient
macrophages and not in the Hif2α-deficient macrophages (Figure 11D). Next, to confirm that
Hif1α associates with the promoter of NMES1 in response to LPS stimulation, we performed a
chromatin immunoprecipitation (ChIP)-qPCR which showed that there was a significant
increase in enrichment in Hif1α binding to the NMES1 promoter (Figure 11E).
In order to demonstrate the transcriptional role of Hif1α for miR-147 expression in vivo
we first assessed, indirectly, whether HIFs are stabilized in the lungs of mice with ALI mice
using a HIF-reporter mouse (ODD-Luc mice).377 ODD-Luc mice have a constitutively expressed
luciferase tagged with the oxygen dependent domain (ODD) of HIFs, which is the targeted
domain for hydroxylation that labels HIFs for subsequent proteasome-dependent degradation.
In this way, ODD-Luc mice express luciferase that is regulated at the protein level in the exact
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manner as HIFs and can be measured for bioluminescent activity in vivo or ex vivo. After giving
ODD-Luc mice intra-tracheal instillation of LPS, we measured significantly elevated
bioluminescent activity in excised lungs up to five days after the onset of ALI (Figure 11F and
G). To confirm HIF stabilization, specifically, in the lungs from mice with ALI, we performed
Western blot analysis and found elevated Hif1α protein levels the nuclear extracts isolated from
lung tissues of mice with ALI, which peaked three days after the onset (Figure 11H and I).
Interestingly, Hif2α protein levels in the lungs did not change significantly (Figure 11H and J).
Lastly, to test whether the presence of Hif1α was also critical for the expression of miR-147 in
vivo, we induced ALI in Hif1aloxp/loxp LysM Cre and Hif2aloxp/loxp LysM Cre mice and measured for
miR-147 in the BAL cells three days after the onset of ALI. Hif1α deletion resulted in abrogated
miR-147 upregulation in the BAL cells after LPS instillation, while Hif2α deletion did not have
any effect (Figure 11K). Altogether, these experiments demonstrated that Hif1α, but not Hif2α,
played an important role in expressing miR-147 in infiltrating alveolar compartment
inflammatory cells during LPS-induced ALI.
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Figure 11: miR-147 is induced during ALI in a Hif1α-dependent manner.
A) Mouse bone marrow-derived macrophages were stimulated with 1 ug/mL
lipopolysaccharide for the indicated time points and then assayed for miR-147 expression
using quantitative PCR (n=3 biological replicates, one-way ANOVA with Dunnett’s test).
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Figure 11 (Continued):
B) Human peripheral monocyte-derived macrophages (hMDMs) were stimulated with 1 ug/mL
lipopolysaccharide for the indicated time points and then assayed for miR-147 expression
using quantitative PCR (n=3 biological replicates, one-way ANOVA with Dunnett’s test).
C) Diagram of transcription factor response element motifs in the promoter region of NEMS1.
Hypoxia response elements (HRE) and NF-ΚB response elements are listed as being
upstream by the indicated number of base pairs from the transcription start site (TSS).
D) BMDMs isolated from LysM Cre, Hif1aloxp/loxp LysM Cre and Hif2aloxp/loxp LysM Cre mice were
treated with 1ug/mL LPS for 24 hours and then assayed for miR-147 expression using
quantitative PCR (n=3 biological replicates, Tukey-adjusted two-way ANOVA).
E) Human MDMs were treated with LPS (1 μg/mL) for 8 hours. Chromatin Immunoprecipitation
(ChIP)-PCR targeting a sequence in the NMES1 promoter was performed to assess fold
enrichment for HIF-1α association with the promoter of NMES1 compared with IgG isotype
control. Data are relative to PBS groups (n=3 biological replicates, one-tailed paired t-test).
F and G) Representative images and quantification of bioluminescent activity from ODD-LUC
mouse lungs after the onset of ALI. Luciferase activity is relative to PBS treated mice
collected and imaged at the same time as ALI lungs (n=3-8 mice per group, one-way
ANOVA with Dunnett’s test).
H, I and J) Representative Western blots and densitometry for Hif-1α and Hif-2α protein
expression in nuclear extracts isolated from mice with ALI at the indicated time points. Tatabox binding protein (TbP) was used as the loading control. Densitometry data are relative to
day 0 signals (n=mice per group, one-way ANOVA with Dunnett’s test).
K) Quantitative PCR was used to measure the expression of miR-147 in the BAL cells isolated
from LysM Cre, Hif1aloxp/loxp LysM Cre and Hif2aloxp/loxp LysM Cre mice three days after the
onset of ALI (n=3-6 mice per group, Tukey-adjusted two-way ANOVA).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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miR-147 targets the mitochondrial complex IV subunit, NDUFA4
Given than miRNAs function by inhibiting the expression of mRNA targets, we sought to
determine the functional role of miR-147 in macrophages by identifying putative target mRNAs.
To do this, we performed mRNA sequencing using cells from the BAL of miR147loxp/loxp LysM
Cre mice three days after the onset of ALI that were depleted of neutrophils, which enriched the
samples for infiltrating macrophages that highly express miR-147 in control mice (Figure 12A).
We found a large number of significantly up- and down-regulated genes in the miR147loxp/loxp
LysM Cre mice BAL macrophages when compared with LysM Cre controls (Figure 12B).
Because miRNAs work by repressing their mRNA targets, we focused on the up-regulated
differentially expressed genes in the miR147loxp/loxp LysM Cre BAL macrophages, presuming at
least one of them were up-regulated due to the absence of miR-147. There were 21
significantly up-regulated mRNAs in miR147loxp/loxp LysM Cre BAL macrophages, of which we
then cross-referenced with a list of predicted target genes based on the in silico prediction
software, TargetScan.405 The comparison of up-regulated genes with the predicted target list
yielded a single common gene, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4
(NDUFA4), which codes for mitochondrial complex IV subunit, (Figure 12C). 406-408 Using qPCR,
we confirmed that Ndufa4 expression was significantly up-regulated in miR147loxp/loxp LysM Cre
BAL cells (Figure 12D). We next sought to confirm the specific target of miR-147 to the
predicted 3’UTR binding site using a reporter system that consisted of a plasmid coding for
luciferase, but with the 3’UTR of NDUFA4. We also constructed another plasmid that is
identical except for a four base mutation in the NDUFA4 3’UTR where the binding site for miR147 is predicted to be located (Figure 12E). In this way, when the plasmids are transfected, the
transcribed luciferase mRNAs will artificially be regulated by miR-147. We then co-transfected
the plasmids into HEK293 cells with either miR-147 mimics or scramble controls. We measured
significantly reduced luciferase activity in cells co-transfected with the wild type 3’UTR plasmid
and miR-147 mimics, which was reversed in the cells transfected with the construct containing
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the mutated miR-147 binding site (Figure 12F). The loss of repressed luciferase by miR-147 in
the mutated construct demonstrated that the binding of miR-147 to the 3’UTR of NDUFA4 is
site specific and indicated that NDUFA4 is a bona fide target gene for miR-147. To determine
that miR-147 regulation of NDUFA4 mRNA levels also resulted in differential protein
expression, we performed western blots in BMDMs derived from miR147loxp/loxp LysM Cre mice
and found a significant upregulation of Ndufa4 protein when compared to LysM Cre control
cells (Figure G). Conversely, when we transfected the monocytic cell line, THP-1 cells, with
miR-147 mimics, we measured a significant reduction in NDUFA4 protein levels, further
supporting that miR-147 regulates both mRNA and protein expression of NDUFA4 (Figure
12H). Altogether, these findings reveal that during ALI, miR-147 targets NDUFA4, which is a
bona fide target gene, and results in regulation of its protein levels.
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Figure 12: miR-147 targets the mitochondrial complex IV subunit, NDUFA4
A) Experimental scheme demonstrating how bronchoalveolar lavage (BAL) cells were
collected from LysM Cre and miR147loxp/loxp LysM Cre mice three days after onset of ALI
and then depleted for neutrophils using prior to RNA isolation. RNA was subsequently
submitted for mRNA-seq.
B) Differentially expressed genes in BAL cells isolated from miR147loxp/loxp LysM Cre mice vs.
LysM Cre controls. An adjusted P-value (False discovery rate) of less than 0.05 was
considered significant. Genes with fold change greater than 2 are colored red and genes
with fold change less than 0.5 are colored blue.
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Figure 12 (Continued):
C) Venn diagram illustrating the common gene (NDUFA4) in both the up-regulated
differentially expressed genes and the predicted target genes for miR-147 determined by
the in silico software, TargetScan.
D) Quantitative PCR measurement of Ndufa4 mRNA expression in the BAL cells collected
from LysM Cre and miR147loxp/loxp LysM Cre three days after the onset of ALI (n=9 mice in
the LysM Cre group, n=6 mice in the miR147loxp/loxp LysM Cre group, Mann-Whitney test).
E) Sequence details for 3’ untranslated region (UTR) reporter plasmids. Luciferase coding
regions were engineered with the wild type 3’UTR of NDUFA4 that contain the putative
binding site for miR-147. In a separate plasmid, the 3’UTR contains a 4 base pair mutation
in the miR-147 binding site, indicated in green.
F) Fold changes in relative fluorescent units (RFU) in the supernatants of luciferase-3’ UTR
reporter expressing HEK-293 cells. Cells were transfected with either the wild type (WT)
3’UTR plasmid or the mutated 3’UTR plasmid (Mut). The cells were subsequently
transfected with miR-147 mimics (147) or scrambled controls (SCR) (n=3 replicates,
Bonferroni-adjusted multiple t-tests).
G) Western blots for Ndufa4 protein expression in mouse bone marrow-derived macrophages
isolated from LysM Cre and miR147loxp/loxp LysM Cre mice (n=3 replicates).
H) Western blots for Ndufa4 protein expression in THP-1 cells transfected with miR-147 or
scramble control mimics (n=3 replicates).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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NDUFA4 deletion dampens inflammatory gene expression independent of LPS-TLR4
signaling
Having identified NDUFA4 as a target gene regulated by miR-147, we next addressed whether
NDUFA4 could play a role in regulation of inflammation in a manner consistent with the
dysregulated inflammatory phenotype we observed during ALI in miR147loxp/loxp LysM Cre mice.
Using the acute monocytic leukemia cell line, THP-1 cells, we used CRISPR-mediated gene
editing to develop NDUFA4-knockout cells (NDUFA4-/-) in addition to control cells that were
transfected with guide-RNA targeting a non-coding region of the genome. Western blotting for
NDUFA4 levels demonstrated high efficiency for protein knockout in NDUFA4-/- cells (Figure
13A). When NDUFA4-/- cells were treated with LPS, we measured a significant reduction in the
inflammatory cytokine genes IL1B, IL6 and TNFA, when compared with the control cells (Figure
13B, C, and D). These results suggest that the deletion of NDUFA4 results in reduced
inflammatory cytokine expression, which is consistent with our data in miR147loxp/loxp LysM Cre
mice, in which NDUFA4 and inflammatory cytokine expressions were elevated.
We next investigated whether the reduction in cytokine expression in NDUFA4-/- LPSstimulated THP-1 cells was associated with a decrease in the activation of intracellular
pathways downstream of the LPS-TLR4 signaling. Upon binding to TLR4, LPS stimulation
results in a cascade of intracellular events that result in the expression of inflammatory genes
orchestrated by several transcription factors, including NF-κB, IRF3 and AP-1, which are
activated when in a phosphorylated state.409, 410 We performed Western blot analysis to
measure the phosphorylated levels of p65 (a subunit of NF-κB), IkBa (an inhibitor of NF-κB that
is inactivated by phosphorylation), c-Jun (a member of the AP-1 transcription factor), and IRF3.
We did not observe any significant changes in the phosphorylation state of any of these
proteins in the NDUFA4-/- THP-1 cells after LPS stimulation (Figure 13E and F). These data
indicate that the down-regulated transcription of inflammatory cytokines in the NDUFA4-/- THP1 cells was not a result of inhibited signaling by the LPS-TLR4 axis.
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Figure 13: NDUFA4 deletion dampens inflammatory gene expression independent of
LPS-TLR4 signaling
A) Western blot of NDUFA4 protein expression in control (CTRL) and NDUFA4-/- THP-1 cells
(n=4 biological replicates).
B, C and D) IL1B, IL6 and TNFA mRNA expression measured by quantitative PCR in CTRL
and NDUFA4-/- THP-1 cells stimulated with 1 ug/mL lipopolysaccharide (LPS) for the
indicated time points (n=3 biological replicates, Bonferroni-adjusted multiple t-tests).
E) Western blot of NF-κB pathway total protein (t) and phospho-protein (p) expression in CTRL
and NDUFA4-/- THP-1 cells stimulated with 1 ug/mL lipopolysaccharide (LPS) for the
indicated time points (n=3 biological replicates).
F) Western blot of total IRF3 and phosphor-IRF3 protein expression in CTRL and NDUFA4-/THP-1 cells stimulated with 1 ug/mL lipopolysaccharide (LPS) for the indicated time points
(n=3 biological replicates).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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NDUFA4 deletion leads to succinate accumulation via dampening the electron transport
chain
Given that NDUFA4-/- THP-1 cells expressed less inflammatory cytokines independent of LPSTLR4 signaling, we hypothesized that – because NDUFA4 is a subunit of the mitochondrial
complex IV406-408 – a metabolic mechanism might play a role in NDUFA4-/- THP-1 cell
inflammatory signaling. Indeed, metabolic programming of macrophages has been
demonstrated to be a critical factor in governing their inflammatory phenotypes, especially in
the context of mitochondria-derived factors such as reactive oxidative species and biologically
active metabolites.411-415 We first interrogated the mitochondrial function of the NDUFA4-/- THP1 cells by measuring their oxygen consumption rates (OCR, an indicator of oxidative
phosphorylation activity) while sequentially treating cells with oligomycin (an adenosine
triphosphate synthase inhibitor), cyanide p-trifluoromethoxyphenyl-hydrazone (FCCP, an
uncoupler of oxidative phosphorylation), and rotenone combined with actinomycin A (Rot/AA,
inhibitors of mitochondrial complex I and III, respectively). NDUFA4-/- THP-1 cells had a
significant reduction in measured OCR, including reduced calculated basal-, max- and ATP
linked-OCR when compared with control cells (Figure 14A and B). To determine whether the
reduction in mitochondrial function in NDUFA4-/- cells was associated with a reduction in redox
capacity across the mitochondrial electron transport chain (ETC) complexes, we measured
OCRs in permeabilized cells that were sequentially treated with pyruvate and malonate (to
provide electrons that enter the ETC at complex I), rotenone, succinate (to provide electrons
that enter the ETC at succinate dehydrogenase (SDH, complex II)), actinomycin A, and then
ascorbate with tetramethyl-p-phenylene diamine (to provide electrons that enter the ETC at
complex IV).386 In this fashion, we were able to measure the oxidative phosphorylation-coupled
redox activities of complex I, SDH, and complex IV in live cells with intact mitochondria.
Consistent with previous reports that NDUFA4 knockdown results in decreased complex IV
activity,407, 408 we observed decreased OCR associated with complex IV redox activity in
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NDUFA4-/- cells (Figure 14C and D). Interestingly, we also measured decreased OCR
associated with complex I and SDH redox activities, suggesting that NDUFA4 deletion had an
effect on upstream ETC complex activities in addition to complex IV (Figure 14C and D).
We next sought to determine whether the reduction in mitochondrial oxidative
phosphorylation capacity and redox activities of ETC complexes in NDUFA4-/- cells resulted in
alterations of mitochondrial matrix-associated metabolites by using high-resolution mass
spectrometry to measure levels of tricarboxylic acid (TCA) cycle metabolites. There was a
significant increase in the intracellular levels of succinate in NDUFA4-/- cells when compared
with controls (Figure 14E). Because succinate accumulation can occur by several means, such
as through the increased generation or the decreased oxidation of succinate, we performed
carbon tracing experiments to first interrogate the carbon source for the elevated succinate
levels. Given that glucose (through glycolysis) and glutamine (through glutaminolysis) are both
critical carbon sources for macrophages,416, 417 we performed heavy-isotope (13C) carbon
tracing experiments by incubating cells with either 13C6-glucose or 13C5-glutamine (Figure 14F).
Carbons from glucose sources enter the TCA cycle as the two-carbon metabolite, acetyl-CoA,
resulting in succinate with two 13C isotopes (m+2), while carbons from glutamine sources are
incorporated into the TCA cycle as five-carbon glutamate, resulting in succinate with four
isotopes (m+4) (Figure 14F). When tracing with

13

C

13

C6-glucose, we measured a reduction in m+2

succinate ions in the NDUFA4-/- cells, whereas when incubation of cells with 13C5-glutamine, we
measured a significant increase in m+4 succinate ions in NDUFA4-/- cells, indicating that the
accumulation of succinate in NDUFA4-/- cells is derived from a glutamine source (Figure 14G
and H). Next, we investigated whether succinate accumulation was a result of increased
glutamine incorporation or decreased succinate oxidation by SDH. By measuring the ratios of
all 13C-labeled α-ketoglutarate ions (the metabolite through which glutamine enters the TCA
cycle) and un-labeled α-ketoglutarate ions, we found no significant differences in the amount of
glutamine entering the TCA cycle, demonstrating that succinate accumulation in NDUFA4-/99

cells is not due to an increase in its generation (Figure 14I). To assess for the oxidation of
succinate, we calculated the fraction of m+4 succinate to m+4 fumarate (the product of
succinate oxidation by SDH). We calculated a significantly increased relative fraction of m+4
succinate to m+4 fumarate, indicating that succinate accumulation in NDUFA4-/- cells is due to
a decrease in succinate oxidation, presumably due to the reduction in redox activity of SDH as
a result of decreased activity of the NDUFA4-deficient complex IV (Figure 14J). Altogether,
these findings demonstrate that when the miR-147 target gene, NDUFA4, is deleted, there is a
resulting dampening of ETC function with a subsequent accumulation of succinate due to a
decrease in the redox activity of SDH.
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Figure 14: NDUFA4 deletion leads to succinate accumulation via dampening the electron
transport chain
A) Extracellular oxygen consumption rates (OCR) of control (CTRL) and NDUFA4-/- THP-1
cells treated sequentially with oligomycin (oligo), Carbonyl cyanide-4-phenylhydrazone
(FCCP), and then a combination of rotenone with actinomycin A (rot/AA). Data are
normalized by cell counts for each sample (n=3 biological replicates).
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Figure 14 (Continued):
B) Calculated basal, max, ATP-linked, and spare capacity rates of extracellular oxygen
consumption of CTRL and NDUFA4-/- THP-1 cells (n=3 biological replicates, Bonferonniadjusted unpaired t-tests).
C) OCR associated with coupled redox activities of mitochondrial complex I, succinate
dehydrogenase (SDH), and mitochondrial complex IV in CTRL and NDUFA4-/- THP-1 cells
(n=3 biological replicates).
D) Calculated rates of extracellular oxygen consumption coupled with the redox capacities of
mitochondrial complex I, succinate dehydrogenase (SDH), and mitochondrial complex IV in
CTRL and NDUFA4-/- THP-1 cells (n=3 biological replicates, unpaired t-tests).
E) Tricarboxylic acid cycle metabolites were measured in CTRL and NDUFA4-/- THP-1 cells
using high-resolution mass spectrometry. Data for abundances are normalized to the CTRL
group for each metabolite (n=6 replicates in each group, Bonferonni-adjusted multiple ttests).
F) Diagram of heavy carbon (13C) tracing experimental design. 13C6-glucose (green) or 13C5glutamine (red) were supplemented into cell growth media for six hours before collection.
Isotopes of metabolites are referred to by their number of

13

C atoms (i.e. m+2 citrate

contains two 13C atoms, and so on). White symbols denote un-labeled carbons ( 12C).
G) Fraction of measured m+2 succinate ions that were derived from

13

C6-glucose tracing in

CTRL and NDUFA4-/- THP-1 cells (n=3 replicates per group, unpaired t-test).
H) Fraction of measured m+4 succinate ions that were derived from

13

C5-glutamine tracing in

CTRL and NDUFA4-/- THP-1 cells (n=3 replicates per group, unpaired t-test).
I)

Fraction of total labeled (m+1, m+2, m+3, and m+4) and un-labeled α-ketoglutarate ions
that were derived from 13C5-glutamine tracing in CTRL and NDUFA4-/- THP-1 cells (n=3
replicates per group).
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Figure 14 (Continued):
J) Ratio of m+4 succinate:m+4 fumarate derived from

13

C5-glutamine tracing in CTRL and

NDUFA4-/- THP-1 cells (n=3 replicates per group, unpaired t-test).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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Succinate accumulation in NDUFA4 knockout cells epigenetically regulates
inflammation
Previous work has demonstrated that succinate is an important metabolite for the control of
transcriptional activity and in the functional status of macrophages. In macrophages, succinate
oxidation was shown to promote pro-inflammatory functions through the generation of
mitochondrial reactive oxygen species.414 Succinate has also been shown to play a potent role
in competitively inhibiting α-ketoglutarate (α-KG)-dependent dioxygenases, including lysine
histone demethylases (KDMs).418-420 Furthermore, epigenetic regulation of inflammatory genes
by KDMs has been shown to control phenotypes of macrophages.421-423 We consequently
sought to investigate whether NDUFA4-/- cell accumulation of succinate was associated with
epigenetic regulation of inflammatory cytokines. We first performed Western blot analysis to
assess for genome-wide tri-methylation marks on histone-3 lysine-27 (H3K27me3), histone-3
lysine-9 (H3K9me3), and histone-3 lysine-4 (H3K4me3) and found a significant upregulation in
H3K27me3 and H3K9me3 marks, both of which are gene-activating marks, in NDUFA4-/- THP1 cells (Figure 15A and B). Interestingly, we did not observe any significant increase in the
gene-silencing mark, H3K4me3 (Figure 14A and B). To test whether the up-regulation in trimethylation of H3K27 could be attributed to succinate accumulation, we treated cells with a
competitive activator of KDMs, octyl-α-ketoglutarate (octyl-α-KG). After treatment of with octylα-KG, we observed a reversal of H3K27me3 in NDUFA4-/- cells back to the levels seen in
control cells (Figure 15E and F). In order to investigate whether reversal of H3K27me3 in
NDUFA4-/- cells could also reverse the decrease in inflammatory cytokine gene expression, we
treated cells with GSK126, a specific inhibitor of enhancer of zeste homolog 2 (EZH2), which is
a lysine methyl transferase that catalyzes the addition of methyl groups onto H3K27me3. After
treating cells with GSK126, we observed a reversal of H3K27me3 in NDUFA4-/- and a
restoration in the expression of IL6 during stimulation with LPS (Figure 15G and H). In
summary, these results suggest that succinate accumulation in NDUFA4-/- cells resulted in
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increased epigenetic gene silencing marks via the inhibition of KDMs. Furthermore, reversal of
elevated levels of H3K27me3 in NDUFA4-/- cells was associated with restored expression of
inflammatory cytokine transcription, thus providing a mechanistic link for how miR-147 targeting
of NDUFA4 could result in the regulation of macrophage inflammatory processes through
epigenetic modification.
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Figure 15: Succinate accumulation in NDUFA4 knockout cells epigenetically regulates
inflammation
A) Western blot of modified Tri-methyl marks on Histone H3 – Tri-Methyl-Histone H3 at lysine
27 (H3K27me3), Tri-Methyl-Histone H3 at lysine 9 (H3K9me3), and Tri-Methyl-Histone H3
at lysine 4 (H3K4me3) – in control (CTRL) and NDUFA4-/- THP-1 cells (n=3 biological
replicates).
B, C and D) Western blot densitometry for H3K27me3, H3K9me3, and H3K4me3 relative to
total Histone H3 in CTRL and NDUFA4-/- THP-1 cells (n=3 biological replicates, unpaired ttests).
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Figure 15 (Continued):
E) Western blot for H3K27me3 modification in CTRL and NDUFA4-/- THP-1 cells that are
treated with octyl-α-ketoglutarate or DMSO vehicle for 24 hours (n=2 biological replicates).
F) Western blot densitometry for H3K27me3 modification relative to total Histone H3 in CTRL
and NDUFA4-/- THP-1 cells that are treated with octyl-α-ketoglutarate or DMSO vehicle for
24 hours (n=2 biological replicates).
G) Western blot for H3K27me3 modification in CTRL and NDUFA4-/- THP-1 cells that are
treated with octyl-α-ketoglutarate, GSK126, or DMSO vehicle for 24 hours. Ratio of
H3K27me3:total H3 are calculated at the bottom (n=1 biological replicate).
H) Quantitative PCR measurement of IL6 mRNA in CTRL and NDUFA4-/- THP-1 cells that are
treated with DMSO or GSK126 for 24 hours, then with 1ug/mL of LPS or PBS (negative
control) for 4 hours (n=1 biological replicate, Bonferonni-adjusted multiple t-tests).
All data are represented as mean ± SD; * P-value <0.05, ** P-value <0.01.
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3.4 Conclusions and Significance
Through their function as inhibitors of gene expression, miRNAs provide a unique opportunity
to intimately understand endogenous regulatory nodes that control biological processes,
including inflammation.356 Here we hypothesized that unique miRNAs expressed after the onset
of ALI may promote recovery and serve as novel therapeutic targets. Through a miRNA
targeted microarray, we screened for the expression of all currently annotated miRNAs in the
lungs of mice with sepsis-associated ALI three days after the onset of ALI and discovered that
miR-147 expression was significantly enriched, particularly during the middle and later time
points of the injury. Using both pharmacologic and genetic approaches, we showed that loss of
miR-147 function resulted in worsened outcomes of ALI in mice. Furthermore, exogenously
overexpressing miR-147 in mice through the utilization of liposome-packaged miR-147 mimics
during peak inflammatory time points accelerated the recovery of ALI in mice, supporting the
protective role of miR-147. By enriching for hematopoietic-lineage positive cells in digested
lungs and sorting BAL cells in ALI mice, we demonstrated that miR-147 is predominantly
expressed in the myeloid cell compartment, particularly in recruited macrophages. Indeed,
specific deletion of miR-147 in the myeloid compartment recapitulated the worsened ALI
phenotype observed in the whole-body deleted mice and also demonstrated increased
expression of inflammatory mediators in the alveolar space. After surveying the promoter
region of primary transcript for miR-147 (NMES1), we established that miR-147 expression in
macrophages is dependent on Hif-1α both in vitro and in vivo. Utilizing a transcriptomic
approach, we identified the mitochondrial complex IV subunit, NDUFA4, as a putative target
gene for miR-147. Through a CRISPR-mediated deletion of NDUFA4 in the monocytic cell line,
THP-1, we measured decreased expression of inflammatory cytokines upon LPS stimulation,
which is consistent with our findings that miR-147 deletion – causing upregulation of NDUFA4 –
resulted in increased inflammation. Using extracellular oxygen consumption rate assays and
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metabolomics, we reveal that NDUFA4 deletion promotes the accumulation of succinate via
dampening the coupled activity of electron transport chain complex II (succinate
dehydrogenase) redox activity. Succinate, in turn, promoted the epigenetic silencing of
inflammatory genes by inhibiting the demethylation of Histone H3. Together, these findings
reveal an intracellular network in myeloid cells beginning with the expression of miR-147 that
works to modulate the signaling metabolite, succinate, which modifies the epigenetic landscape
to limit the expression of inflammatory cytokines during lung inflammation.
The anti-inflammatory role of miR-147 during lung inflammation adds to a growing body
of evidence that implies the importance of miRNA-mediated negative-feedback regulation of
inflammation in macrophages.424, 425 MiR-146 is upregulated in macrophages upon LPS
stimulation and was found to target IL-1 associated kinase-1 (IRAK1), IRAK2, and TNF
associated factor 6 (TRAF6), all of which are transduction molecules that mediate TLR4
signaling to activate NF-κB and inflammatory gene expression, in order to promote negative
feedback. Furthermore, miR-146 was shown to be induced by the pro-resolving mediator,
Resolvin D1, and to mediate the development of endotoxin-induced tolerance in macrophages
upon subsequent stimulations by LPS.426-433 Other miRNAs have also been found to be upregulated by LPS-TLR4 activation and subsequently dampen NF-κB activation in a negative
feedback manner. These include miR-149 that targets Myd88, which is an adapter protein that
relays the TLR4 signaling into the cell, and miR-21, which acts to negatively regulate NF-κB
activation by targeting the tumor suppressor PDCD4. 433, 434 Indeed, a prior study also identified
miR-147 as a suppressor of inflammatory gene expression in macrophages, but did not
implicate a target gene or mechanism for this function. 390 Additionally, another study by Vlacil et
al. found miR-147 to be down-regulated by the activation of nucleotide-binding oligomerization
domain-containing proteins (NOD) 1 and 2, which resulted in increased levels of Il-6 and Tnf-α
transcript levels in endothelial cells.435 Our work showed that, unlike the previously mentioned
miRNAs, miR-147 did not regulate the expression of inflammatory genes by acting on
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intracellular signaling events or the activation of NF-κB, but by altering the epigenomic
landscape of macrophages. Though we demonstrate that miR-147’s ability to alter the
epigenome was attributed to the accumulation of the known lysine demethylase (KDM) inhibitor
succinate as a result of the inhibition of NDUFA4, it is possible that there are additional targets
for miR-147 that regulate inflammatory signaling at the level of signal transduction initiated by
TLR4 activation by LPS. Our discovery of NDUFA4 as a miR-147 target was based on a
transcriptomic approach, but it may not have identified target genes that are regulated on a
protein level (i.e. miR-147 inhibits the translation of a gene without degrading its mRNA).
Proteomic or tagged-argonaute2 pull-down assays could be used to more inclusively screen for
additional target genes for miR-147.436
Epigenetic regulation of macrophage inflammatory functions is a rapidly expanding field
with several studies showing that pro-inflammatory gene expression is both promoted and
suppressed via post-translational modifications of histones. 437, 438 Among the most reported
epigenetic modifiers in macrophages is the lysine-specific demethylase, jumonji domain
containing-3 (JMJD3). JMJD3 is normally induced in LPS stimulated macrophages, where it
acts as an eraser of methyl groups on H3K27me2/3 – a gene silencing mark – and was shown
promote transcriptional activity.422,434 The induction of pro-inflammatory cytokines in
macrophages in response to serum amyloid A stimulation has also been shown to be
dependent on the activity of JMJD3439, 440 Furthermore, JMJD3 is α-ketoglutarate-dependent
and studies have shown that α-ketoglutarate accumulation in macrophages can promote
epigenetic activation of gene transcription.441 In contrast, treating macrophages with a specific
inhibitor of JMJD3 reduces LPS induced pro-inflammatory cytokine gene expression. 421
Similarly, succinate accumulation secondary to succinate dehydrogenase inhibition has been
shown to inactivate JMJD3, leading to hyper-methylation of histones. 418, 419, 442 Though our
findings demonstrate an endogenous network for epigenomic regulation of pro-inflammatory
cytokines via the accumulation of succinate, it remains to be established whether H3K27me3
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marks are associated with pro-inflammatory genes and whether the regulation by succinate
occurs in a JMJD3-dependent manner. Further studies using pharmacologic and genetic
inhibition of JMJD3 and chromatin immunoprecipitation (ChIP)-seq studies are currently being
pursued to answer these questions. Furthermore, LPS stimulation has also been shown to
induce histone activating marks, such as histone H3 and H4 acetylation at the IL-12 p40 loci, to
activate gene transcription.443, 444 Whether other histone modifications, such as acetylation, are
altered downstream of the miR-147:NDUFA4 axis were not explored and remains an additional
possibility.
Succinate and the activity of succinate dehydrogenase (SDH) has demonstrated a
growing role in inflammatory functions of macrophages.430,438 Early reports suggested that
exogenous succinate promoted IL-1β expression via increased reactive oxygen species (ROS)
and HIF-1α-stabilization, though later studies specified that the oxidation of succinate by SDH
is the critical event leading to HIF-1 stabilization and IL-1β expression. 445 414 Targeting SDH
with an inhibitor or through genetic knockdown resulted in the accumulation of succinate in
macrophages and dampened inflammatory gene expression.414 This phenomenon mirrors our
findings that inhibition of SDH as a result of NDUFA4 targeting by miR-147 promoted the
accumulation of succinate and dampened inflammatory cytokine expression. Other
mechanisms of inhibiting SDH in macrophages have also been described, such as the
accumulation of itaconate, which is produced by the upregulation of the mitochondrial enzyme,
immune-Responsive Gene 1 (Irg1), in response to LPS stimulation. Itaconate is a potent
inhibitor of SDH and results in succinate accumulation, leading to anti-inflammatory phenotypes
in macrophages both in vitro and in vivo.446 In our studies, it does not appear that itaconate
contributed to the inhibition of SDH due to its lack of accumulation in NDUFA4-/- THP-1 cells
(data not shown). Succinate has also been shown to act via its cellular surface G-protein
coupled receptor, SUNCR1. Depending on the pathophysiological context, the activation of
SUNCR1 by succinate can induce either pro- or anti-inflammatory effects in macrophages. 447111
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Our data did indicate that there was also an accumulation of extracellular succinate in

NDUFA4-/- THP-1 cells (data not shown), but whether there is a contributory role for SUNCR1
was not investigated and is still a possibility.
Early studies have established that macrophages are critical players in both the
initiation and resolution of ALI, with functions depending on the type of insult, chronicity, and
severity.281 Though macrophages are considered initiators of lung inflammation during ALI,
macrophage phenotypic switching towards decreasing pro-inflammatory functions and
increasing resolving functions is an important event that limits the duration and severity of lung
injury.450 Furthermore, the clearance of pro-inflammatory macrophages is also a protective
mechanism during acute lung injury. As an example, macrophage depletion using liposomal
clodronate or genetic approaches reduced the severity of inflammation and tissue injury in
murine models of ALI.451, 452 Additionally, Fas-mediated apoptosis of pro-inflammatory recruited
macrophages is a requirement for resolution of LPS-induced ALI. 290 Our results are in
agreement that recruited macrophages require restraint in their inflammatory phenotypes in
order to prevent tissue injury. Through the induction of miR-147, we demonstrate that
dampening the electron transport chain is another mechanism by which macrophage
inflammation is regulated to limit tissue injury in ALI.
Our findings that miR-147 expression is dependent on HIF-1α also adds to an
established line of work that HIF-1α is a critical player in macrophage inflammatory processes.
HIF-1α has been shown to have both anti- and pro-inflammatory roles in macrophages. In an
early genetic study, Cramer et al. demonstrated in Hif1aloxp/loxp LysM Cre mice that HIF-1α is
essential for pro-inflammatory macrophage activity in an LPS-induced sepsis model. 453
Furthermore, HIF-1α has also been shown to act as a transcription factor for IL-1β, IL-6 and
inducible nitric oxide synthase.445, 454 On the other hand, myeloid-cell stabilization of HIF-1α has
also been demonstrated as a key regulator in the promotion of resolution in murine colitis
models and also in murine Helicobacter pylori-induced gastritis models454, 455 Furthermore, HIF112

1α is a critical regulator of inflammation in alveolar epithelial cells during ALI, and promotes the
expression of the anti-inflammatory neuronal guidance protein, Netrin1. 190, 456
There are recognizably several limitations to our work. Firstly, the use of the LysM Cre
mouse to target myeloid cells is not perfect. The LysM Cre promoter targets all granulocytes,
including neutrophils, and has also been reported to have activity in alveolar type II cells. 457, 458
Further in vivo studies will benefit this work by using macrophage specific recombinase for
miR-147 deletion, such as the hCD68-rtTA/Teto-Cre, which is specifically expressed in
peripheral recruited monocytes.459 Additionally, our data lack translational significance with
human subjects. Currently we are gathering BAL samples from ARDS patients with the intent
on answering whether miR-147 expression, succinate levels, and ARDS outcomes are
correlated.
Altogether, our findings highlight a novel role in which myeloid cell-derived miR-147 is
upregulated in response to stimulation by bacterial endotoxin during ALI to repress excessive
inflammation. The impact of miR-147 is mediated through its regulation of NDUFA4, with
subsequent dampening of the electron transport chain and accumulation of the metabolite,
succinate, which acts as an epigenetic repressor of inflammatory gene expression. Further
investigating the specific enzyme(s) that succinate interacts with to regulate the epigenome will
be important moving forward because it may contribute towards identifying a drug target that
may translate into novel ALI treatment. Additionally, our work suggests that miR-147 might be
targeted directly as a therapeutic using nano-particle packaged mimics. Future work should be
focused on utilizing miR-147 therapeutically in additional models of ALI, including more
clinically-relevant infectious models, to further establish its pre-clinical efficacy and safety as a
treatment modality.
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Figure 16: Proposed mechanism for miR-147-mediated regulation of inflammation during
ALI
During ALI, pro-inflammatory recruited macrophages are activated through TLR4 by LPS which
results in HIF-1α stabilization and translocation to the nucleus where it activates the
transcription of miR-147. MiR-147 then acts by blocking the translation of NDUFA4 subunits,
which are a subunit of the mitochondrial complex IV. Decreasing NDUFA4 levels results in
dampened electron transport chain activity, resulting in diminished redox activity of succinate
dehydrogenase (SDH). The reduced activity of SDH leads to an accumulation of succinate,
which then acts to inhibit lysine-specific demethylases (KDMs) and promote the epigenetic
silencing of inflammatory cytokine genes. Created with BioRender.com.
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Chapter 4: The role of netrin-1 in the regulation of inflammation during ALI
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4.1 Introduction
Persistent and uncontrolled inflammation is the hallmark of sepsis, and sepsis-associated lung
inflammation, which significantly contributes to morbidity and mortality of critical illness. 460, 461
Inflammation by itself is an essential adaptive response to noxious stimuli such as infection and
tissue injury.331, 462-465 However, in situations where an infectious burden is excessive or
inflammation becomes dysregulated (i.e. fails to terminate or resolve), inflammation can result
in profound collateral tissue damage and systemic impact.14, 466-472 Indeed, endogenous
mechanisms and immune-modulators are programmed to limit inflammation and restore tissue
homeostasis.360, 473-479 Such mechanisms include negative feedback pathways that serve to
dampen inflammation and active stimulation by pro-resolution mediators that coordinate the
termination of inflammation.477, 480-486 Myeloid cells, such as macrophages and neutrophils, are
a crucial part of innate immunity and key drivers of the initiation and resolution of inflammation.
For example, during lung inflammation, monocytes are recruited to the inflamed air space to
differentiate into macrophages secreting cytokines that act locally to stimulate chemotaxis and
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activate neutrophils.487 Therefore, understanding how myeloid cells contribute to the proper
inflammatory responses are areas of intense investigation. 488-494
Neuronal guidance proteins (NGPs) were first characterized for their role in
neurogenesis through their ability to act as chemoattractant and chemorepellent cues to guide
axons to their target synapses.495-498 However, increasing evidence has recognized NGPs as a
class of immune-modulators499, which can regulate inflammatory processes by limiting or
promoting the migration of leukocytes during acute and chronic inflammatory conditions.500-510
For example, netrin 1, as one of the most investigated NGPs in immune modulation, is
expressed by endothelial cells and plays a crucial role in inhibiting the migration of neutrophils
to different chemoattractants.511 In addition, several lines of evidence from mice with partial
deletion of netrin 1 (Ntn1+/-) indicated that netrin-1 plays an important role in limiting the
transmigration of leukocytes during models of acute lung injury, peritonitis, and colitis. 502, 503, 505,
512

Additionally, exposure of hypoxia results in netrin 1 induction in mucosal epithelial cells in a

hypoxia-inducible factor HIF-1α dependent manner, and Ntn1+/- mice exhibit increased
myeloperoxidase activity in the colon tissue upon hypoxia exposure. 503 Furthermore,
recombinant netrin 1 treatment inhibits chemokine (C-C motif) ligand 2 (CCL2) and chemokine
(C-C motif) ligand 19 driven macrophage migration in vitro.513 Besides its role in leukocyte
migration, netrin-1 was shown to suppress inflammatory macrophage functions514, 515 and to
promote resolution of inflammation by stimulating the production of specialized pro-resolving
mediators and tissue regeneration.516, 517 However, the functional role of myeloid cells-derived
netrin 1 during lung inflammation has not been elucidated. Our studies demonstrated that, for
the first time, myeloid cell-specific expression of netrin 1 confers lung protection through the
modulation of CCL2 dependent natural killer (NK) cell migration.
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4.2 Materials and Methods
Mice. Wild type (C57BL/6J), Ntn1loxp/loxp 518, Hif1αloxp/loxp 375, and LysM Cre 378 mice were
purchased from Jackson Laboratory. Detailed information on the mice strains is listed in table
3. Mice were housed and bred in a pathogen-free suite at the Center for Laboratory Animal
Medicine and Care at the University of Texas Health Science Center at Houston (UTHealth). All
experimental animal protocols were approved by the UTHealth Institutional Animal Care and
Use Committee. Accounting for sex as a variable, for experiments using C57BL/6J or
Ntn1loxp/loxp LysM Cre mice, experiments were performed with age and weight-matched equal
numbers of male and female mice throughout all groups. In our experiments using Hif1αloxp/loxp
LysM Cre mice, sex-dependent differences in mice were not observed and we used age and
weight-matched mice (Figure 17).
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Table 3: Mouse strain details for chapter 4.
Species
mice
mice

Vendor or Source
Jackson Laboratory
Jackson Laboratory
Species

Parent
- Male

Mice,
Netrin1loxP/loxP
Parent Mice,
NetrinFemale 1loxP/loxP
Parent Mice, Lyz2
- Male Cre+
Parent Mice, Lyz2
Cre+
Female
Parent Mice,
- Male Hif1αloxp/loxp
Parent Mice,
Hif1αloxp/loxp
Female

Vendor or
Source
Jackson
Laboratory
Jackson
Laboratory
Jackson
Laboratory
Jackson
Laboratory
Jackson
Laboratory
Jackson
Laboratory

Background Strain
C57BL/6J
C57BL/6J

Sex
Male
female

Persistent ID / URL
https://www.jax.org/strain/000664
https://www.jax.org/strain/000664

Background
Strain
(129X1/SvJ x
129S1/Sv)F1Kitl+
(129X1/SvJ x
129S1/Sv)F1Kitl+
129P2/OlaHsd

Other
Information
B6.129(SJL)Ntn1tm1.1Tek/J

(129X1/SvJ x
129S1/Sv)F1Kitl+
(129X1/SvJ x
129S1/Sv)F1Kitl+

B6.129Hif1atm3Rsjo/J

https://www.jax.org/strain/007561

B6.129Hif1atm3Rsjo/J

https://www.jax.org/strain/007561

B6.129(SJL)Ntn1tm1.1Tek/J

Persistent ID / URL
https://www.jax.org/strain/028038

https://www.jax.org/strain/028038

https://www.jax.org/strain/004781
B6.129P2Lyz2tm1(cre)Ifo/J
https://www.jax.org/strain/004781
129P2/OlaHsd B6.129P2Lyz2tm1(cre)Ifo/J
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Figure 17: Lack of significant sex differences in Hif1aloxp/loxp LysM Cre Mice.
A) Relative expression of Ntn1 transcript in bronchoalveolar lavage (BAL) cells isolated from
LysM cre and Hif1aloxp/loxp LysM Cre mice 3 days after lipopolysaccharide (LPS)-induced lung
inflammation (n=3 mice per group, unpaired t-test). Data are represented as mean +/- SD.
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Generation of Ntn1loxp/loxp LysM Cre+ and Hif1αloxp/loxp LysM Cre+ mice. To conditionally
achieve myeloid-cell specific deletion, Ntn1loxp/loxp and Hif1αloxp/loxp mice were crossbred with
LysM Cre+ to generate Ntn1loxp/loxp LysM Cre and Hif1αloxp/loxp LysM Cre mice, respectively.
Knock out in Ntn1loxp/loxp LysM Cre mice was confirmed by performing RT-qPCR measuring
knockout efficiency of the Ntn1 mRNA transcript levels in bone marrow and in bronchoalveolar
lavage (BAL) cells of intratracheal LPS-treated mice (Figure 18). Hif1αloxp/loxp LysM Cre mice
have been previously genotyped and characterized. 380
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Ntn1
Figure 18: Confirmation of Ntn1 knockout in Ntn1loxp/loxp LysM Cre mice.
A) Relative expression of Ntn1 transcript in bone marrow cells isolated from naïve LysM cre
and Ntn1loxp/loxp LysM Cre mice (n=3 mice per group, * p-value = 0.05, Mann-Whitney test). B)
Relative expression of Ntn1 transcript in bronchoalveolar lavage (BAL) cells isolated from LysM
cre and Ntn1loxp/loxp LysM Cre mice 3 days after LPS-induced lung inflammation (n=5-8 mice per
group, * p-value < 0.01, Mann-Whitney test). All data are represented as mean +/- SD.
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Isolation of human polymorphonuclear cells (PMNs) After isolation of human monocyte
derived macrophages (described in the general materials and methods), the remaining cell
pellet, which consists of PMNs were also washed twice with cold HBSS+25mM HEPES+10%
FCS. PMNs were then cultured for experiments in DMEM+25mM HEPES+20%FCS, 2mM Gln,
1% Antibiotic/Antimycotic solution. To obtain hMDMs, PBMCs were cultured for 7 days in
macrophage differentiation media: RPMI 1640 (supplemented with 10% heat inactivated fetal
bovine serum and 10 ng/mL recombinant human M-CSF). Treatment with lipopolysaccharide
(LPS, Sigma-Aldrich) was performed using a concentration of 1 μg/mL.
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Table 4: Reagents for chapter 4

Description
Ficoll-Paque PLUS
Red Blood Cell Lysis Solution
citrate-dextrose buffer
recombinant human M-CSF
lipopolysaccharide (LPS, Escherichia
coli 0111:B4)
QIAzol Lysis Reagent
Applied Biosystems High Capacity Reverse
Transcription Kit
TaqMan Universal PCR Master Mix
TB Green Premix Ex Taq II (Tli RNase H
Plus)
protease inhibitor cocktails
phosphatase inhibitor cocktails
BCA protein assay
SuperSignal West Femto Maximum
Sensitivity Substrate
pentobarbital (Nembutal)
Albumin ELISA
IL-6 ELISA
IL-1β ELISA
CCL2 ELISA
the citric acid-based antigen unmasking
solution
normal goat serum
VECTASTAIN Elite ABC-HRP Kit
DAB (3,3'-diaminobenzidine) Substrate Kit
Red Blood Cell Lysis Solution
RNeasy Mini Kit
MojoSort Mouse Ly-6g Selection Kit
Proteome Profiler Mouse Cytokine Panel A

Source / Repository
GE Healthcare
Miltenyi Biotec
Sigma-Aldrich
R&D Systems
Sigma-Aldrich

Catalog number #
17-1440-02
130-094-183
C3821
216-MC
L4391

Qiagen
Thermo Fisher

79306
4368814

ThermoFisher
Takara Bio Inc

4305719
RR820A

New England Biolabs
New England Biolabs
ThermoFisher
Thermo Scientific

5871S
5870S
23225
34094

Akorn Inc
Bethyl Laboratories
BD Biosciences
R&D Systems
R&D Systems
Vector Laboratories

76478050150
E90-134
555240
DY401
DY479
H-3300

Vector Laboratories
Vector Laboratories
Vector Laboratories
Promega
Qiagen
BioLegend
R&D Systems

S-1000
PK-6101
SK-4100
Z3141
74104
480123
ARY006
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RT-qPCR. Quantitative PCR was performed using TaqMan probes targeting netrin-1
(ThermoFisher, Human: Cat# 4331182 and Mouse: Cat# 4331182) and 18S for control
(ThermoFisher, cat# 4331182).
Neuronal Guidance Peptide mRNA array. hMDMs were stimulated with LPS for 8 hours and
then collected for RNA isolation. Screening for Neuronal Guidance Peptide mRNA expression
was performed using the Axon Guidance PrimerArray (cat.# PH006) and TB Green Premix Ex
Taq II from Takara Bio Inc. (Shiga, Japan) according to the manufacture’s protocols.
Western Blotting. Detailed information on the antibodies is listed in table 5.
Immunohistochemistry. The lung slices were cut in 5 µm in thickness and mounted on glass
slides. Antigen retrieval was performed with the citric acid-based solution (Vector Laboratories)
using a pressure cooker following deparaffinization and rehydration. The BAL cell slides were
prepared with cytospin (Hettich ROTOFIX 32A centrifuge, Germany) and cells were fixed with
freshly made 4% Paraformaldehyde (PFA) for 20 minutes (room temperature) followed by
permeabilization (0.3% Triton X-100, 20 minutes). Endogenous peroxidase activity was
quenched (3% hydrogen peroxide solution, 5 minutes). After blocking with 2.5% normal goat
serum, slices were incubated with primary antibodies (4°C, overnight). The following steps
were performed with ABC-HRP Kit (Vector Laboratories) and DAB (3,3'-diaminobenzidine)
according to the manual instruction followed by hematoxylin counterstaining. Negative control
slides were incubated with the recombinant rabbit IgG (Abcam, Cat#ab172730) instead of
primary antibody at the same concentration. A Leica DM2500 light microscope was used to
evaluate the staining and pictures were taken with a Leica DMC5400 digital camera. Detailed
information on the antibodies is listed in table 5.
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Table 5: Antibodies used in chapter 4.
Target antigen

Vendor or
Source
Anti-mouse CD16/CD32
BioLegend
recombinant rabbit IgG
Abcam
FITC-anti-NK1.1 (Clone PL136) ThermoFisher
APC-anti-CD3 (Clone 17A2)
ThermoFisher
Alexa Fluor 546 goat anti-rabbit Invitrogen
IgG(H+L)
anti-F4/80 antibody (FITC)
Abcam
Netrin-1 Antibody
LifeSpan
BioSciences
Netrin-1 Antibody
Abcam
β-Actin Antibody
Anti-rabbit IgG, HRP-linked
Antibody
Anti-mouse IgG, HRP-linked
Antibody

Catalog
number
101301
ab172730
11-5941-82
17-0032-82
A11010

Working concentration

ab60343
LS-C743016

Flow cytometry 1:100
Flow cytometry 1:100
Flow cytometry 1:100
Immunofluorescence 1:200

Santa Cruz
Cellsignaling

sc-47778
7074

Immunofluorescence 1:200
immunohistochemistry paraffin
1:200
western blot 1:1000
Immunofluorescence 1:200
western blot 1:2000
western blot 1:5000

Cellsignaling

7076

western blot 1:5000

ab126729
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Flow cytometry of BAL cells. After collection and red blood cell lysis, BAL cells were blocked
with anti-mouse CD16/32 Antibody (Clone 93, BioLegend) for 10 minutes on ice and then
stained with FITC-anti-NK1.1 (Clone PL136, ThermoFisher) and APC-anti-CD3 (Clone 17A2,
ThermoFisher) for 30 minutes on ice. After two washes with flow cytometry buffer, cells were
analyzed on a CytoFLEX LX (Beckman Coulter, Indianapolis IN). Detailed information on the
antibodies is listed in table 5.
Immunofluorescence. The BAL cell slides were prepared with cytospin (Hettich ROTOFIX
32A centrifuge, Germany) and cells were fixed with freshly made 4% Paraformaldehyde
solution for 20 minutes at room temperature. Following blocking with 2.5% normal goat serum
at room temperature for 1 hour, the slides were incubated with primary antibody at 4°C
overnight. Negative control slides were incubated with the recombinant rabbit IgG. Conjugated
secondary antibodies were used to apply the fluorescence dye. Slides were mounted after
counterstaining with DAPI. A confocal microscope (Leica, Germany) was used to observe and
document the staining. Detailed information on the antibodies is listed in table 5.
mRNA-sequencing of bronchoalveolar lavage (BAL) cells. After mRNA sequencing
described in the general materials and methods standard Gene Ontology (GO) and KEGG
pathway enrichment analyses were performed using the online tool WebGestalt (v0.4.3)

519

.

Up-regulated differentially expressed genes were matched to cell-type ontology using the
CellKb database (v2.0) software.
Antibody-mediated neutralization of CCL2. For CCL2 neutralization, mice were treated with
intraperitoneal injections of 10ug/g of body weight of anti-mouse CCL2 (clone 2H5, Cat#
BE0185) or control IgG (Cat# BE0091). Both antibodies were purchased from BioXCell
(Lebanon, NH).
Profiling for cytokine and chemokine expression in mouse BAL fluid. To screen for
expression of cytokine and chemokines in the BAL fluid of mice, we performed the Proteome
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Profiler Mouse Cytokine Panel A (R&D Systems, Minneapolis, MN) using 100 uL of mouse BAL
fluid. Dot blot membranes were imaged and densitometry was performed using ImageJ
software (National Institutes of Health).
Chromatin immunoprecipitation-quantitative PCR. Primers for the Netrin1 promoter were as
follows: Forward: TCCTCCTCCTCTTCCTCACG, Reverse: CTCTAACCCAGCCTGATGGC.
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4.3 Results
Netrin-1 is upregulated in endotoxin stimulated myeloid cells
Previous studies have demonstrated that NGPs play significant roles in regulating the
inflammatory processes of macrophages.506, 512, 514, 515, 520, 521 Along these lines of evidence, we
hypothesized that NGPs may be upregulated by macrophages in response to inflammatory
stimuli as a potential endogenous anti-inflammatory mechanism. To investigate the induction of
NGP expression in macrophages, we treated human monocyte-derived macrophages (MΦs)
with LPS for 8 hours and then performed an RT-qPCR array for NGP gene expression (Figure
19A). NTN1 (the gene encoding for netrin-1) was the highest expressed NPG in the array
reaching statistical significance, and the result was further confirmed using an alternate
TaqMan based qPCR assay (Figures 19B, C). Besides the upregulation of NTN1, cell lysates
also demonstrated increased levels of netrin-1 protein following LPS exposure (Figures 19D,
E). In addition, we investigated the expression of netrin-1 in LPS treated human
polymorphonuclear cells (PMNs) and found increased levels of netrin-1 transcript and protein
levels (Figure 19F, G, H). Together these results demonstrate that netrin-1 expression is
significantly induced in myeloid cells during treatment with LPS.
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Figure 19: Netrin-1 is significantly upregulated in endotoxin treated myeloid cells.
(Figure on previous page)
A) Monocytes were isolated from blood of healthy donors and differentiated into macrophages
(MΦs) then treated with LPS (1 ug/mL for 8 hours). RNA was isolated and used to perform a
neuron guidance-specific RT-qPCR array.
B) The top upregulated genes from the array demonstrated the netrin-1 gene (NTN1) as the
top-statistically significant induced gene (n=4, Bonferroni adjusted unpaired or Welch’s t test).
C) PCR confirmation of NTN1 upregulation in LPS stimulated human blood-derived MΦs (n=3
per group, one-way ANOVA with Dunnett’s post-hoc tests).
D and E) Representative image and quantification for Western blot for netrin-1 protein
expression in LPS treated MΦs (n=3 per group, one-way ANOVA with Dunnett’s post-hoc
tests).
F) Peripheral polymorphonuclear neutrophils (PMNs) were isolated from healthy donors and
treated with 1 ug/mL of LPS for 8 hours.
G) NTN1 RT-qPCR using RNA isolation from LPS treated PMNs (n=3 per group, unpaired ttest).
H and I) Representative image and quantification for Western blot for netrin-1 protein
expression in LPS treated PMNs (n=3, unpaired t-test).
All data are represented as mean ± SD; * p-value <0.05.
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Myeloid cells express high levels of netrin-1 during LPS-induced lung injury
In order to investigate whether netrin-1 is expressed in myeloid cells during sepsis-associated
lung inflammation, we utilized a murine model of LPS-induced lung injury, which results in
significant recruitment and activation of leukocytes.349, 522-525 After intratracheal (i.t.) instillation
of a weight-based dose of LPS (Figure 20A), Mice had the highest measured peak weight loss
and bronchoalveolar lavage (BAL) cell counts 3 days after LPS challenge (Figure 20B, C).
Because peak leukocyte infiltration was observed 3 days post LPS instillation, we performed
western blot analysis for netrin-1 protein expression in lung tissue lysates collected at this time
point. Netrin-1 protein was significantly upregulated in lung tissue lysates (Figure 20D, E). Next,
we further characterized the localization of netrin-1 in the lungs of mice with LPS-induced lung
injury by immunohistochemistry staining for netrin-1. Netrin-1 staining was observed primarily in
alveolar airspace infiltrating leukocytes (Figure 20F). Furthermore, we quantified the netrin-1
expression on the surface of naïve alveolar macrophages (Ly6G - F4/80+, collected from i.t.
PBS-treated controls), BAL macrophages (Ly6G- F4/80+), and PMNs (Ly6G+ F4/80-) isolated
from mice 3 days after i.t. instillation of LPS by flow cytometry. Netrin-1 levels were significantly
elevated in BAL macrophages after i.t. LPS instillation when compared to naïve alveolar
macrophages (Figure 20G, H). Interestingly, netrin-1 expression was significantly reduced in
infiltrating PMNs when compared with both naïve alveolar macrophages and macrophages
collected from i.t. LPS-treated mice (Figure 20G, H). Finally, immunofluorescence staining of
BAL cells demonstrated macrophage dominant netrin-1 expression 3 days after i.t. LPS
treatment (Figure 20I). Taken together, these data indicate that netrin-1 is highly expressed in
BAL macrophages during i.t. LPS-induced lung injury.
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Figure 20: Myeloid cells recruited during endotoxin-induced lung injury have high levels
of netrin-1.
A) Schematic for LPS-induced lung injury in mice. Mice were administered intra-tracheal
instillation of LPS (3.75 μg/g of body weight) or PBS for control and then monitored for weight
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Figure 20 (Continued):
loss or collected 1, 3, 5, or 7 days later for quantification of bronchoalveolar lavage (BAL)
leukocytes.
B) Fractional weight loss measured in mice during LPS-induced lung injury (n=10 in the PBS
group, n=29 in the LPS group).
C) BAL leukocytes counts in mice collected 1, 3, 5, or 7 days after LPS-induced lung injury
(n=4-9 per group, one-way ANOVA with Bonferroni post-hoc tests).
D and E) Image and densitometry quantification for Western blot for netrin-1 protein expression
in lung tissue isolated from mice 3 days after LPS or PBS instillation (n=4 mice per group,
Mann-Whitney test).
F) Representative immunohistochemistry staining for netrin-1 in formalin-fixed paraffinembedded lung from mice 3 days after LPS or PBS instillation (n=3 replicates per group,
images are magnified 40X with 120X inserts).
G) Representative flow cytometry histogram counts for netrin-1 expression in PBS control BAL
alveolar macrophages (Naïve AlvMΦ, Ly6G- F4/80+) or in BAL macrophages (MΦ, Ly6GF4/80+) and neutrophils (PMN, Ly6G+ F4/80-) from mice 3 days after LPS instillation (n=3-4
mice per group, counts relative to mode).
H) Netrin-1 flow cytometry mean fluorescent intensity quantification (n=3-4 per group, one-way
ANOVA with Bonferroni post-hoc tests).
I) Representative immunofluorescence staining of BAL leukocytes isolated 3 days after LPS or
PBS instillation demonstrating co-staining for F4/80 with netrin-1 (n=3 mice per group).
All data are represented as mean ± SD; * p-value <0.05.
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Netrin1 expression in myeloid cells is dependent on HIF-1α
Previous work has demonstrated that HIF-1α directly targets the promoter of the netrin-1 to
induce its transcription.503 Consistently, we identified an essential DNA binding element for HIF1α, named hypoxia response element (HRE; 5’-GCGTG-3’) 309, located 303 nucleotide base
pairs upstream from the transcriptional start site of netrin-1 (Figure 21A). To investigate the role
of HIF-1α in the expression of netrin-1 in LPS-stimulated human monocyte derived MΦs, we
performed chromatin immunoprecipitation (ChIP) quantitative PCR to assess HIF-1α binding to
the HRE located in the netrin-1 promoter. After stimulation with LPS for 8 hours, we observed a
significant increase in HIF-1α association to the netrin-1 promoter compared with PBS treated
controls (Figure 21B). Next, we sought to determine if the expression of netrin-1 in BAL
leukocytes is dependent on HIF-1α during LPS-induced lung injury in vivo. To address this
question, we utilized Hif1aloxp/loxp LysM Cre mice that contain a conditional deletion for Hif1a in
myeloid cells.526 On day 3 after LPS instillation, BAL leukocytes isolated from Hif1aloxp/loxp LysM
Cre mice had a significant reduction in netrin-1 transcript levels when compared to LysM Cre
control mice (Figure 21C). Similarly, immunohistochemistry staining revealed abrogated netrin1 protein in BAL cells collected from Hif1aloxp/loxp LysM Cre mice on day 3 after LPS-induced
lung injury (Figure 21D). In order to assess for potential non-myeloid contributions of netrin-1
during lung inflammation, we measured the protein level of netrin-1 in total lung tissue of
Hif1aloxp/loxp LysM Cre mice 3 days after LPS instillation. As we previously observed in C57BL/6
mice, netrin-1 expression is increased in lung tissue of LysM Cre control mice 3 days after LPS
instillation, which was completely abolished in Hif1aloxp/loxp LysM Cre mice (Figure 21E, F).
These results indicate that netrin-1 expression in infiltrating myeloid cells during LPS-induced
lung injury is dependent on HIF-1α and support the importance of myeloid cells in netrin-1
induction during lung inflammation.
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Figure 21: LPS-induced netrin-1 expression in myeloid cells is regulated by HIF-1α.
A) Schematic illustrating the location of a hypoxia response element (HRE) 303 base pairs
upstream of the transcriptional start site (TSS) of NTN1.
B) Human monocyte-derived MΦs were treated with LPS (1 μg/mL) for 8 h and then fixed to
induce DNA-protein cross-linking. Chromatin Immunoprecipitation (ChIP)-PCR targeting a
sequence proximal to the HRE was performed to demonstrate fold enrichment for HIF-1α
association with the promoter of NTN1 compared with IgG isotype control. Data are normalized
relative to PBS treated MΦs (n=3, unpaired t-test).
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Figure 21 (Continued):
C) Relative expression of Ntn1 in BAL cells collected from mice with conditional genetic
deletion of Hif1α in myeloid cells (Hif1α loxp/loxp LysM Cre) 3 days after onset of LPS-induced
lung injury compared with LysM Cre mice for control (n=4-6 mice per group, Mann-Whitney
test).
D) Representative immunohistochemistry staining for netrin-1 protein in BAL cells isolated from
Hif1α loxp/loxp LysM Cre mice 3 days after onset of LPS-induced lung injury compared with LysM
Cre mice (n=3).
E and F) Densitometry and western blot image and quantification for netrin-1 protein
expression in lung tissue of LysM Cre and Hif1α loxp/loxp LysM Cre 3 days after the onset of LPSinduced lung injury (n=3 mice per group, two-way ANOVA with Bonferroni post-hoc tests).
All data are represented as mean ± SD; * p-value <0.05.
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Netrin-1 deletion in myeloid cells results in exacerbated LPS-induced lung injury
In order to investigate the functional role for myeloid-cell derived netrin-1 during LPS-induced
lung injury, we cross-bred Ntn1loxp/loxp mice with LysM Cre mice to generate offspring that are
deficient for netrin-1 in myeloid cells (Ntn1loxp/loxp LysM Cre). Following LPS instillation,
Ntn1loxp/loxp LysM Cre mice had statistically increased mortality and delayed recovery of weight
loss in surviving mice compared to LysM Cre mice (Figure 22A, B). Additionally, increased
albumin concentration was observed in bronchoalveolar lavage fluid (BALF) from Ntn1loxp/loxp
LysM Cre mice at 3 days post LPS instillation, suggesting elevated pulmonary edema (Figure
22C). Additionally, we observed elevated BAL neutrophil counts and BALF IL-1β and IL-6
protein levels in Ntn1loxp/loxp LysM Cre mice 3 days after LPS instillation compared with LysM
Cre controls, suggesting increased levels of pulmonary inflammation in these animals (Figure
22D, E, F). Finally, blinded pathological scoring of lung tissue harvested from mice 3 days after
LPS instillation suggested increased lung pathology in Ntn1loxp/loxp LysM Cre mice (Figure 22G,
H). Altogether, netrin-1 deletion in myeloid cells results in a worsened outcome, increased
inflammatory markers and lung pathology during LPS-induced lung injury.
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Figure 22: Netrin-1 deletion in myeloid cells exacerbates LPS-induced lung injury.
A) Mortality of mice with conditional deletion of Ntn1 in myeloid cells (Ntn1loxp/loxp LysM Cre)
compared with LysM Cre control mice in LPS-induced lung injury (n=10 mice in LysM Cre
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Figure 22 (Continued):
group, n=12 mice in Ntn1loxp/loxp LysM Cre group, Kaplan-Meier curves, log-rank test).
B) Fractional weight loss in Ntn1loxp/loxp LysM Cre mice compared with LysM Cre controls (n=1012 mice per group, Bonferroni-adjusted Welch’s or unpaired t test).
C) Pulmonary edema was assessed by enzyme-linked immunosorbent assay (ELISA)
quantification of bronchoalveolar lavage fluid (BALF) albumin in Ntn1loxp/loxp LysM Cre and LysM
Cre mice with LPS-induced lung injury at indicated time points (n=5-7 mice per group,
Bonferroni-adjusted unpaired t-test).
D) Quantification of BAL neutrophils in Ntn1loxp/loxp LysM Cre and LysM Cre mice with LPSinduced lung injury at indicated time points (n=5-7 mice per group, Bonferroni-adjusted
unpaired t-tests).
E and F) ELISA quantification of inflammatory cytokines, IL-1β and IL-6, in BALF collected from
Ntn1loxp/loxp LysM Cre and LysM Cre mice with LPS-induced lung injury at indicated time points
(n=5-7 mice per group, Bonferroni-adjusted unpaired t-test).
G and H) Representative sections and lung injury scoring of hematoxylin and eosin stained
lung tissue collected from Ntn1loxp/loxp LysM Cre and LysM Cre mice 3 days after onset of LPSinduced lung injury (40X magnification, n=5-13 mice per group, unpaired t-test).
All data are represented as mean ± SD. * p-value <0.05.

139

Increased NK cell infiltration in Ntn1loxp/loxp LysM Cre mice during LPS-induced lung
injury
Based on the profound increase in lung inflammation in Ntn1loxp/loxp LysM Cre mice following i.t.
LPS instillation, we next set out to gain mechanistic insight on the regulatory role of myeloidderived netrin-1 by transcriptomic approach. Because we initially demonstrated an insignificant
contribution of neutrophils in netrin-1 expression, we performed mRNA sequencing using RNA
isolated from BAL cells collected on day 3 after LPS instillation that was depleted of neutrophils
(Figure 23A). Differential gene regulation analysis revealed 105 down-regulated (fold change
<0.5) and 145 up-regulated (fold change >2) statistically significant (False Discovery Rate <
0.05) genes (Figure 23B). Gene Ontology and KEGG pathway enrichment analysis of downregulated genes did not identify any enriched pathways, but up-regulated genes revealed an
increase in multiple pathways, with the highest enrichment being in NK cell-mediated
cytotoxicity (Figure 23C). To determine if the enrichment in the NK-cell mediated cytotoxicity
KEGG pathway was attributed to an increased number of NK cells in the total BAL cells, we
first analyzed the up-regulated genes using CellKB, which uses a rank-biased overlap method
to match the up-regulated genes to cell-type marker sets that are published in the literature
(CellKB, https://cellkb.combinatics.com/). We found that 87 of the 145 up-regulated genes were
matched to NK cell gene sets, with an expression-weighted match score of 66.31, both of
which were the strongest signals amongst other cell types that were matched (Figure 23D).
Interestingly, the macrophage cell type represented the weakest match result from the CellKB
algorithm (Figure 23D), suggesting differential gene regulation was not a result of
transcriptomic changes between Ntn1loxp/loxp LysM Cre and LysM Cre control macrophages. In
order to investigate whether there is an increase in NK cell numbers in the alveolar airspace
during LPS-induced lung injury in Ntn1loxp/loxp LysM Cre mice, we performed flow cytometry
using BAL cells collected 3 days after LPS instillation and gated for NK cells (CD3 - NK1.1+).
Consistent with our transcriptomic results, we observed an increased percentage and the total
number of NK cells in the BAL of Ntn1loxp/loxp LysM Cre mice when compared with LysM Cre
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controls (Figure 23F, G). Altogether, these results demonstrate that myeloid-cell derived netrin1 plays a critical role in NK cell recruitment during LPS-induced lung injury.
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Figure 23: Ntn1loxp/loxp LysM Cre mice display increased natural killer (NK) cell infiltration
in the airway during LPS-induced lung injury.
A) Experimental scheme: bronchia alveolar lavage (BAL) cells were collected from LysM Cre
and Ntn1loxp/loxp LysM Cre mice 3 days after onset of LPS-induced lung injury and then depleted
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Figure 23 (Continued):
for neutrophils before RNA isolation. RNA was then submitted for analysis via mRNA-seq.
B) Volcano plot of up- and down-regulated genes in BAL cells collected from Ntn1loxp/loxp LysM
Cre mice when compared with LysM Cre controls (n=3 mice the Ntn1loxp/loxp LysM Cre group,
n=4 in LysM Cre group, the threshold for FDR was < 0.05, thresholds for fold change were <0.5
or >2).
C) Pathway enrichment analysis for up-regulated genes in BAL cells collected from Ntn1loxp/loxp
LysM Cre mice when compared with LysM Cre controls.
D) CellKB analysis was used to match up-regulated genes with cell-type marker sets that are
published in the literature. Diameters of circles indicate the number of genes matching to each
cell-type marker set and the prediction match score is weighted by the fold enrichment of the
corresponding matching genes.
E, F, and G) Representative gating and quantification (percentage and total) for NK cells (CD3 NK1.1+) in the BAL of LysM Cre and Ntn1loxp/loxp LysM Cre mice 3 days after onset of LPSinduced lung injury (n=3 mice per group, unpaired t-test).
All data are represented as mean ± SD; * p-value <0.05.
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CCL2 elevation in Ntn1loxp/loxp LysM Cre mice is associated with increased NK cell levels
and inflammation
After having shown an increased NK cell infiltration in Ntn1loxp/loxp LysM Cre mice during LPSinduced inflammation, we subsequently pursued studies to address a potential mechanistic
cause. Previous studies of lung inflammation have demonstrated a role for chemokinemediated recruitment of NK cells.527-529 We, therefore, hypothesized that chemoattractant signal
is responsible for the increased accumulation of NK cells in Ntn1loxp/loxp LysM Cre mice during
LPS-induced lung injury. To identify potential chemokine or cytokine mediators, we performed a
membrane-based antibody array to measure relative levels of cytokines and chemokines in the
BALF of Ntn1loxp/loxp LysM Cre mice and LysM Cre mice 3 days after intratracheal LPS
instillation. We found protein expression of CCL2, a chemoattractant for NK cells527, 530, 531, to
be the most elevated cytokine or chemokine in BALF of Ntn1loxp/loxp LysM Cre mice (Figure 24A,
B). Using ELISA, we confirmed the elevation of CCL2 in the BALF of Ntn1loxp/loxp LysM Cre mice
compared with LysM Cre mice 3 days after intratracheal LPS instillation (Figure 24C).
Consequently, we pursued the notion that CCL2 inhibition might reverse the elevated NK cell
recruitment and lung inflammation in Ntn1loxp/loxp LysM Cre mice. Thus, we treated Ntn1loxp/loxp
LysM Cre mice with intraperitoneal neutralizing antibodies against CCL2 on days 1 and 2 after
intratracheal instillation of LPS, and then assessed NK cell recruitment and lung inflammation
on day 3 (Figure 24D). Compared with IgG treated controls, Ntn1loxp/loxp LysM Cre mice treated
with CCL2 neutralizing antibodies had a statistically significant reduction in total BAL NK cells
via flow cytometry (Figure 24E). Ntn1loxp/loxp LysM Cre mice treated with CCL2 neutralizing
antibodies also had a significant reduction in infiltrating BAL neutrophils and in alveolar barrier
permeability, as indicated by reduced BALF albumin concentration (Figure 24F, G). Upon
histological evaluation of hematoxylin and eosin-stained lung tissue, there was a statistically
significant reduction in lung pathology as determined by blinded pathological scoring (Figure
24H, I). Taken together, these studies support the role of myeloid-derived netrin-1 in limiting
CCL2-mediated NK cell recruitment during lung inflammation.
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Figure 24: C-C motif chemokine ligand 2 (CCL2) neutralization in Ntn1loxp/loxp LysM
Cre mice reduces natural killer (NK) cell infiltration in the airway and improves LPSinduced lung injury.
A) Using Bronchoalveolar lavage fluid (BALF) collected from LysM Cre and Ntn1loxp/loxp LysM
Cre mice 3 days after onset of LPS-induced lung injury, we performed a membrane-based
sandwich immunoassay to profile for changes in inflammatory cytokines and chemokines.
Representative dot-blot of the membrane-based immunoassay.
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Figure 24 (Continued):
B) Quantified pixel density of the top ten up-regulated cytokines/chemokines in Ntn1loxp/loxp
LysM Cre mice relative to LysM Cre controls (n=2 per group).
C) CCL2 up-regulation was confirmed in BALF of Ntn1loxp/loxp LysM Cre mice relative to LysM
Cre mice 3 days after onset of LPS-induced lung injury using enzyme-linked immunosorbent
assay (ELISA) (n=4-7 mice per group, Bonferroni-adjusted unpaired t-test).
D) Experimental scheme: Ntn1loxp/loxp LysM Cre were given LPS-induced lung injury and then
subsequently given intraperitoneal (i.p.) injections of neutralizing CCL2 antibodies (αCCL2) or
IgG isotype control (10 μg/g of body weight) on days 1 and 2 after the onset of lung
inflammation. Mice were subsequently euthanized for analysis on day 3 after the onset of lung
inflammation.
E) Quantification of total NK cells (CD3- NK1.1+) in the BAL collected from αCCL2-treated
Ntn1loxp/loxp LysM Cre mice 3 days after onset of LPS-induced inflammation was measured by
flow cytometry (n=4-6 mice per group, unpaired t-test).
F) Quantification of total polymorphonuclear neutrophils (PMNs) in the BAL collected from
αCCL2-treated Ntn1loxp/loxp LysM Cre mice 3 days after onset of LPS-induced lung injury (n=4-6
mice per group, unpaired t-test).
G) Pulmonary edema was assessed by enzyme-linked immunosorbent assay (ELISA)
quantification of bronchoalveolar lavage fluid (BALF) albumin in αCCL2-treated Ntn1loxp/loxp
LysM Cre mice (n=4-6 mice per group, Mann-Whitney test).
H and I) Representative hematoxylin and eosin staining and lung pathology scoring of lung
sections from αCCL2-treated Ntn1loxp/loxp LysM Cre mice (n=4-6 mice per group, unpaired ttest).
All data are represented as mean ± SD; * p-value <0.05.
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4.4 Conclusions and Significance
An increasingly recognized class of immune-modulators is the NGPs. 499 The present studies
aim at investigating the role of myeloid cell-derived NGPs during sepsis-associated lung
inflammation. Through a qPCR-based screen, we identified netrin-1 to be highly upregulated in
LPS stimulated human monocyte-derived macrophages, as well as in peripheral circulating
neutrophils. During LPS-induced lung injury in mice, pulmonary netrin-1 was significantly
elevated 3 days after the onset of inflammation, which coincided with the peak infiltration of
immune cells into the alveolar airspace. Using immunohistochemistry and flow cytometry, we
localized netrin-1 expression to infiltrating immune cells, particularly in macrophages.
Subsequent transcriptional studies identified Hif-1α as a key transcriptional factor for netrin-1
regulation, and transgenic mice lacking HIF-1α in the myeloid compartment failed to induce
netrin 1 during LPS-induced lung injury. Furthermore, the deletion of netrin-1 in the myeloid cell
compartment (Ntn1loxp/loxp LysM Cre) resulted in worsened outcomes during LPS-induced lung
injury in mice, indicating a protective role for myeloid cell-derived netrin-1. Surprisingly,
increased NK cell and CCL2 accumulation are observed in Ntn1loxp/loxp LysM Cre mice. Lastly,
when Ntn1loxp/loxp LysM Cre mice were treated with CCL2 neutralizing antibodies, we observed
a reduction in NK cell recruitment and improvement in lung inflammation. Together, these data
reveal myeloid-derived netrin-1 as a critical negative feedback mechanism during lung
inflammation.
Our findings that myeloid-derived netrin-1 protects mice against lung inflammation are
in alignment with other studies. Netrin-1 has been reported to dampen inflammation in several
models of inflammatory conditions including peritonitis,512 acute lung injury502, 532 kidney
ischemia-reperfusion injury,514, 533 arthritis,534 and colitis.535 Mechanistically, netrin-1 serves to
limit inflammation by regulation of leukocyte migration and accumulation 534, 536-538 and is also
shown to facilitate the active resolution of inflammation by promoting pro-resolving mediator
expression during peritonitis517 and liver ischemia-reperfusion injury.539 Ex vivo netrin-1
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treatment of macrophages and endogenous overexpression of netrin-1 in vivo was found to
promote the transition to an anti-inflammatory M2-like phenotype macrophage, which acts to
limit inflammation and encourage wound healing.514, 533, 538 Previous studies have also
demonstrated that netrin-1 is expressed by myeloid cells and plays a functional role in disease
conditions. For example, macrophage-derived netrin-1 has been shown to promote retention of
adipose tissue macrophages leading to insulin resistance, 540 promote the development of
atherosclerosis,504 and to support the progression of aortic aneurysms.541 Thus, myeloid cellderived netrin-1 plays diverse regulatory roles under different inflammatory conditions, such as
in the case of adenosine signaling.331, 344
Several previous studies have demonstrated hypoxia and HIF-1α-dependent expression
of netrin-1 during inflammatory conditions. HIF-1α-dependence netrin-1 induction in mucosal
epithelial cells has been illustrated in models of hypoxia-induced mucosal inflammation. 503 In
addition, macrophages found in hypoxic regions of atherosclerotic show increased netrin-1
level in both human and mouse studies, and HIF activation induces netrin-1 expression in
macrophages in a HIF-1α dependent manner.542 Besides HIF-1α dependent induction, netrin-1
expression is also controlled by NF-κB, and NF-κB can act as both a transcriptional activator 543
and repressor.502 Furthermore, vagal nerve innervation has also been shown to regulate
pulmonary expression of netrin-1 as unilateral vagotomy decreases netrin-1 expression in the
lung.517 However, the neuronal stimulation of netrin-1 expression in myeloid cells is unknown.
Netrin-1 imparts cellular functions through interacting with its receptors. The best
described netrin-1 receptors during inflammatory regulation are uncoordinated receptor 5
(UNC5b), the neogenin receptor, and the adenosine 2B (A2B) receptor. 502, 503, 505, 512 Netrin-1
interacting with UNC5b on leukocytes has been implicated in regulating migratory functions as
well as dampening inflammatory cytokine expression.504, 540, 541, 544 The A2B receptor is involved
in regulating inflammation in response to elevated extracellular adenosine levels that are
commonly present during settings of tissue injury and has also been demonstrated to be a
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critical mediator for netrin-1 regulation of inflammation.340, 525, 537, 545, 546 Previous studies have
shown that the A2B receptor mediates netrin-1 induced expression of resolution mediators to
promote regeneration during liver inflammation,539 dampening of inflammation during
peritonitis,512 attenuate experimental colitis,535 and limit pulmonary inflammation.502 In contrast
with UNC5b and the A2B receptor, the netrin-1 receptor, neogenin, has been shown to promote
acute inflammation and inhibit monocyte polarization toward anti-inflammatory and proresolution phenotypes.547, 548
The present studies have established an exciting new link between myeloid-derived
netrin 1 and NK cell migration during endotoxin-induced lung injury. Indeed, others have
reported NK cells as drivers of immune-pathology in several models of organ injuries. 549-552 For
example, tissue-resident NK cells promote ischemic kidney injury by mediating local
responses.550 During LPS-induced lung injury, it was shown that NK cell depletion in mice
resulted in reduced chemokine-mediated neutrophil recruitment and improved outcomes. 551
Additionally, NK cells were reported to be primary drivers of immune-pathology during a model
of interstitial pneumonia.552 In models of viral infection, NK cells were implicated as the critical
players in causing excessive inflammation leading to bystander lung tissue injury which was
reversed by antibody-mediated depletion.553, 554 Interestingly, pre-infecting mice with Klebsiella
pneumoniae provided protection in subsequent lethal challenges of influenza virus, which was
attributed to K. pneumoniae-conditioned reduction of NK cell recruitment and inflammation. 555
Consistent with our findings of CCL2-driven NK cell accumulation in Ntn1loxp/loxp LysM Cre mice,
previous work has implicated CCL2 in the recruitment of NK cells during a model of invasive
pulmonary aspergillosis infection.527
Our studies have several limitations. Ntn1loxp/loxp LysM Cre mice have a deletion of netrin
1 in macrophage and neutrophil populations, as well as in other granulocytes

457, 458

. Thus, the

profound phenotype in these mice could be mediated by several cell types together. To further
dissect the specific role of netrin 1 in macrophages and neutrophils during endotoxin-induced
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lung injury, Ntn1loxp/loxp mice could be cross-bred with hCD68-rtTA/ Teto-Cre mice, and MRP8Cre mice, respectively. Furthermore, the contribution of myeloid netrin 1 in NK cell recruitment
was only indicated in in vivo studies. Further in vitro experiments will facilitate the determination
of direct or indirection interaction between these two cell populations. Finally, although we have
identified the upregulation of netrin 1 in human neutrophils and macrophages during
inflammatory stimulation, the functional role of netrin 1 in NK cell recruitment during human
endotoxin-induced lung injury was not explored in our study. Additional studies employing lung
tissues and cells isolated from respiratory washout from patients suffering from lung gramnegative bacteria infection or sepsis would be crucial to illustrate this particular interaction.
Altogether, these findings highlight a novel role of myeloid cell-derived netrin-1 during
pulmonary inflammation in limiting excessive inflammation. The impact of myeloid-derived
netrin 1 is achieved by orchestrating CCL2 mediated NK cell infiltration during lung
inflammation. Our studies indicate a novel mechanism for the immune-modulatory effect of
netrin-1 in myeloid cells, particularly during lung injury. Our studies have also implied a
functional role of myeloid-derived netrin 1 in NK cell recruitment, which contributes to the
complexity of netrin 1 biology for the field. Moreover, our studies suggest that myeloid-derived
netrin 1 might play an important role in other diseases where NK cells play major functional
roles, e.g. cancer556, autoimmune diseases557, and viral infection558. Thus, investigating how
myeloid-derived netrin 1 contributes to the pathophysiology of these conditions could be of
great interest to the field. Finally, future work should focus on dissecting the target cells of
myeloid-derived netrin-1 as the sources of CCL2, as well as the receptor that mediates its
immune-modulatory effects.
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Figure 25: Proposed mechanism for myeloid cell-derived Netrin-1 during LPS-induced
acute lung injury.
During acute lung injury initiated by intratracheal injection of LPS, macrophages are activated
through toll-like receptor 4. Netrin-1 is expressed by activated macrophages via stabilization of
the transcription factor, hypoxia inducible factor-1 alpha (Hif-1α), which binds to and activates
the promoter of Netrin-1. Myeloid-derived Netrin-1 plays a critical role in regulating chemokine
(C-C motif) ligand 2 (CCL2) and subsequently limits the recruitment of proinflammatory natural
killer (NK) cells. The ultimate effect of regulating NK cell accumulation by myeloid-derived
Netrin-1 is to dampen inflammation, polymorphonuclear neutrophil (PMN) accumulation and
lung injury. Created with BioRender.com.
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Chapter 5: Conclusion of dissertation
The findings reported in this dissertation highlight several endogenous mechanisms in myeloid
cells that work to regulate inflammation during ALI. In the first study (Chapter 3), we
demonstrate the novel role for miR-147 in regulating macrophage-mediated inflammation by
dampening their inflammatory functions via the epigenetic silencing of cytokine gene
expression. In the second study (Chapter 4), the neuronal guidance peptide, Netrin-1,
expressed in macrophages during ALI played an important role in the regulation of excessive
inflammation associated with NK cell infiltration. Both findings are consistent with previous
works establishing that the regulation of pro-inflammatory macrophages is critical for the proper
resolution of ALI.281, 450, 452 Genetic deletion of either miR-147 or Netrin-1 resulted in
exacerbated inflammation and tissue injury during LPS-induced ALI. As a consequence, we
posit that these two regulatory genes might be leveraged as therapeutic targets.
In Chapter 3, we demonstrated that exogenous administration of liposome-packaged
miR-147 mimics provided a therapeutic benefit for mice with LPS-induced ALI. This pre-clinical
finding is exciting and invokes the potential for clinical translation. MicroRNA-based
therapeutics have previously been proposed and are currently under investigation. 559, 560 The
first microRNA-based therapy was miR-34a. As a transcriptional target of p53 and potent tumor
suppressor, miR-34a has shown potent pre-clinical evidence for controlling tumors and became
the first miRNA-mediated treatment to enter clinical trials.561-563 To date, there are over 15
miRNA-targeting therapies in development (clinical and pre-clinical trials). 564 Though our results
suggested that NDUFA4 is the primary target for miR-147 that is responsible for limiting
inflammation in macrophages, it is possible there are other targets we did not identify in our
RNA-based screen that work in concert with NDUFA4. An added benefit to a therapeutic
miRNA approach is that exogenous administration of miR-147 would also account for these
additional targets.
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An important consideration of utilizing miR-147, as with most anti-inflammatory
treatments (e.g. anti-TNF agents, steroids, etc.) is the concern that it may dampen the host’s
ability to clear or contain infection. Subsequent studies in our lab are already underway
investigating the effects and timing of miR-147 treatment in infectious ALI models in mice in
order to address these possibilities.
Therapeutic leveraging of Netrin-1 is another translational approach under investigation
and has been studied as a biomarker for several disease types, but has not yet been utilized in
clinical trials.565-570 In pre-clinical work, Netrin-1 imparts anti-inflammatory effects to protect a
number of organ injuries, including acute lung injury,502, 532 peritonitis,512 arthritis,534 kidney
ischemia-reperfusion injury,514, 533, myocardial ischemia,570 and colitis.535 With such strong preclinical evidence for Netrin-1 treatment as an anti-inflammatory agent, clinical trials in patients
will be crucial in translating these findings.
In both Chapters of this dissertation, there is a commonality for the dependence on Hif1α. Both miR-147 and Netrin-1 were established as Hif-1α transcriptional targets in
macrophages, signifying that targeting hypoxia and Hif-1α might also provide for a therapeutic
approach for ALI and ARDS. HIF-stabilizing drugs have been developed and have
demonstrated safe and effective use for anemia associated with chronic kidney disease. 325, 326
With great excitement, a clinical trial utilizing the oral HIF activator, Vadadustat, is currently
ongoing as a treatment for the prevention and treatment of ARDS in patients with COVID-19
(NCT04478071). The results of this trial could be the first to demonstrate whether there is
efficacious use of HIF-stabilizing drugs in an inflammatory organ injury in human patients.
Regulating inflammatory processes of macrophages is a highly desirable approach to
limiting inflammatory tissue damage leading to ALI and ARDS. Altogether, the work in this
dissertation outlines two endogenous pathways that could provide targeted treatments towards
dampening inflammation and promoting recovery from lung injury.
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